Differential expression of pro- and anti-inflammatory mediators in pulmonary macrophages upon Toll-like receptor activation by Hoppstädter, Jessica
  
 
Differential expression of pro- and anti-inflammatory 
mediators in pulmonary macrophages upon Toll-like 
receptor activation 
 
 
 
 
 
Dissertation 
zur Erlangung des Grades 
 des Doktors der Naturwissenschaften 
der Naturwissenschaftlich-Technischen Fakultät III 
Chemie, Pharmazie, Bio- und Werkstoffwissenschaften 
der Universität des Saarlandes 
 
 
 
 
von 
Jessica Hoppstädter 
 
Saarbrücken 
2010 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tag des Kolloquiums:  20.12.2010 
Dekan:    Prof. Dr.-Ing. Stefan Diebels 
Berichterstatter:   Prof. Dr. Alexandra K. Kiemer 
    Prof. Dr. Ludwig Gortner 
    Prof. Dr. Bernhard Brüne 
Vorsitz:   Prof. Dr. Petra Bauer 
Akad. Mitarbeiter:   Dr. Britta Diesel 
 
 
 
Contents 
 
 
 
Contents 
 
Abbreviations                                                                                                                    1 
 
Abstract / Zusammenfassung                                                                                         5 
 
1. Background                                                                                                                   7 
 
1.1 Inflammatory lung diseases   9
 1.1.1 Tuberculosis   9
 1.1.2 Asthma and allergic diseases 10
 1.1.3 Chronic obstructive pulmonary disease (COPD) 
 
  11
1.2 Macrophages as mediators of pulmonary inflammation   12
 1.2.1 Overview of macrophage functions   12
 1.2.2 Macrophages in inflammatory lung disease   14
 1.2.3 Macrophage populations within the respiratory tract 
 
  15
1.3 Toll-like receptors (TLRs)   17
 1.3.1 Ligands   17
 1.3.2 Signalling   19
 1.3.3 TLR expression within the lung   20
 1.3.4 TLRs and pulmonary inflammation 
 
  20
1.4 Glucocorticoid-induced leucine zipper (GILZ)   22
 1.4.1 Structure   22
5.00 1.4.2 The diverse functions of GILZ   23
 1.4.3 GILZ in pulmonary inflammation 
 
  25
1.5 Aim of the present work 26
 
2. Chapter I                                                                                                                       29 
Attenuated activation of macrophage TLR9 by DNA from mycobacteria 
 
2.1 Introduction 
 
  31
2.2 Results   33
 2.2.1 Human macrophages are responsive to mycobacterial DNA   33
 2.2.2 Different potency of mycobacterial DNA to activate human macrophages 
 
  39
2.3 Discussion   41
 2.3.1 Responsiveness of human macrophages towards mycobacterial DNA   41
 2.3.2 Differential activatory potential of mycobacterial DNA   42
5.00 2.3.3 What distinguishes DNA from virulent and attenuated mycobacteria   43
 
 
Contents 
 
 
 
3. Chapter II                                                                                                                      45 
Differential cell reaction upon Toll-like receptor activation in human alveolar 
and lung interstitial macrophages 
 
3.1 Introduction 
 
  47
3.2 Results   49
 3.2.1 Cell number and appearance   49
 3.2.2 Expression of intracellular and surface markers   51
 3.2.3 Phagocytosis   52
 3.2.4 TLR expression   54
 3.2.5 Cell reaction upon TLR4 and TLR9 stimulation   54
 3.2.6 Response to MyD88-dependent and –independent TLR activation 
 
  59
3.3 Discussion   61
 3.3.1 Isolation procedure   61
 3.3.2 Morphology   61
 3.3.3 CD14 and HLA-DR expression   61
 3.3.4 Comparison to dendritic cells   62
 3.3.5 Phagocytic activity   62
 3.3.6 TLR expression   62
 3.3.7 Baseline cytokine expression and response to LPS   63
 3.3.8 Differential response to TLR1/2, TLR3 and TLR4 activation   65
5.00 3.3.9 Cell reaction upon TLR9 activation   66
 
4. Chapter III                                                                                                                    69 
Downregulation of the glucocorticoid-induced leucine zipper upon Toll-like 
receptor activation in human alveolar macrophages 
 
4.1 Introduction 
 
  71
4.2 Results   73
 4.2.1 Constitutive and dexamethasone –induced GILZ expression in AM   73
 4.2.2 TLR9 activation attenuates GILZ expression   74
 4.2.3 GILZ downregulation in response to TLR4 activation   75
 4.2.4 Enhanced expression of pro-inflammatory cytokines due to reduced GILZ 
         levels 
  77
 4.2.5 GILZ downregulation upon MyD88-dependent and –independent TLR 
         activation 
  79
 4.2.6 MyD88-dependent GILZ mRNA downregulation    82
 4.2.7 Decrease of GILZ mRNA half-life in response to LPS   83
 4.2.8 Involvement of TTP in GILZ mRNA destabilization   84
5.00 4.2.9 Proteasome-dependent GILZ downregulation    88
 4.2.10 TNF--mediated GILZ downregulation   89
 4.2.11 GILZ mRNA expression in endotoxin tolerance 
 
  90
4.3 Discussion   92
 4.3.1 Constitutive and dexamethasone-induced GILZ expression in pulmonary 
         macrophages 
  92
Contents 
 
 
 
 4.3.2 TLR-mediated GILZ downregulation   93
 4.3.3 MyD88- and TTP-dependent GILZ mRNA downregulation   94
 4.3.4 Proteasome-dependent GILZ downregulation   96
 4.3.5 TNF--mediated GILZ downregulation   98
5.00 4.3.6 GILZ in endotoxin tolerance   98
 
5. Experimental procedures                                                                                         101 
 
5.1 Materials 
 
103
5.2 Mice 
 
104
5.3 Cell culture 104
 5.3.1 Alveolar macrophages (AM) 104
5.0.0 5.3.2 Lung interstitial macrophages (IM) 105
 5.3.3 Monocyte-derived macrophages 105
 5.3.4 Monocyte-derived immature and mature dendritic cells (iDC, mDC)  106
 5.3.5 Cell lines 106
 5.3.6 Determination of cell viability 
 
107
5.4 Bacterial culture 108
 5.4.1 Escherichia coli (E.coli) strains 108
 5.4.2 Culture of mycobacteria 
 
109
5.5 Plasmid generation 109
 5.5.1 Vectors for mammalian cell transfections 109
 5.5.2 Real-Time RT-PCR standard plasmids 
 
110
5.6 Isolation of bacterial DNA 110
 5.6.1 Plasmid purification 110
 5.6.2 Isolation, digestion and methylation of mycobacterial DNA 110
 5.6.3 Determination of DNA concentrations 
 
111
5.7 Agarose gel electrophoresis 112
 5.7.1 Detection of DNA 112
 5.4.2 Detection of RNA 
 
112
5.8 RNA isolation and reverse transcription 112
 5.8.1 RNA isolation 112
 5.8.2 Measurement of RNA concentrations 112
 5.8.3 Alu PCR 113
 5.8.4 Reverse transcription 
 
113
5.9 Real time RT-PCR 114
 5.9.1 Primer and probe sequences 114
 5.9.2 Standard dilution series 115
 5.9.3 Experimental procedure 
 
116
5.10 Western Blot analysis 118
 5.10.1 Preparation of protein samples 118
 5.10.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 118
 5.10.3 Blotting 119
5.0.0 5.10.4 Immunodetection 119
Contents 
 
 
 
5.11 Transfection of THP-1 cells 120
 5.11.1 Plasmid transfection 120
 5.11.2 siRNA transfection 
 
120
5.12 Determination of mRNA stability 
 
120
5.13 Flow cytometry 121
 5.13.1 Antibodies 121
 5.13.2 Cell staining and analysis 
 
121
5.14 Phagocytosis Assay 122
 5.14.1 Sample preparation 122
5.0.0 5.14.2 Flow cytometry assessment of fluorosphere uptake 122
 5.14.3 Confocal laser scanning microscopy 
 
122
5.15 Pappenheim staining 
 
123
5.16 Cytokine measurement 
 
123
5.17 Atomic force microscopy 
 
124
5.18 Statistics 124
 
6. Summary                                                                                                                    126 
 
7. References                                                                                                                 130 
 
Publications                                                                                                                   159 
 
Acknowledgements / Danksagungen                                                                          161 
 
Abbreviations 
 
 
 1
Abbreviations 
 
A Ampere 
amp ampicillin 
AM alveolar macrophage 
AP-1 activator protein 1 
APS ammonium persulfate 
atto 10-18 
BHQ1 black hole quencher 1 
BAL bronchoalveolar lavage 
BCG M. bovis Bacille Calmette-Guerin 
bp base pairs 
BSA bovine serum albumin 
CD cluster of differentiation 
cDNA complementary DNA 
COPD Chronic obstructive pulmonary disease 
CpG undermethylated 5’-CG-3’ sequences 
DAMP danger-associated molecular pattern 
dATP 2’-deoxyadenosine-5’-triphosphate 
DC dendritic cell 
dCTP 2′-deoxycytidine 5′-triphosphate 
DEPC diethyl dicarbonate 
dGTP 2′-deoxyguanosine 5′-triphosphate 
DMEM Dulbecco's modified eagle medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DNase deoxyribonuclease 
dNTP dATP, dCTP, dGTP or dTTP 
dTTP 2’deoxythymidine 5′-triphosphate 
E. coli Escherichia coli 
EDTA ethylenediaminetetraacetic acid 
EtBr ethidium bromide 
FACS fluorescence activated cell sorter 
Fc fragment crystalline 
FCS fetal calf serum 
FITC fluorescein isothiocyanate 
FSC forward scatter 
x g x-fold gravitational force 
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g gram 
G guanine 
GILZ glucocorticoi -induced leucine zipper 
h fluoresceinisothiocyanat 
H37Ra M.tuberculosis, attenuated strain H37Ra 
H37Rv M.tuberculosis, virulent strain H37Rv 
HLA-DR human leukocyte antigen-DR 
HMGB1 high-mobility group box 1 protein 
HuR human antigen R 
iDC immature dendritic cell 
IFN interferon 
Ib inhibitory protein B 
IL Interleukin 
IL1ra IL1 receptor antagonist 
IM Interstitial macrophage 
IP10 IFN inducible protein 10 
IRF IFN regulating factor 
ISS immunostimulatory sequences 
kb kilo bases 
kDa kilo Dalton 
l litre 
LB Luria Bertani 
LPS lipopolysaccheride 
m milli (10-3) 
M molar 
MAPK mitogen-activated protein kinase 
M. bovis Mycobaterium bovis 
MCP-1 macrophage chemoattractant protein-1 
mDC mature dendritic cell 
MHC major histocompatibility complex 
µ micro (10-6) 
min minute 
MIP macrophage inflammatory protein 
MOPS 3-(N-morpholino)propanesulfonic acid 
mRNA messenger RNA 
M. tuberculosis Mycobacterium tuberculosis 
MyD88 myeloid differentiation factor 88 
n nano (10-9) 
N normal 
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NF-B nuclear factor-b 
ODN oligodeoxynucleotide 
p pico (10-12) 
PAMP pathogen-associated molecular pattern 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
Poly(I:C) polyinosinic:polycytidylic acid 
PRR pattern recognition receptor 
RNA ribonucleic acid 
RNase ribonuclease 
RNI reactive nitrogen intermediates 
ROS reactive oxygen species 
rpm rounds per minute 
RPMI Roswell Park Memorial Institute 
RT reverse transcription 
SAGM small airway epithelial cell growth medium 
SEM standard error of the mean 
SSC sideward scatter 
STAT signal transducer and activator of transcription 
TBE tris borate EDTA buffer 
TE tris EDTA buffer 
TGF transforming growth factor 
TIR Toll/IL-1 receptor 
Th T helper 
TLR toll-like Receptor 
TNF- tumor necrosis factor- 
TRIF TIR domain-containing adapter inducing IFN-β 
Tris -tris-(hydroxymethyl)-methylamine 
TTP tristetraprolin 
U unit 
UV ultra violet 
[v/v] volume per volume 
V volt 
[w/v] weight per volume 
zeo zeocin 
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Abstract 
 
Toll-like receptor (TLR) activation plays a crucial role in both infectious as well as non-
infectious lung disease. TLRs are capable of sensing different microbial and viral 
molecular patterns, and TLR engagement is a prerequisite for the initiation of macrophage 
responses to infections. Thus, aim of this work was to elucidate different aspects of TLR 
activation in human pulmonary macrophages. 
Interestingly, the activation profiles of the two macrophage populations examined, i.e. 
alveolar and interstitial macrophages, differed largely, indicating that alveolar 
macrophages are more effective as a non-specific first line of defence against inhaled 
pathogens, whereas interstitial show a more pronounced regulatory function.  
The glucocorticoid-induced leucine zipper (GILZ) is highly expressed in human alveolar 
macrophages and critically attenuates inflammatory signalling pathways. The mechanisms 
of GILZ regulation in inflammation, however, have as yet been completely unknown. Our 
investigations on the expression of GILZ in human alveolar macrophages upon TLR 
activation reveal that GILZ is downregulated by different post-transcriptional mechanisms.  
Both the TLR signalling pathways and GILZ have emerged as potential therapeutic targets 
for the treatment of inflammatory lung diseases. Our results support this concept and 
contribute to a better understanding of their role in pulmonary immune homeostasis. 
 
 
 
Zusammenfassung 
 
Die Aktivierung von Toll-like Rezeptoren (TLRs) ist von großer Bedeutung für den Verlauf 
infektiöser sowie nicht infektiöser Erkrankungen der Lunge. TLRs ermöglichen die 
Erkennung verschiedenster mikrobieller und viraler Muster, und die Aktivierung von TLRs 
stellt eine Vorraussetzung für die Einleitung von Abwehrmechanismen in 
Lungenmakrophagen dar. 
Im Rahmen dieser Arbeit wurde die Expression von pro- und anti-inflammatorischen 
Mediatoren nach TLR-Aktivierung in humanen Lungenmakrophagen untersucht. Dabei 
ließen sich große Unterschiede zwischen Alveolarmakrophagen und interstitiellen 
Makrophagen feststellen. Unsere Ergebnisse legen nahe, dass Alveolarmakrophagen eine 
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effektive erste Abwehr von Pathogenen vermitteln, während interstitielle Makrophagen 
eher in regulatorische Prozesse involviert sind.  
Der anti-inflammatorische Faktor GILZ (glucocorticoid-induced leucine zipper) wird von 
Lungenmakrophagen stark exprimiert. Die Regulationsmechanismen, denen GILZ im 
Rahmen einer Entzündungsreaktion unterliegt, waren bisher jedoch unbekannt. Unsere 
Untersuchen zur Expression von GILZ in Alveolarmakrophagen zeigen erstmals, dass 
GILZ nach TLR-Aktivierung herabreguliert wird und liefern Einblicke in die zugrunde 
liegenden Mechanismen.  
Die Aufklärung der Mechanismen, die in die Regulation von GILZ und TLR-Signalwegen 
involviert sind, kann zu einem besseren pathophysiologischen Verständnis und somit zu 
einer besseren Therapierbarkeit von entzündlichen Lungenerkrankungen beitragen. 
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1.1. Inflammatory lung diseases 
 
Inflammatory processes in the lung play an important role in pulmonary diseases, such as 
bacterial and viral infections. The pharyngeal mucosa is colonized by microorganisms, 
which do not necessarily cause inflammatory reactions (Wissinger et al., 2009; Tlaskalová-
Hogenová et al., 2004). In contrast, the lower respiratory tract is considered to be sterile, 
and invasion of pathogenic microbes into the lower respiratory tract leads to immediate 
immune responses (Harris et al., 2007). The World Health Organization (WHO) estimates 
429 million cases of acute lower respiratory tract infections in 2004 worldwide, making it 
the third leading cause of death in the world (WHO, 2010a). Besides infectious diseases 
like tuberculosis, also non-infectious diseases, such as asthma and chronic obstructive 
pulmonary disease (COPD), are characterized by chronic inflammatory processes and 
have gained major clinical relevance (Caramori and Adcock, 2003; Peden and Reed, 
2010). 
 
1.1.1 Tuberculosis 
Tuberculosis is the one of the most important examples of pulmonary infections: one third 
of the world population is infected with its causative agent, Mycobacterium tuberculosis, 
and an estimated 1.3 million people died from TB in 2008 (WHO, 2010b). Those infected 
with Mycobacterium tuberculosis usually display an asymptomatic, latent infection 
progression, with only a 10% lifetime chance that a latent infection will progress to active 
tuberculosis (WHO, 2010b). If untreated, however, the mortality in active cases of 
tuberculosis was reported to be greater than 50% (Onyebujoh and Rook, 2004).  
When mycobacteria reach the pulmonary alveoli, they invade and replicate within the 
endosomes of alveolar macrophages (Houben et al., 2006). Bacteria are also engulfed by 
dendritic cells, leading to the transport of mycobacteria to local lymph nodes. In this 
manner, bacteria are enabled to further spread through the bloodstream. As a result, 
secondary tuberculosis lesions can develop in other parts of the lung, but also in 
peripheral lymph nodes, kidneys, brain, and bone (Herrmann and Lagrange, 2005). 
Tuberculosis is characterized by the formation of granulomas, in which different cell types, 
such as macrophages, T cells, B cells, and fibroblasts are involved, with lymphocytes 
surrounding the infected macrophages. The granuloma not only prevents spreading of the 
mycobacteria, but also provides an environment for a rather efficient immune response. 
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However, bacteria are not always eliminated within the granuloma, which results in a latent 
infection (Houben et al., 2006; Onyebujoh and Rook, 2004).  
Antibiotic therapy of tuberculosis is difficult due to the structure of the mycobacterial cell 
wall (Onyebujoh and Rook, 2004; Brennan and Nikaido, 1995). The two antibiotics 
commonly used are rifampicin and isoniazid, which have to be applied up to 24 months to 
entirely eliminate mycobacteria from the body. Increasing numbers of extensively drug-
resistant tuberculosis infections complicate efficient tuberculosis treatment (WHO, 2010b). 
Attempts to prevent tuberculosis involve the Bacillus Calmette-Guérin (BCG) vaccine, 
which originates from an attenuated mycobacterial strain, Mycobacterium bovis. Although 
BCG provides protection against serious forms of tuberculosis in children, it has been 
shown to be ineffective against adult pulmonary tuberculosis (Onyebujoh and Rook, 2004). 
 
1.1.2 Asthma and allergic diseases 
The prevalence of allergic respiratory diseases such as rhinosinusitis and bronchial 
asthma has risen in industrialized countries over the last 30 years (D'Amato et al., 2010), 
possibly as a result of the decreasing number of childhood infections (Cookson and 
Moffatt, 1997; Rook and Stanford, 1998).  
In 2009, 300 million people worldwide were affected by asthma, leading to 250,000 deaths 
per year. Bronchial asthma is characterized by airway inflammation, hyperresponsiveness 
and chronic airflow obstruction. Bronchoconstriction not only occurs in response to 
allergens to which an individual is sensitized, but also to a range of nonspecific stimuli, 
such as cold air and air pollutants (D'Amato et al., 2010). Acute symptoms are usually 
treated with bronchodilators like salbutamol, whereas symptom prevention can be 
achieved by long-term usage of inhaled glucocorticoids or leukotriene modifiers (Yawn, 
2008).  
Apart from environmental parameters including allergen exposure, the development of an 
asthma or atopy phenotype is also influenced by genetic factors (Cookson and Moffat, 
2000; von Mutius et al., 1992). Sequence variants in hundreds of genes have been found 
to be related to asthma (Halapi and Bjornsdottir, 2009). Many of these genes are coding 
for factors associated with immune response, e.g. the interleukin (IL) 4 receptor or Major 
Histocompatibilty Complex (MHC) II molecules. In fact, various cell types of innate and 
adaptive immunity, such as macrophages, mast cells and T helper 2 (Th2) cells, were 
found to be critically involved in dysregulation of lung homoestasis in asthma, resulting in 
Background 
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airway inflammation and tissue damage (Ichinose, 2009; Schröder, 2009). However, 
mechanisms underlying this chronic inflammatory state are poorly understood. 
 
1.1.3 Chronic obstructive pulmonary disease (COPD) 
COPD is a chronic inflammatory disease characterized by chronic bronchitis, fibrosis, 
irreversible narrowing of small airways, and emphysema. The WHO estimates that more 
than 3 million people died of COPD in 2005, which is equal to 5% of all deaths globally that 
year, and total deaths from COPD are projected to increase by more than 30% in the next 
10 years (WHO, 2010c). In contrast to asthma, airway obstruction associated with COPD 
is poorly reversible and usually progresses over time. Cigarette smoking represents the 
primary risk factor for COPD, as inhalation of noxious components of tobacco smoke leads 
to a dysregulation of the inflammatory response in the lung (Rabe et al., 2007; Hogg et al., 
2004; Barnes, 2004). Inflammation of the larger airways results in chronic bronchitis, 
whereas in the alveoli, the inflammatory response causes destruction of the lung 
parenchyma, thus leading to emphysema. In addition, respiratory infections might also 
play a role in the development and progression of the disease and are the major cause of 
acute exacerbations (Sethi and Murphy, 2008; Barnes, 2008; Sabroe et al., 2007).  
There is a specific pattern of inflammation in COPD, characterized by increased numbers 
of macrophages, neutrophils, and cytotoxic (CD8+) T-lymphocytes (Barnes et al., 2003). 
This pattern of inflammation is also seen in cigarette smokers with normal lung function, 
but the intensity of the inflammation is increased in COPD with increased numbers of 
inflammatory cells and mediators. The chronic inflammation in COPD is associated with 
increased expression of multiple inflammatory genes, involving cytokines, chemokines, 
and adhesion molecules. Many of these inflammatory genes are regulated by the 
transcription factor nuclear factor (NF)-B, which has been shown to be constitutively 
activated in inflammatory cells of COPD patients, particularly in alveolar macrophages (Di 
Stefano et al., 2002). COPD is not curable, but treatment can slow the progress of the 
disease. Besides the avoidance of risk factors such as smoking, bronchodilator 
medications are central to the symptomatic management of COPD.  
Additional treatment with inhaled glucocorticosteroids is considered to be appropriate for 
patients with severe forms of COPD and repeated exacerbations (Rabe et al., 2007). 
Interestingly, in COPD and asthma patients who smoke, glucocorticoids fail to suppress 
inflammation, which is considered to be due to a loss of histone deacetylase (HDAC2) 
activity and expression as a result of oxidative and nitrative stress (Barnes et al., 2004).  
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1.2. Macrophages as mediators of pulmonary inflammation 
 
1.2.1 Overview of macrophage functions 
Macrophages are a major component of the mononuclear phagocyte system that consists 
of cells of bone marrow origin, including blood monocytes, and tissue macrophages 
(Hume, 2006). They are capable of many functional activities that contribute to the 
initiation of a cell-mediated immune response and also act as effectors of inflammation. 
During the course of their activation, macrophages can display both inflammatory and anti-
inflammatory activities (Mosser and Edwards, 2008; Fujiwara and Kobayashi, 2005; figure 
1). 
 
 
 
Figure 1: The diverse functions of macrophages. Modified after Stout and Suttles (1997). IL: interleukin, 
IFN: interferon, IP10: IFN inducible protein 10, MCP1: macrophage chemoattractant protein 1, MIP1: 
macrophage inflammatory protein 1TNF-tumor necrosis factor-, TGF-: transforming growth factor-, 
IL1ra: IL1 receptor antagonist. 
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Macrophages differentiate from circulating peripheral blood mononuclear cells, which 
migrate into tissue in the steady state or in response to inflammation (Gordon and Taylor, 
2005). Mononuclear cells develop from a common myeloid progenitor cell in the bone 
marrow, which represents the precursor of many different cell types, including neutrophils, 
eosinophils, basophils, macrophages, dendritic cells, and mast cells. Myeloid progenitor 
cells sequentially develop to monoblasts, pro-monocytes, and finally monocytes, which are 
released from the bone marrow into the bloodstream (Gordon and Taylor, 2005). 
Monocytes then migrate from the blood into tissue to differentiate into long-lived tissue 
specific macrophages of the alveoli, liver (Kupffer cells), central nervous system 
(microglia), skin (Langerhans cells), bone (osteoclasts), connective tissue, gastrointestinal 
tract, spleen and peritoneum (Gordon and Taylor, 2005). 
Macrophages are highly phagocytic cells. One of their major functions is to clear 
extraneous cellular material, such as erythrocytes, apoptotic cells or cellular debris 
generated during tissue remodelling. Interestingly, the removal of apoptotic cells seems to 
result in little or no production of inflammatory mediators by unstimulated macrophages 
(Kono and Rock, 2008). The receptors that mediate phagocytosis in these clearance 
processes include scavenger receptors, phosphatidyl serine receptors, integrins and 
complement receptors (Erwig and Henson, 2007). Generally, activation of these receptors 
either fails to induce transcription of proinflammatory mediators or actively induces 
inhibitory signals and cytokines. Thus, most processes involving phagocytosis by 
macrophages are independent of other immune cells (Mosser and Edwards, 2008).  
In contrast, uptake of cellular debris resulting from necrosis due to trauma or stress 
markedly alters the physiology of macrophages. The released endogenous molecules are 
then called danger-associated molecular patterns (DAMPs) and include heat-shock 
proteins, nuclear proteins, such as high-mobility group box 1 protein (HMGB1), histones, 
DNA and other nucleotides, and components of the extracellular matrix (Zhang and 
Mosser, 2008). The DAMP recognition by macrophages leads to inflammatory responses 
upon sterile tissue damage by production of cytokines and pro-inflammatory mediators 
(Kono and Rock, 2008). 
During infections, macrophages recognize components of bacterial or viral origin 
(pathogen assiciated molecular patterns, PAMPs) via pathogen recognition receptors 
(PRRs). These include the well-characterized Toll-like receptors (TLRs), as well as the 
recently described cytosolic NOD-like receptors, RIG-I–like receptors, and DNA sensors 
(Opitz et al., 2010). Additionally, many PRRs are also activated by DAMPs. Once a 
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pathogen is recognized and engulfed, macrophages produce a wide range of biologically 
active molecules, including proinflammatory cytokines, chemokines, growth factors, and 
immunomodulatory mediators (figure 1). Cytokines released by macrophages, such as 
interferons, TNF-, and IL1/, stimulate activity of both the innate and adaptive immune 
response. Moreover, macrophages represent professional antigen presenting cells, as 
they are able to present antigens to T cells, thus generating a highly specific T-cell 
response (Fujiwara and Kobayahi, 2005).  
Activated macrophages are deactivated in response to various mediators, including IL10, 
prostaglandins, G-protein coupled receptor ligands or glucocorticoids (Mosser and 
Edwards, 2008). IL10 and other anti-inflammatory factors, such as C-C chemokine ligand 
1 (CCL1), are also produced by macrophages themselves, and failure to induce these 
mediators might lead to nonresolving inflammation (Fujiwara and Kobayashi, 2005; 
Mosser and Edwards, 2008; Nathan and Ding, 2010). Macrophages not only contribute to 
resolution of inflammation by suppression of inflammation, but also by driving tissue repair. 
Macrophages associated with wound healing arise in response to IL4 secreted by 
granulocytes during an innate immune response as well as Th2 cells during an adaptive 
immune response and contribute to tissue repair by producing components of the 
extracellular matrix (Mosser and Edwards, 2008). 
 
1.2.2 Macrophages in inflammatory lung disease 
During infections, the first line of defense in the respiratory tract is provided by the barrier 
function of epithelia, the mucociliary system that carries inhaled particles away from the 
lower respiratory tract, and constitutively expressed antimicrobial peptides, lysozyme, and 
surfactant proteins (Bals et al., 2004; Mizgert, 2008). In addition, the pharyngeal microflora 
also contributes to host defense by out-competing some pathogenic species, but can also 
become harmful when aspirated into the lower respiratory tract (Wissinger et al., 2009). 
The important second- and third-line defenses are provided by the innate and the adaptive 
immune responses, both of which, directly or indirectly, depend on macrophage action. In 
addition, DAMP recognition by macrophages leads to inflammatory responses upon sterile 
tissue damage and appears to be critically involved in noninfectious inflammations 
associated with lung injury (Rock and Kono, 2008; Jiang et al., 2005; Imai et al., 2008). 
Stimulation of macrophages by PAMPs, DAMPs or tobacco smoke is involved in 
remodeling and destruction of lung parenchyma, potentially leading to emphysema or 
interstitial fibrosis (Dostert et al., 2008; Barnes, 2008; Doz et al., 2008). There is also 
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evidence for macrophages being critically involved in pathogenesis of allergic and 
granulomatous diseases like asthma and sarcoidosis (Ichinose, 2009; Bedoret et al., 2009; 
Gerke and Hunninghake, 2008). Excessive macrophage activation is also considered to 
play a key role in the pathogenesis of COPD (Barnes, 2004). 
 
1.2.3. Macrophage populations within the respiratory tract 
At least three different types of mononuclear cells were reported to reside within distinct 
compartments of the lung: the alveolar macrophage (AM) the interstitial macrophage (IM), 
and the dendritic cell (DC) (figure 2; Lohmann-Matthes et al., 1994; Laskin et al., 2001; 
Bedoret et al., 2009). AM and IM represent the two largest macrophage populations of the 
lung, with the number of AM being equal to or slightly exceeding the number of IM, 
whereas lung DC account for less than 4% of all pulmonary mononuclear cells (Demedts 
et al., 2004; Lohmann-Matthes et al., 1994). 
 
 
 
Figure 2: Localization of AM, IM and lung DC. Modified after Laskin et al. (2001). 
 
 
AM are located within the alveoli, thus taking a unique position with direct contact to both 
air- and bloodborne materials. They represent the primary defence against inhaled 
micoorganisms, particles, and environmental toxins that enter the lower respiratory tract. 
AM constitute the best characterized lung macrophage population, as they are easily 
accessible by bronchoalveolar lavage. The less extensively characterized IM reside within 
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the connective tissue surrounding the alveoli. They have been described as small 
compared to alveolar macrophages, and in general more closely resemble monocytes. 
This lead to the conclusion that IM might be a precursor of AM, with the interstitium 
providing the environment for maturation of freshly arrived monocytes (Laskin et al., 2001).  
However, there is some evidence in the literature indicating that AM and IM are distinct cell 
populations with their own functional properties. Several studies using primary rat or 
mouse macrophages suggest that AM are more effective than IM in producing cytokines 
involved in an antimicrobial defence whereas IM express higher levels of MHCII molecules 
and have a more pronounced accessory function (Lohmann-Matthes et al., 1994; Franke-
Ullmann et al., 1996; Laskin et al., 2001; Bedoret et al., 2009). 
Lung DC, which may or may not belong to the macrophage lineage (Hume, 2008), can be 
morphologically distinguished by their typical cytoplasmatic extensions (“dendrites”). Lung 
DCs are localized within airway epithelium and in the connective tissue surrounding 
pulmonary vessels and alveoli. They exhibit a high expression of major histocompatibility 
complex (MHC) II molecules, as their major function is to process antigens and to present 
them on their surface. Once activated, they migrate to the local lymph nodes to interact 
with B and T cells, thereby initiating an adaptive immune response. In general, lung DC 
possess an immature phenotype with an enhanced endocytotic capacity, but, unlike other 
immature DC populations, they are powerful stimulators of T cell response (Demedts et al., 
2004; Cochand et al., 1999; Lohmann-Matthes et al., 1994).  
Most interestingly, a recently published study indicated that IM can be distinguished fom 
AM by their ability to suppress lung DC maturation and migration upon LPS stimulation 
(Bedoret et al., 2009). In this manner, IM are considered to prevent LPS-triggered 
responses to harmless inhaled antigens, which would otherwise provoke the development 
of allergic diseases or asthma. 
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1.3. Toll-like receptors (TLRs) 
 
TLRs represent the most prominent family of PRRs. TLRs enable cells, especially those of 
the innate immune system, to recognize a broad spectrum of PAMPs associated with 
bacterial and viral infections. Moreover, many TLRs are involved in DAMP recognition and 
thereby also play a crucial role in sterile inflammation.  
TLRs owe their name to their homology to the Toll-protein, which was originally identified 
in Drosophila melanogaster (Anderson and Nüsslein-Vollhardt, 1984). Ten human and 
thirteen murine TLRs have as yet been identified. The members of the TLR family consist 
of a cytoplasmic Toll/IL-1 receptor homology (TIR) domain mediating downstream 
signalling, and of an extracellular leucine-rich repeat (LRR) domain, that is most likely 
responsible for ligand binding. All TLRs function as homodimers, except TLR2 which also 
forms heterodimeric complexes with TLR1 and TLR6. TLRs are either located at the cell 
surface (TLR1/2 and TLR2/6 heterodimers, TLR2 homodimers, TLR4, TLR5, TLR10) or in 
endosomal membranes (TLR3, TLR7–9; figure 3) (Lundberg and Hansson, 2010, Opitz et 
al., 2010, Kawai and Akira, 2006).  
 
1.3.1 Ligands 
Different microbial as well as endogenous ligands have been identified for most human 
TLRs except TLR10, whose function presently remains elusive (Lundberg and Hansson, 
2010; Opitz et al., 2010; figure 3).  
TLR2, together with TLR1, recognizes bacterial triacetylated lipopeptides from Gram 
negative bacteria or mycobacteria as well as the synthetic compound Pam3CSK4. In 
cooperation with TLR6, TLR2 detects diacytylated lipopeptides from mycoplasma or Gram 
positive bacteria, bacterial lipoteichoic acids, and zymosan from yeast (Lundberg and 
Hansson, 2010; Opitz et al., 2010; Kawai and Akira, 2006). Recognition of lipoteichoic 
acids by TLR2 homodimers has also been described (Beutler, 2004). Moreover, TLR2 
appears to be involved in the recognition of endogenous hyaluronan and high-mobility 
group box 1 (HMGB1) (Jiang et al., 2005; Park et al., 2006).  
TLR3 detects double-stranded (ds)RNA, which represents an intermediate in viral 
replication, as well as its synthetic analogon Poly(I:C) (Alexopoulou et al., 2001; Blasius 
and Beutler, 2010). TLR3 has also been reported to respond to endogenous mRNA 
released from necrotic cells (Cavassani et al., 2008; Kariko et al., 2004).  
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TLR4 recognizes LPS of Gram negative bacteria, but also other bacterial structures or 
toxins. Binding of LPS to TLR4 is considered to require a number of accessory proteins, 
namely CD14, Ligand Binding Protein (LBP), and MD2. Additionally, TLR4 also detects 
endogenous componds, such as HMGB1, hyaluronan, oxidized lipoproteins, and oxidized 
phospholipids (Kawai and Akira, 2006; Opitz et al., 2010)  
 
 
 
 
Figure 3: TLR activation and signalling. See text for details. Modified after Opitz et al. (2010). 
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In contrast to the TLRs described above, TLRs 5, 7, 8 and 9 seem to be specific for only 
one type of pathogen associated structure, each. TLR5 recognizes extracellular bacterial 
flagellin, TLR7 and TLR8 are both intracellular receptors for microbial single-stranded 
(ss)RNA. Bacterial DNA is recognized by TLR9 via its unmethylated CpG motifs, thereby 
distinguishing mammalian from bacterial DNA (Lundberg and Hansson, 2010; Opitz et al., 
2010; Kawai and Akira, 2006). 
 
1.3.2 Signalling 
The binding of TLR ligands initiates the activation of transcription factors, such as NF-B 
and IRFs (IFN regulating factors), finally resulting in a proinflammatory response. TLRs 
display a differential abilty to activate transcription factors due to varying involvement of 
the four TIR domain–containing adapter molecules MyD88 (myeloid differentiation primary 
response gene 88), Mal (MyD88-adapter-like, also known as TIRAP, Toll/IL1 domain 
containing adapter protein), TRIF (TIR domain-containing adapter inducing IFN-β), and 
TRAM (TRIF-related adapter molecule) in their signalling pathways (Lundberg and 
Hansson, 2010, Opitz et al., 2010; figure 3).  
 
MyD88 dependent signalling 
All TLRs with the exception of TLR3 are able to initiate MyD88-dependent signalling. 
Whereas TLRs 5, 7, 8 and 9 directly interact with MyD88, TLR2 and 4 signalling 
additionally requires Mal for MyD88 association. Binding of MyD88 subsequently recruits 
protein kinases of the IL1 receptor asscociated kinase family (IRAK), thus leading to 
IRAK1 phosphorylation by IRAK4. IRAK1 then binds to tumor necrosis factor receptor 
associated factor (TRAF) 6, which activates the inhibitor B kinase (IKK) complex in 
return. As a result, the NF-B inhibitor IB is sequentially phosphorylated, ubiquitinylated 
and degraded, thereby allowing NF-B to translocate into the nucleus. NF-B induces the 
transcription of proinflammatory genes, such as TNF-, IL-8, and other cytokines, which 
subsequently regulate the inflammatory response and contribute to leukocyte recruitment 
(Jenkins and Mansell, 2010). Additionally, TRAF6 is capable to induce the mitogen 
activated protein kinase (MAPK) signalling cascade via activation of transforming growth 
factor (TGF)- activated kinase 1 (TAK1). Phosphorylation of c-Jun NH2-terminal kinase 
(JNK) and the p38 MAPK via TAK1 finally results in the activation of transcription factor 
activator protein 1 (AP-1) and thereby in proinflammatory gene expression. 
Background 
 
 
 20
Apart from NF-B and MAPK activation, TLRs 7 and 8 are able to activate IRF 
transcription factors. Thereby, they mediate type I IFN responses, which play a key role in 
the antiviral defense (Jenkins and Mansell, 2010; Opitz et al., 2010). 
 
MyD88 independent signalling 
MyD88 independent signalling via TLR3 or TLR4 utilizes the TIR domain containing 
adapter inducing IFN- (TRIF) for signal transduction. In contrast to TLR3, TLR4 signalling 
additionally requires the TRIF-related adapter protein (TRAM). Upon activation, TRIF 
interacts with TRAF6 and/or TRIF/receptor-interacting protein 1 (RIP1), resulting in NF-B 
activation due to IB degradation. In addition, TRIF can also activate the TRAF family 
member-associated NF-B activator (TANK)-binding kinase 1 (TBK1), which 
phosphorylates the transcription factors IRF3 and 7, which subsequently leads to the 
expression of type I IFNs (Jenkins and Mansell, 2010; Opitz et al., 2010). 
 
1.3.3 TLR expression within the lung 
Most cell types residing in the lung, including macrophages, DCs, epithelial and  
endothelial cells, express TLRs. Human AM were recently shown to express all ten TLRs 
(Kiemer et al., 2009), although previous studies suggested that TLR3, TLR5 and TLR9 
were absent in this cell type (Maris et al., 2006). Similarly, murine AM were reported to 
lack TLR9 (Suzuki et al., 2005). IM were reported to respond to LPS, indicating that they 
express TLR4 (Lohmann-Matthes et al., 1994; Bedoret et al., 2009). Both TLR9 and TLR7 
were highly expressed in plasmacytoid DCs of the human lung, whereas TLRs 1-4 were 
detected in human myeloid lung DCs (Holt et al., 2008). Tracheal, bronchial, and alveolar 
epithelial cells express most TLRs, including TLR1–6 as well as TLR9 (Mayer et al., 2007; 
Greene and McElvaney, 2005). Lung endothelial cells are equipped with TLR2, TLR4, 
TLR8 and possibly additional TLRs (Li et al., 2004; Fan et al., 2003). Furthermore, lung 
fibroblasts have been shown to express TLRs 2, 3, 4, and 9 (He at al., 2009; Meneghin et 
al., 2008; Sugiura et al., 2009), and airway smooth muscle cells were shown to respond to 
ligands of TLRs 2, 3, and 4 (Sukkar et al., 2006). 
 
1.3.4 TLRs and pulmonary inflammation 
TLRs play a key role in infections of the lung, but also in noninfectious diseases such as 
COPD and asthma. Specifically, the cell surface TLRs (e.g. TLR2, 4, and 5) are key 
players in immune responses to extracellular bacteria, whereas the endosomal TLRs 
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(TLR7–9) are particularly important in viral infections, but also contribute to host defence 
against bacterial infections. Mice deficient in the TLR adapter molecule MyD88 are highly 
susceptible to Streptococcus pneumoniae or Klebsiella pneumoniae infections due to an 
impaired immune response. Similar findings were reported for TLR4 or TLR9 knockout 
mice (Opitz et al., 2010). Furthermore, Mycobacterium tuberculosis bears agonists for 
several TLRs, such as TLR1/2 or TLR9. Accordingly, MyD88-/- mice fail to control the 
replication of M. tuberculosis H37Rv, resulting in reduced cytokine production, acute 
necrotic pneumonia and increased mortality (Scanga et al., 2004; Fremond et al., 2004). 
Interestingly, studies in mice and human macrophages suggested that exposure to 
tobacco smoke activates TLR4, either directly by smoke components or release of DAMPs 
upon cell injury. As a result, TLR4 activation might trigger chronic inflammation in COPD 
(Doz et al., 2008; Karimi et al., 2006). COPD patients also exhibit an increased 
susceptibility to pulmonary infections, e.g. with S. pneumoniae or Haemophilus influenzae. 
Infections with these and other pathogens are considered to contribute to chronic 
inflammation as well as acute excerbations. The increased pulmonary colonization with 
pathogens appears to be related to an impaired innate immune response in addition to a 
dysfunctional mucociliary clearance (Opitz et al., 2010). In line with those findings, AM 
isolated from bronchoalveolar lavage fluids from smokers and COPD patients were shown 
to express decreased levels of TLR2 and to produce less TNF- in response to TLR3 and 
4 ligands (Droemann et al., 2005; Gaschler et al., 2008), suggesting that TLRs are 
critically involved in the pathogenesis of COPD.  
The influence of TLRs on the pathogenesis of asthma presently remains elusive. A 
common mouse model for asthma is based on the combined inhalation of ovalbumin as an 
antigen and low dose LPS or dsRNA for sensitization and challenge. Exposure to 
ovalbumin alone does not result in sensitization, suggesting a critical role for TLRs 
(Eisenbarth et al., 2002; Bedoret et al., 2009; Schröder, 2009). However, epidemiologic 
studies focusing on TLR polymorphisms yielded conflicting results. For example, the 
Asp299Gly polymorphism of TLR4, which is found at a frequency of approximately 10% 
among whites and impairs cytokine induction by LPS, was either positively correlated to 
the prevalence of asthma in children, positively associated with milder forms of asthma, or 
not found to be related to the pathogenesis of asthma at all (Schröder, 2009). 
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1.4. Glucocorticoid-induced leucine zipper (GILZ) 
 
1.4.1 Structure 
The glucocorticoid-induced leucine zipper (GILZ) was originally identified as an anti-
inflammatory protein inducible by glucocorticoids in murine T-lymphocytes (D’Adamio et 
al., 1997). Later on, GILZ was found to mediate numerous glucocorticoid actions, mainly 
via direct interaction and subsequent inhibition of the transcription factors NF-B and AP-1 
(Ayroldi and Riccardi, 2009). 
The human GILZ gene, located on chromosome X, encodes a 135 amino acid (aa) protein. 
The similarity of the nucleotide sequence of human GILZ to murine GILZ is 89% in the 
entire mRNA and 97% in the coding region, and the human GILZ protein has been 
reported to be highly homologous to murine GILZ (Cannarile et al., 2001). Murine GILZ is 
a 137 aa protein with a molecular mass of 17 kDa, characterized by a leucine zipper (LZ) 
domain (76–97 aa) containing a heptad repeat of leucine residues, an N-terminal domain 
(1–75 aa) that, contrary to other leucine zipper family members, does not display an 
obvious DNA-binding sequence, and a C-terminal (98–137 aa), proline (P) and glutamic 
acid (E) rich (PER) region. GILZ homodimerization, by which GILZ becomes functionally 
active, occurs through the LZ domain via the formation of short parallel coiled-coil α-
helices (figure 4). Both GILZ homodimerization and the PER region have been reported to 
be necessary for GILZ interaction with the p65 subunit of NF-B (DiMarco et al., 2007).  
 
 
 
Figure 4: Correlation of GILZ protein sequence and homodimerization. Adapted fom DiMarco et al. 
(2007). NTD: N-terminal domain, LZ: leucine zipper, PER: proline and glutamic acid rich region. 
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Other GILZ isoforms were found in mice, but have not been described for human GILZ yet 
(Soundajaran et al., 2007; Bruscoli et al., 2010). 
The promoter region of human GILZ includes six glucocorticoid responsive elements 
(GREs), putative binding sites for signal transducer and activator of transcription 6 
(STAT6), nuclear factor of activated T cell (NFAT), Oct-1, c-myc, cyclic AMP response 
element-binding protein (CREB), Forkhead responsive elements (FHREs) and estrogen-
responsive sequences. GILZ induction by glucocorticoids involves interaction of the 
activated glucocorticoid receptor with the GRE sequences and might require additional 
activation of the transcription factor Forkhead box class O3 (FoxO3) (Ayroldi and Riccardi, 
2009).  
 
1.4.2 The diverse functions of GILZ 
GILZ plays a role in distinct cell functions, such as the inflammatory response, cell 
proliferation, and renal sodium transport (figure 5). It is constitutively expressed in many 
murine and human tissues and has been shown to be upregulated by glucocorticoids in 
numerous cell types, e.g. macrophages, monocytes, dendritic cells, B cells, T cells, and 
epithelial cells (Ayroldi and Riccardi, 2009). In addition, GILZ was reported to be induced 
by IL10 in macrophages (Berrebi et al., 2003) and by aldosterone in murine kidney cells 
(Ayroldi and Riccardi, 2009). 
Both glucocorticoids and IL10 attenuate inflammation and favour immune tolerance by 
deactivating macrophages and antigen-presenting cells. These actions are considered to 
be mediated to a significant extent via induction of GILZ (Berrebi et al., 2003; Eddleston et 
al., 2007; Ayroldi and Riccardi, 2009). GILZ impairs the inflammatory process mainly via 
inhibition of the nuclear translocation of NF-B by direct binding to the NF-B subunit p65 
(Berrebi et al., 2003; Ayroldi and Riccardi, 2009). GILZ was reported to inhibit AP-1 
activation in a similar fashion by interaction with its subunits c-fos and c-jun (Ayroldi and 
Riccardi, 2009). In this manner, GILZ decreases the expression of proinflammatory 
mediators, such as MIP1, TNF- or IFN, and inhibits TLR2 expression (Berrebi et al., 
2003; Gomez et al., 2010; Hirschfelder et al., 2010). Moreover, GILZ regulates T cell 
activation and development and redirects the maturation of dendritic cells, thereby 
preventing an antigen-specific T-cell response (Cohen et al., 2006; Ayroldi and Riccardi, 
2009). Interestingly, GILZ was reported to be downregulated in macrophages from 
inflammatory lesions of delayed-type hypersensitivity reactions, activated lymphocytes and 
Background 
 
 
 24
cytokine challenged epithelial cells (Ayroldi and Riccardi, 2009; Eddleston et al., 2007; 
Berrebi et al., 2003). 
The antiproliferative effects of GILZ, mainly described for T cells, are associated with its 
interaction with the small GTPase Ras and the kinase Raf. GILZ binds Ras and Raf in 
dimeric or trimeric complexes and diminishes the activation of Ras / Raf downstream 
targets, including extracellular-signal regulated kinase (ERK) 1/2 and Akt / protein kinase B 
(PKB), which results in inhibition of Ras and Raf dependent cell proliferation (Ayroldi and 
Riccardi, 2009). Accordingly, GILZ was reported to mediate the antiproliferative effects of 
glucocorticoids in multiple myeloma (Grugan et al., 2008).  
 
 
 
Figure 5: The diverse functions of GILZ expression. Modified after Ayroldi and Riccardi (2009). See text 
for details. AL: aldosterone; GC: glucocorticoid; MR: mineral corticoid receptor; GR: glucocorticoid receptor; 
eNaC: epithelial sodium channel.  
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The role of GILZ in oncogenesis, however, is poorly understood. In contrast to the reports 
mentioned above, GILZ expression was shown to promote proliferation in epithelial 
ovarian cancer (Redjimi et al., 2009). Moreover, tumor infiltrating macrophages in Burkitt 
lymphomas were reported to express high levels of GILZ. Thus, GILZ expression in tumor 
associated macrophages might contribute to immune tolerance, thereby helping the tumor 
to avoid detection by the immune system (Berrebi et al., 2003).  
Besides its influence on inflammation and cell proliferation, GILZ also modulates epithelial 
sodium transport in the kidney. GILZ, induced by alsosterone, inhibits ERK phoshorylation, 
leading to increased expression of the epithelial sodium channel (eNaC) and thus 
stimulates eNaC mediated sodium transport (Ayroldi and Riccardi, 2009; figure 5). 
 
1.4.3 GILZ in pulmonary inflammation 
The highest GILZ expression throughout the human body is found within the lung, 
indicating that GILZ plays an important role in respiratory immune homeostasis (Berrebi et 
al., 2003; Cannarile et al., 2001). The fact that GILZ is able to trigger pathways central to 
inflammation, such as TLR signalling, underlines that thesis. However, only few studies 
described the effects of GILZ expression within the respiratory tract.  
GILZ was recently shown to be constitutively expressed in airway epithelial cells and to 
mediate NF-b dependent glucocorticoid actions in this cell type. Moreover, GILZ is 
downregulated by cytokines involved in airway inflammation (Eddleston et al., 2007). 
Alcohol abuse and smoking are both considered to predispose individuals to infections by 
bacteria, fungi and viruses (van der Haart et al., 2004; Nelson and Kolls, 2002), although 
the mechanisms underlying this phenomenon are not entirely clear. Interestingly, cigarette 
smoke was reported to induce GILZ expression while attenuating TLR3 signalling in airway 
epithelial cells (Lee et al., 2009). In rats, chronic ethanol ingestion was shown to diminish 
inflammatory cytokine production of AM (D'Souza et al., 1996). Accordingly, exposure of 
airway epithelial cells to ethanol leads to a reduced responsiveness to inflammatory 
stimuli, whereas GILZ was upregulated, and overexpression of GILZ partially mimicked the 
anti-inflammatory actions of ethanol in these cells (Gomez et al., 2010). These findings 
suggest that GILZ upregulation might contribute to pulmonary immune suppression due to 
smoking and chronic alcohol abuse. 
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1.5. Aim of the present work 
 
Inflammatory processes in the lung caused by infections or tissue damage are often 
associated with TLR-mediated activation of lung macrophages. The primary function of 
macrophages in the innate immune response is to contain and kill invading microbial 
pathogens, which is achieved by a series of rapid and coordinated responses. 
Macrophages have a potent antimicrobial arsenal that includes reactive oxygen and 
nitrogen species, proteolytic enzymes and cationic micobicidal proteins. Under 
pathological circumstances, however, unregulated release of microbicidal compounds into 
the extracellular space can damage host tissues. In contrast, an impaired immune 
response leads to persistance of the infection and prevents recovery. Thus, macrophage 
actions can both be beneficial or detrimental to the host. Aim of the present work was to 
elucidate macrophage actions upon TLR activation, as an understanding of the 
mechanisms involved might help to develop strategies for the therapy of diseases resulting 
from unbalanced macrophage activation. The three sections of this thesis focus on distinct 
aspects of TLR activation in macrophages. 
 
I. 
In tuberculosis, AM are the first line of host defence against mycobacteria. However, an 
insufficient host response allows survival of bacteria within macrophages. Thus, the first 
part of this work focuses on the role of TLR9 activation in macrophage defence against 
mycobacteria. 
 
II. 
Investigations on pulmonary macrophages mostly focus on AM as a well-defined cell 
population, whereas characteristics of IM are rather ill-defined. In the second part of the 
present study, we therefore aimed to examine differences between AM and IM obtained 
from human lung tissue. 
 
III. 
Induction of glucocorticoid-induced leucine zipper (GILZ) by glucocorticoids is critical for 
their anti-inflammatory action, whereas GILZ expression is reduced under inflammatory 
conditions. The mechanism regulating GILZ expression during inflammation, however, has 
not yet been fully characterized. Therefore, we aimed to examine GILZ expression in 
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primary human alveolar macrophages under inflammatory conditions, i.e. following Toll-
like receptor activation. The results of our investigations are presented in the third and final 
part of this work. 
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2.1 Introduction 
 
Mycobacterium tuberculosis is an intracellular pathogen that can persist and propagate 
within human macrophages. Control and resolution of mycobacterial infections has been 
shown to depend on a coordinated innate and adaptive immune response, primarily 
involving macrophages and CD4+ T cells, respectively (Doffinger et al., 2006). Over the 
last several years, TLRs have emerged as important transducers of the innate immune 
response (Kawai and Akira, 2006; Opitz et al., 2010). Although DNA isolated from 
mycobacteria was the first DNA to be shown to induce immunostimulatory action in 
mammalian cells more than 25 years ago (Shimada et al., 1985; Tokunaga et al., 1984), 
the relevance of TLR activation by mycobacterial DNA during tuberculosis infection has 
only recently been a matter of interest (Bafica et al., 2005; Juarez et al., 2010). 
Bacterial DNA is now recognized as the natural ligand for toll-like receptor 9 (TLR9) 
(Hemmi et al., 2000; Schneberger et al., 2010). What distinguishes bacterial from 
mammalian DNA is its highly increased content of undermethylated 5’-CG-3’ sequences, 
usually referred to as CpG. The frequency of the base sequence CG is suppressed in 
mammals. 
In addition to these differences in the frequency of CpG sequences between bacterial and 
mammalian DNA, there are also differences in the methylation state of the DNA. Whereas 
most CpG sequences in mammalian DNA are methylated, practically all bacterial CpG 
sequences are non-methylated. Non-methylated CpG sequences within defined motifs 
have been shown to bind to and signal via intracellular TLR9 (Leifer et al., 2004; Latz et 
al., 2004).  
Whether human monocytes or human macrophages express functional TLR9 and 
therefore can be activated by bacterial DNA or synthetic CpG oligonucleotides has been 
controversial (Miettinen et al. 2001; Hornung et al., 2002; Doyle et al., 2004; Takeshita et 
al., 2004). Evidence that these mononuclear phagocytes do not express TLR9 was 
supported by a study showing lack of responsiveness of primary monocyte-derived 
macrophages and THP-1 cells towards CpG oligonucleotides (Remer et al., 2006). While 
activation of human monocytes by CpG had been described (Hartmann and Krieg, 1999), 
this activation was suggested to depend on a contamination of the primary monocyte 
preparation with plasmacytoid dendritic cells (Hornung et al., 2005). Other data, however, 
argue in favour of the presence of TLR9 in cells of the human monocytic lineage 
(Sawamura et al., 2005; Fenhalls et al., 2003; Hoene et al., 2006; Mao et al., 2005; Juarez 
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et al., 2010) and reveal that bacterial DNA might represent a much better stimulus for 
TLR9 activation in macrophages than CpG oligonucleotides (Roberts et al., 2005a). 
Moreover, low but readily detectable levels of TLR9 mRNA in THP-1 macrophages, 
monocyte-derived macrophages, and AM were previously found by our group. TLR9 
protein was also clearly detectable in THP-1 macrophages, human monocyte-derived 
macrophages, and human AM.  
Thus, TLR9 activation by mycobacterial DNA could influence the innate response of 
macrophages to infection. Therefore, we sought to clarify the impact of mycobacterial DNA 
on macrophage function.  
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2.2 Results 
 
2.2.1 Human macrophages are responsive to bacterial DNA 
We first tested whether TLR9 in human macrophages was functional by determining 
whether macrophages were responsive to stimulation with TLR9 ligands. Monocyte-
derived human macrophages were treated with different concentrations of a CpG-
containing oligonucleotide (phosphorothioate-modified immunostimulatory sequence ISS 
1018, 5'-TGA CTG TGA ACG TTC GAG ATG A-3′), then induction of cytokine mRNA was 
measured by real-time RT-PCR. While we observed a dose-dependent increase in TNF- 
mRNA (figure 6 A), the extent of cytokine induction observed was relatively weak 
compared to the increase of cytokine induction in other TLR9 ligand-responsive cells (Krug 
et al., 2001). 
Employment of a different ISS (ODN 2006, sequence: 5’-TCG TCG TTT TGT CGT TTT 
GTC GTT-3’) also resulted in a low but significant induction of TNF- at a concentration of 
10 µg/ml, whereas the respective GC-control (sequence: 5’- TGC TGC TTT TGC TTT TGT 
GCT T -3’) did not induce TNF- in the highest concentration tested (figure 6 C). This 
suggests that the activatory potential of ISS is not due to an unspecific effect of 
phosphorothioate groups. 
Since bacterial DNA has previously been reported to be a much stronger inducer of TLR9-
dependent responses in macrophages compared to CpG-containing oligonucleotides 
(Roberts et al., 2005a), we assessed the impact of genomic DNA (isolated from the 
attenuated M. bovis BCG strain) as an alternative activator of TLR9 (Tokunaga et al., 
1984). Interestingly, we saw a markedly higher TNF- response in human macrophages 
treated with BCG DNA compared to treatment with ISS (figure 6A). We also confirmed that 
stimulation of macrophages with BCG DNA caused a marked induction of other cytokine 
mRNAs, such as IP10 as well as IL12 and IL10 (figure 6 B, Kiemer et al., 2009). 
Indeed, the fold-induction of IP10 mRNA by BCG DNA was even greater than that 
observed for TNF- (figure 6 B). 
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Figure 6 : Activation of human monocyte-derived macrophages by immunostimulatory 
oligonucleotides and mycobacterial DNA – A, B: Primary monocyte-derived macrophages were left 
untreated (Co) or treated with immunostimulatory sequences (ISS 1018) or with genomic DNA from M. bovis 
BCG for 3 h in the indicated concentrations (0.1-10 µg/ml). C: Cells were treated for 3 h with ODN2006 (10 
µg/ml), the respective GC-control (10 µg/ml) or left untreated (Co). Treatment was followed by real-time RT-
PCR analysis for TNF- (A, C) or IP10 (B). Values were normalized to the housekeeping gene -actin. Data 
are expressed as x-fold induction with expression levels of untreated cells set as 1. Data show means ± SEM 
from two experiments with cells from different donors performed in triplicate. * P < 0.05 compared to Co. 
 
 
The differences in the extent of activation seen between BCG DNA and ISS DNA were not 
due to differences in the kinetics of the cytokine mRNA induction since induction time 
patterns were comparable for ISS and BCG DNA (figure 7).  
Although we did observe an inter-experiment variability in the extent of macrophage 
activation depending on the blood donor, the intra-experiment variability was low. Thus, we 
always stimulated macrophages with ISS and mycobacterial DNA on the same day using 
the same macrophage preparation in order to allow direct comparison. All experiments 
show means from two or three cell preparations performed in triplicate, each. 
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Figure 7: Time patterns for ISS and BCG DNA induced activation – Primary monocyte-derived 
macrophages were left untreated (Co) or treated with either ISS1018 (10 µg/ml, A) or genomic DNA from M. 
bovis BCG (5 µg/ml, B) for the indicated times (1-16 h). Treatment was followed by real-time RT-PCR for 
TNF-. Data were normalized to b-actin and are expressed as x-fold induction with Co values set as 1. Data 
show means ± SEM from two experiments performed in triplicate. * P < 0.05 compared to Co. 
 
 
We then performed several experiments to demonstrate that the activation of human 
macrophages by BCG DNA was due to DNA and not evoked by contaminants. Potential 
contamination of the DNA preparations with endotoxin was assessed using a commercially 
available endotoxin assay (Limulus Amoebocyte Lysate, LAL) with a detection sensitivity 
of 0.03 EU/ml. None of our DNA preparations showed any reactivity using this sensitive 
assay. Additional controls were performed in order to exclude effects from other potential 
contaminants, most likely TLR2 agonists as mycobacterial cell wall components. First, we 
co-treated cells with the TLR9 inhibitor chloroquine, which does not interfere with TLR2 
activation (Rutz et al., 2004; Sanjuan et al., 2006), together with BCG DNA. Chloroquine 
completely abrogated TNF- induction by BCG DNA treatment whereas it had no effect 
when given to the cells alone (figure 8 A). 
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The effects of chloroquine were not due to impaired macrophage viability, as assessed by 
MTT assay (figure 8 B). As a complementary control, we methylated cytosine residues 
(C5) on BCG DNA with SssI methylase. As expected, methylation of the cytosine residues 
largely abrogated TNF- mRNA induction by our DNA preparation (figure 8 C). Taken 
together, these experiments strongly support the interpretation that it is the DNA itself that 
mediates the profound effect of mycobacterial DNA preparations on macrophage 
activation, and that this effect is transduced through its interaction with TLR9. 
 
 
 
 
Figure 8: Activation by DNA preparations is specific for non-methylated DNA – A, C: DNA from M. 
bovis BCG mycobacteria was added to primary monocyte-derived macrophages for 3 h, followed by real-
time RT-PCR for TNF-. Expression levels for TNF-were normalized to -actin and data are expressed as 
x-fold TNF- induction. Data show means ± SEM of two or three experiments performed in triplicates, each. 
A: Cells were either left untreated (Co), or treated with chloroquine (CQ, 10 µM), BCG DNA (5 µg/ml) or a 
combination of both whereby CQ was added to the cells 1 h before BCG DNA. B: Monocyte-derived 
macrophages were either treated with CQ (10 µM) or left untreated (Co) for 20 h and an MTT assay was 
performed. In addition, cells were treated with 10% [v/v] ethanol (EtOH) to confirm the functionality of our 
assay. Viability is expressed as percentage of absorbance of untreated cells. Data show means ± SEM of n 
= 10. C: DNA from BCG mycobacteria was methylated with SssI methylase. In vitro differentiated 
macrophages were either left untreated (Co), mock treated (inactivated methylase and respective buffers 
only), or treated with methylated or respectively mock-treated (w/o methylase) DNA. * P < 0.05. 
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Next, we wondered how the differences in activation by ISS and BCG DNA preparations 
can be explained, since the chemical nature of the stimulants is comparable. As the sole 
distinction is the difference in molecule lengths, we hypothesized that the difference in 
activation might be related to different uptake mechanisms. Since macrophages represent 
a cell type well equipped with phagocytic and endocytic capacity, we speculated that 
macromolecular DNA might spontaneously form nanoparticulate structures (Kerkmann et 
al., 2005), which can be taken up into the cells by a mechanism involving the actin 
cytoskeleton. We therefore aimed to test whether genomic DNA containing 
macromolecular DNA molecules formed nanoparticulate structures leading to an increased 
activatory profile. Atomic force microscope measurements of the two DNA preparations 
were performed in collaboration with Prof. Karin Jacobs (Saarland University, Department 
of Physics) according to a previously described method (Kerkmann et al., 2005). The 
experiments revealed that the large genomic DNA molecules in fact spontaneously formed 
nanoparticles, whereas oligonucleotides did not (figure 9 A - C). 
Inhibition of actin polymerization by cytochalasin D attenuated BCG DNA-induced TNF- 
expression (figure 9 D), suggesting that the cytoskeleton is involved in the activation 
mechanism induced by BCG DNA particles, most likely by mediating their uptake. 
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Figure 9: Activation of macrophages by nanoparticular BCG DNA requires actin polymerization – A-
C: Macromolecular DNA spontaneously forms nanoparticles. A - B: AFM analysis of DNA dried from a 
solution of 6 mg/ml in PBS on MgCl2 pretreated mica. Measurement was performed in dynamic mode (5 x 5 
µm). A: oligonucleotide DNA (ISS1018) B: genomic macromolecular BCG DNA. White dots represent 
nanoparticulate DNA aggregates (detected by height). C: Number of particles of macromolecular BCG DNA 
on an area of 5 x 5 µm vs. diameter. D: AM were left untreated (Co) or treated with BCG DNA for 2 h with or 
without pretreatment with the actin polymerization inhibitor cytochalasin D (CytD, 10 µM, 30 min) followed by 
real-time RT-PCR quantification of TNF-. Values were normalized to the housekeeping gene -actin. Data 
are expressed as x-fold induction with expression levels of untreated cells set as 1. Data show means ± SEM 
from two experiments. * P < 0.05 compared to Co. AFM imaging was performed by Ralf Jungmann 
(Saarland University, Department of Physics). 
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2.2.2 Different potency of mycobacterial DNA to activate human macrophages 
Data obtained within a collaboration of our group with the group of Lee W. Riley (UC 
Berkeley) had shown that intracellular replication of attenuated mycobacteria (H37Ra) was 
higher in TLR9-deficient mouse macrophages than in wild-type macrophages, whereas 
virulent mycobacteria (H37Rv) showed equal survival in wild-type or mutant cells. 
Increased bacterial survival was accompanied by altered cytokine production. In vivo 
infection experiments also showed differential cytokine production in TLR9-deficient mice 
compared to wild-type animals (Kiemer et al., 2009) 
We reasoned that there could be several mechanisms explaining the differences in 
macrophage activation in response to acute infection with H37Rv versus H37Ra 
mycobacteria as well as the diminished activation of macrophages in TLR9 deficient  
macrophages versus wild-type macrophages following infection with H37Ra mycobacteria. 
One possibility is that virulent mycobacteria fail to activate TLR9 because less efficient 
intracellular bacterial killing of the virulent organisms results in less free genomic DNA able 
to interact with intracellular TLR9.  
Alternatively, DNA from virulent bacteria could have less potency to activate human 
macrophages than DNA from attenuated bacteria. To discriminate between these possible 
mechanisms, we isolated DNA from virulent and attenuated mycobacteria, and then 
treated human AM with equal concentrations of the different DNA preparations. 
Remarkably, DNA from attenuated mycobacteria (H37Ra and M. bovis BCG) consistently 
stimulated a more vigorous macrophage TNF-response than did DNA from virulent 
mycobacteria (H37Rv, figure 10 A). This observation was also confirmed in human 
monocyte derived macrophages (Kiemer et al., 2009). In order to check whether the action 
of H37Ra DNA preparations results in fact from its DNA content and not from any 
contaminants, H37Ra DNA was digested with DNase. The effect of this preparation was 
compared to the stimulatory potency of non-digested DNA. We saw that digestion in fact 
abrogated the ability to stimulate TNF- mRNA when added to human macrophages 
(figure 10 B). Taken together, our data suggest that virulent mycobacteria have evolved a 
mechanism of attenuated TLR9 activation by their genomic DNA. 
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Figure 10: Activation of human macrophages by DNA from virulent and attenuated mycobacteria – 
AM were treated with DNA from the virulent M. tuberculosis (H37Rv) strain or from the attenuated H37Ra 
and M. bovis BCG strains for 2 h. Subsequently, real-time RT-PCR analysis for TNF- was performed. Data 
are expressed as TNF- induction after normalization to -actin expression. Data show means ± SEM of four 
experiments with cells obtained from 2 donors. B: DNA was isolated from H37Ra mycobacteria and digested 
with DNase. Primary monocyte-derived macrophages were either left untreated (Co), mock treated 
(inactivated DNase and respective buffers only) or treated with digested or respectively mock-treated (w/o 
DNase) DNA followed by RNA isolation and real-time RT-PCR analysis for TNF-. Data are expressed as x-
fold TNF- induction after normalization to -actin values. Data show means ± SEM of four experiments (A) 
or two experiments performed in triplicate (B). * P < 0.05. 
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2.3 Discussion 
 
Control of infection by Mycobacterium tuberculosis requires an effective combined innate 
plus adaptive immune response by the host. The innate response mounted by infected 
macrophages and the adaptive CD4 T-cell response are key contributors to an effective 
host defence (Doffinger et al., 2006). Studies using MyD88 null mice have demonstrated 
that TLR signalling plays a critical role in the success of the innate host response (Scanga 
et al., 2004; Fremond et al., 2004). The specific role of individual TLRs, however, remains 
elusive. The results presented within this chapter and in Kiemer et al. (2009) suggest that 
TLR9, the sensor for bacterial CpG DNA, plays an important role in shaping the innate 
macrophage response to mycobacterial infection. 
 
2.3.1 Responsiveness of human macrophages towards mycobacterial DNA 
Several reports had suggested that human monocytic cells contained functional TLR9 
receptors. Sawamura et al. (2005) showed that monocytes were primarily responsible for 
the inflammatory reaction induced by injection of plasmid DNA into human skin. Mao et al. 
(2005) reported that human monocytes showed marked responsiveness to CpG 
stimulation, and two groups reported THP-1 monocytes as target cells for ISS (Sanjuan et 
al., 2006; Kuo et al., 2005). Furthermore, addition of CpG sequences was demonstrated to 
attenuate growth of virulent Mycobacteria tuberculosis (Erdman) in human monocyte-
derived macrophages (Wang et al., 2005). Our group had previously shown that that 
human monocyte-derived macrophages express TLR9. Here, we demonstrate that they 
are activated by treatment with bacterial DNA. Interestingly, we found that human 
macrophages respond far more vigorously to bacterial DNA than they do to CpG ODNs at 
the same concentration. Many of the published effects ascribed to specific CpG 
sequences were recently proven to be due to CpG-independent effects of phosphodiesters 
(Roberts et al., 2005b). As shown by the employment of GpC ODN controls, such non-
specific effects seem to be of little importance in human macrophages, leading to a weak 
activation by the use of phosphorothioate-modified ISS. In addition, multimerization of 
DNA has been reported crucial for optimal TLR9 activation, suggesting that genomic DNA 
has a higher potential of aggregation (Wu et al., 2004). This was confirmed by the 
observation that bacterial genomic DNA is much more efficient than oligonucleotides in 
activating mouse macrophages (Roberts et al., 2005a). Here, we show for the first time 
that such a difference can also be observed in human macrophages.  
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The differential activatory potential of CpG DNA preparations, either dissolved, 
oligonucleotide DNA or nanoparticulate genomic DNA, seems to be related to different 
uptake/interaction modes, as inhibition of actin polymerization by cytochalasin D 
attenuated BCG DNA-induced TNF-expression. Ongoing work in our group supports this 
suggestion: first data demonstrate that exposure of macrophages to genomic 
nanoparticulate DNA induces stronger actin polymerisation than oligonucleotide treatment 
(Robert Zarbock, Saarland University, Pharmaceutical Biology, unpublished data).  
Besides monocyte-derived macrophages, we also show TLR9-mediated activation of 
human AM after stimulation with bacterial DNA. This contrasts to the report by Suzuki et 
al. (2005) who described impaired TLR9 signalling in mouse alveolar macrophages 
despite detectable TLR9 expression. Like other publications that failed to find evidence of 
TLR9 signalling in human monocytes or macrophages (Hornung et al., 2002; Remer et al., 
2006; Doyle et al., 2004), Suzuki et al. only tested the effect of CpG ODNs - not of larger, 
bacterial DNA. Thus, the use of the suboptimal stimulus might explain the lack of 
responsiveness. The use of bacterial DNA in fact seems to more adequately reflect the in 
vivo situation. This notion is largely supported by the demonstration of different responses 
of macrophages obtained from TLR9 deficient mice towards mycobacterial infection 
compared to cells from wild-type animals (Kiemer et al., 2009). In addition, theoretical 
calculations indicate that the small volume of endosomes (the organelle known TLR9 
signalling takes place in) promotes signalling even from a limited number of TLR agonists 
(Crozat and Beutler, 2004).  
 
2.3.2 Differential activatory potential of mycobacterial DNA 
Previous studies done in our group in collaboration with The Scripps Research Institute 
(La Jolla, USA) and the University of California (Berkeley) indicated that macrophage 
TLR9 activation in fact plays a role in mycobacterial infection. When macrophages from 
wild-type (C57BL/6) or TLR9 deficient (TLR9CpG1/CpG1) mice (Tabeta et al., 2004) were 
infected with mycobacteria, there was no difference in intracellular replication of the 
virulent H37Rv strain between wild-type and TLR9-deficient macrophages. This result 
corroborates an in vivo study demonstrating that TLR9 deficient animals did not show 
differences in survival compared to wild-type animals when infected with a low dose of 
H37Rv (Bafica et al., 2005). In contrast, when macrophages were infected with the 
attenuated H37Ra strain, bacteria replicated much faster in TLR9CpG1/CpG1 macrophages 
than in wild-type cells. The TLR9CpG1/CpG1 macrophages also showed a distinct activation 
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pattern compared to wild-type macrophages one day after infection, indicating an impaired 
TLR9 activation. Interestingly, knockdown of TLR9 lead to completely different cytokine 
responses upon infection with H37Ra or H37Rv. Whereas TLR9CpG1/CpG1 mice displayed 
reduced cytokine production after H37Ra infection, it was increased after H37Rv infection. 
This observation definitely shows differences in TLR9 activation between virulent and 
attenuated mycobacterial strains (Kiemer et al., 2009).   
Taken together, the infection data suggest that virulent H37Rv mycobacteria elicit an 
altered TLR9 response compared to attenuated H37Ra mycobacteria. Here, we stimulated 
AM with DNA preparations made from virulent (H37Rv) or attenuated (H37Ra and M. 
bovis BCG) mycobacteria to address the mechanism underlying this difference. We 
demonstrated that DNA from attenuated mycobacteria is more efficient in activating AM 
than DNA from virulent mycobacteria, thus confirming previous findings for monocyte 
derived macrophages (Kiemer et al., 2009). These results might explain data from the 
literature reporting that the ability of mycobacteria to induce the secretion of TNF- is 
inversely related to their virulence in murine macrophages (Falcone et al., 1994). 
 
2.3.3 What distinguishes DNA from virulent and attenuated mycobacteria 
A recent genome-wide screening analyzed immunostimulatory sequences in genomic 
mycobacterial DNA (Lee et al., 2006). The data showed that not only the CpG motifs but 
also the context of the sequence surrounding the CpG motif are important for the 
immunostimulatory activities of genomic DNA of M. bovis. The generally higher CG 
content in Mycobacteria compared to other bacteria, such as E. coli (65% vs. 51%) 
together with an even higher frequency of CpG sequences in mycobacteria compared to 
E. coli suggested a specifically high potential of mycobacteria to activate TLR9. Since the 
different mycobacterial strains have a >99% DNA homology and possess a comparable 
CG content of about 65% (Baess et al., 1978; Garnier et al., 2003), one might wonder how 
differences in the extent of TLR9 activation can occur between genomic DNA from 
different strains. There are at least three possible explanations for the observed 
differences in the efficiency of TLR9 activation by different mycobacterial DNA: (I) 
attenuated strains might have a reduced frequency of activatory CpG sequences based on 
subtle differences in the surrounding DNA sequences; (II) virulent strains might have an 
increased number of immunosuppressive DNA sequences in their genomes; or (III) 
virulent strains may have developed strategies to mask their CpGs, such as by expressing 
DNA methylases. Since the genomes of attenuated strains have not been sequenced yet, 
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whole-genome sequence comparisons cannot be performed in order to check hypotheses 
(I) and (II). Most interestingly, however, data from the literature suggest that the virulent 
H37Rv strain is able to methylate cytosines whereas the H37Ra strain is not (Srivastava et 
al., 1981; Hemavathy et al., 1995). This observation might explain why DNA from virulent 
strains has a lower potential to activate TLR9 in human macrophages than DNA from 
attenuated strains. 
 
Taken together, these studies establish that human macrophages express functional 
TLR9, and suggest suggest that signalling through TLR9 contributes to the innate 
macrophage response to infection by mycobacteria. Furthermore, the differences between 
the stimulatory activities of DNA from virulent versus attenuated mycobacteria indicate that 
TLR9-induced macrophage activation may influence the host’s ability to limit and then kill 
intracellular mycobacteria. The altered TLR9 activation by virulent mycobacteria might 
represent a mechanism how they evade the host immune response.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parts of the results presented in this chapter have been published in:  
 
Attenuated activation of macrophage TLR9 by DNA from virulent mycobacteria. 
Kiemer AK, Senaratne RH, Hoppstädter J, Diesel B, Riley LW, Tabeta K, Bauer S, Beutler 
B, Zuraw BL. J Innate Immun 2009; 1:29-45. 
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3.1 Introduction 
 
AM play a central role in pulmonary innate immune response against inhaled particles and 
pathogens due to their localization in the lung alveoli. Besides their function in the defence 
against infectious diseases, they are known to play a role in inflammatory airway diseases, 
such as COPD (Barnes, 2004) and to participate in the dysregulation of immune 
responses in allergic disease (Vissers et al., 2004). In contrast to AM as a rather well-
defined macrophage population commonly obtained by bronchoalveolar lavage (BAL), little 
is known about another potential macrophage-like cell population in human lungs, which 
are commonly referred to as interstitial macrophages (IM).  
Studies using primary rat or mouse macrophages suggest that AM display a high 
microbicidal and phagocytic potential and produce numerous pro-inflammatory and 
chemotactic mediators upon activation. In contrast, rodent IM have been reported to be 
less effective in Fc-receptor-independent phagocytosis, production of cytokines such as 
TNF-α or interferon (IFN)-α/β, and production of reactive oxygen and nitrogen 
intermediates. In contrast, accessory function and MHCII expression have been suggested 
to be increased compared to AM (Lohmann-Matthes et al., 1994; Laskin et al., 2001; 
Ferrari-Lacraz et al., 2006; Bedoret et al., 2009). The relevance of these observations in 
humans has not been described in the literature. One of the very few studies investigating 
functional differences between human AM and IM describes a higher phagocytic activity of 
AM compared to IM (Fathi et al., 2001). Moreover, a higher production of matrix 
metalloproteinases in IM compared to AM has been reported (Ferrari-Lacraz et al., 2001), 
indicating that IM might play a more pronounced role in tissue remodelling. 
Lung DC have recently gained marked scientific interest. This cell type resides in small 
numbers in the lung interstitial tissue in close proximity to both the large airways and the 
alveoli and is specialized for antigen presentation and accessory function (Lohmann-
Matthes et al., 1994; Cochand et al., 1999). A study using mouse models only recently 
revealed that IM are able to inhibit maturation and migration of lung dendritic cells (Bedoret 
et al., 2009). This makes IM the cell type responsible for the suppression of allergic 
reactions towards harmless antigens. The relevance of these findings for humans, 
however, needs to be confirmed. 
In order to investigate the role of AM and IM in the pathogenesis of human lung disease, 
aim of the present study was to characterize respective cell populations isolated from 
human lung tissue. Since TLRs represent key mediators of infectious as well as non-
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infectious lung disease (Doffinger et al., 2006; Rohde et al., 2006; Opitz et al., 2010), a 
special focus was laid on potential differences in AM and IM with respect to activation via 
TLR4 and TLR9. 
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3.2 Results 
 
3.2.1 Cell number and appearance 
The AM and IM fractions obtained from 30 – 50 g of human non-tumor lung tissue from 
patients undergoing lung resection each contained 2-20 x 106 cells, with the number of IM 
being equal to or exceeding the number of AM. The overall viability of cells obtained by 
washing or enzyme digestion of lung tissue was > 90% as determined by trypan blue 
staining. 
Both AM and IM preparations almost exclusively contained highly auto-fluorescent cells 
compared to low fluorescent cells like DC, as observed by flow cytometry and 
fluorescence microscopy (data not shown).  
AM populations consisted mostly of large, round cells heterogeneous in size whereas IM 
appeared to be smaller, but more heterogeneous in shape compared to AM as observed 
by light microscopy (figure 11 A). FACS analysis assessing FSC confirmed the smaller 
size of IM (figure 11 B). 
 
 
 
Figure 11: Morphology of AM and IM – A: Macrophage visualization by Pappenheim staining. Images are 
representative for cell preparations from at least two different donors. C: Comparison of macrophage sizes 
by forward scatter as measured by flow cytometry. Light grey line: IM; filled / dark grey: AM.  
 
Chapter II 
 
 
 50
Phenotypic differences could be seen directly after isolation and persisted for at least 5 
days. As tissue macrophages isolated by enzyme perfusion have been shown previously 
to require several days to recover surface receptor functionality (Kiemer et al., 2002), cells 
were cultured 3-4 days before use for further experiments. 
Since the presence of fibroblasts can alter phagocyte functions (Chomarat et al., 2000; 
Oshikawa et al., 2003), we determined a potential contamination with this cell type. 
However, neither AM nor IM exhibited a significant contamination with fibroblasts as 
shown by immunostaining of CD90 (figure 12). This surface marker is highly expressed in 
fibroblasts (Kunisch et al., 2004; Pilling et al., 2009), as we confirmed for the human 
fibroblast cell lines MRC-5 and HSF-1. In contrast, CD90 is expressed only to a very low 
extent in macrophages, as was shown in the literature (Kunisch et al., 2004; Pilling et al., 
2009) and confirmed by ourselves in human differentiated THP-1 macrophages. CD90 
staining of AM and IM preparations revealed that mean percentages of CD90 positive cells 
were very low (0.9 ± 0.5 % in AM vs. 1.3 ± 0.5 % in IM) and did not significantly differ 
between the two cell types. 
 
 
 
Figure 12: CD90 surface expression of macrophages and fibroblasts – AM, IM, fibroblasts (MRC-5 and 
HSF-1 cell lines) and macrophage-like PMA-differentiated THP-1 cells were stained for CD90 and analyzed 
by flow cytometry. Filled / dark grey: isotype control; light grey line: antibody staining. MFI values are given 
within graphs. Data show one representative out of three independent experiments. AM and IM were 
obtained from three different donors.  
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3.2.2 Expression of intracellular and surface markers 
In order to define potential phenotypic differences between AM and IM, we analyzed their 
expression of the cell-surface molecules CD14 and human leukocyte-associated antigen-
DR (HLA-DR). Moreover, the expression of surface markers CD83 and CD1a as well as 
intracellular CD68 in both populations was compared to in vitro differentiated immature 
and mature dendritic cells (iDC and mDC). Among the cell–surface molecules studied, 
only the expression of HLA-DR displayed significant differences between IM and AM, 
whereas CD14 expression was low or not detectable in both cell types. With respect to 
donor dependent differences in absolute mean fluorescence intensity (MFI) values, HLA-
DR-expression in IM was almost 3-fold higher than in AM (figure 13 A and B). 
 
 
 
Figure 13: CD14 and HLA-DR expression – AM and IM were stained and analyzed by flow cytometry. A: 
Data show one representative out of four independent experiments. Filled / dark grey: isotype control; light 
grey line: antibody staining. B: Comparison of AM and IM concerning CD14 and HLA-DR expression. Data 
are expressed as MFI related to AM values. Data show means ± SEM of independent experiments with cells 
derived from four different donors. * P < 0.05 compared to AM values.  
 
 
CD68, often used as a specific marker for macrophages (Bedoret et al., 2009; Holness 
and Simmons, 1993; Kôhalmi et al., 1996) was highly expressed in both AM and IM, but 
could also be found in iDC as well as mDC. The dendritic cell markers CD1a and CD83 
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were not detectable in AM and IM (figure 14). These data suggest that IM share many 
phenotypic characteristics with AM, whereas no similarities to dendritic cells were 
observed. 
 
 
 
Figure 14: Expression of CD68, CD83 and CD1a – AM and IM as well as in vitro differentiated iDC and 
mDC were stained and analyzed by flow cytometry. Filled / dark grey: isotype control; light grey line: 
antibody staining. MFI values are given within graphs. Data show one representative out of three 
independent experiments with cells originating from different donors.  
 
 
3.2.3 Phagocytosis 
The internalization of fluorescent latex beads was quantified by flow cytometry. After 
incubation with fluorescent particles for 4 h, about two thirds of both macrophage 
populations had internalized fluorespheres. Particle uptake was significantly lowered by 
pretreatment of the cells with cytochalasin D or incubation with fluorospheres at 4°C, but it 
was not abrogated completely (figure 15 A and B). This might be due to particle 
attachment to the cell surface, which can not be distinguished from internalization by flow 
cytometry. Therefore, fluorosphere uptake was visualized by confocal laser scanning 
microscopy. Upon incubation with the fluorescent particles for 4 h, most macrophages had 
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internalized several fluorospheres. As most of the particles were found to be internalized 
and not attached to the surface, quenching was supposed not to be necessary for flow 
cytometry analysis.  
 
 
 
Figure 15: Phagocytic Activity – AM and IM were cultured with fluorescent FITC-labeled microspheres for 
4 h at 37°C. As a control, cells were pretreated with cytochalasin D (10 µg/ml, CytD) for 1 h prior to particle 
addition. Alternatively, cells were preincubated at 4°C for 1 h and incubated with microspheres for 4 h at 4°C 
afterwards. Experiments were performed with cells derived from at least three different donors. A, C: 
representative results are shown. A: Fluoresphere-associated fluorescence (marked with black bars) was 
detected in AM and IM using flow cytometry. B: Average of percentage of macrophagespositive for 
fluorosphere-associated fluorescence. Data represent mean ± SEM. * P < 0.05 as compared to cells left 
untreated at 37°C. C: Particle uptake in AM and IM was visualized by CLSM. F-actin was stained with 
rhodamin-phalloidine (red), nuclei with TOTO-3 iodide (blue). Latex beads are shown in green. Co: untreated 
cells. CLSM imaging was done by Robert Zarbock (Saarland University, Pharmaceutical Biology). 
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Pretreatment with cytochalasin D or incubation at 4 °C for 1 h prior to particle addition 
blocked particle uptake completely (figure 15 C). Pre-treatment of cells with DMSO, the 
solvent used for cytochalasin D, did not affect particle uptake (data not shown).  
 
3.2.4 TLR expression 
To investigate the expression of TLR1-10, we performed real time RT-PCR with samples 
from untreated AM and IM. TLR mRNA expression levels were not significantly different in 
AM and IM (figure 16). Among the TLRs recognizing bacterial patterns, TLR1, 2 and 4 
were expressed strongest, whereas TLR8 as a sensor of viral infections showed highest 
expression of the RNA-responsive receptors. 
 
 
 
Figure 16: TLR expression – RNA was isolated from AM and IM and real-time RT-PCR analysis for TLR1-
10 was performed. Data were normalized to -actin values. Data show means ± SEM of independent 
experiments performed with cells from 3 to 4 different donors. 
 
 
 
3.2.5 Cell reaction upon TLR4 and TLR9 stimulation 
As most comparative data for AM and IM focus on TLR4 activation, we treated respective 
cell populations with LPS and then determined induction of cytokine mRNA. Though we 
observed an increase in TNF-, IL10 and IL6 mRNA in both cell types, the extent of TNF- 
induction observed in IM was weak compared to the LPS-induced increase of TNF- in 
AM. IM expressed both more IL6 and IL10 mRNA upon TLR4 activation than AM (figure 
17). Interestingly, AM and IM differed also largely in basal IL10 and IL6 mRNA levels with 
IL10 expression in IM exceeding IL10 expression in AM 9.7-fold ( 2.4) and IL6 expression 
in IM being 16.9-fold ( 3.8) higher compared to AM (figure 17). These high basal 
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expression levels of IL6 and IL10 in IM are also the reason why x-fold cytokine mRNA 
inductions upon TLR4 activation compared to respective untreated controls were higher in 
AM for all cytokine mRNAs investigated (figure 17 D).  
 
 
 
Figure 17: Activation of AM and IM by LPS – AM or IM were left untreated (Co) or treated with LPS (100 
ng/ml) for 4 h, followed by RNA isolation and real-time PCR analysis for TNF-(A), IL6 (B) or IL10 (C). Data 
are normalized to -actin values. D: Comparison of x-fold cytokine mRNA inductions. Data show means ± 
SEM of four independent experiments with cells derived from different donors. *P < 0.05. 
 
 
AM have only recently been shown to be highly activated by BCG DNA as TLR9 ligand 
despite low TLR9 expression levels (Kiemer et al., 2009; Chapter I). Due to this interesting 
fact, we decided to also test responsiveness of IM towards TLR9 ligands. Cells were 
treated with different stimuli including a CpG-containing oligonucleotide (phosphorothioate-
modified immunostimulatory sequence ISS 1018) and genomic DNA isolated from the 
attenuated M. bovis BCG strain. In accordance with observations for monocyte-derived 
macrophages (Kiemer et al., 2009; Chapter I), TNF- induction by ISS was weak or absent 
in both cell types. Treatment with BCG DNA resulted in a markedly stronger TNF- 
induction in AM, but an only moderate response in IM (figure 18 A). Interestingly, AM 
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completely lacked IL10 induction upon stimulation with BCG DNA, whereas IM showed a 
distinct IL10 induction upon TLR9 activation (figure 18 C). IL6 was induced in both cell 
types by BCG DNA (figure 18 E). In contrast, the extent of IL10 as well as IL6 induction by 
ISS was minimal in both AM and IM. 
 
 
 
Figure 18: Activation of AM and IM by TLR9 ligands – AM or IM were left untreated (Co) or incubated with 
TLR9 ligands, followed by RNA isolation and real-time PCR analysis for TNF- (A, B), IL10 (C, D) or IL6 (E, 
F). A, C, E: Cells were treated either with immunostimulatory sequences (ISS 1018 phosphorothioate-
modified oligonucleotide, 20 µg/ml) or genomic DNA from M. bovis BCG (20 µg/ml) for 2 h. B, D, F: DNA 
isolated from virulent M. tuberculosis (H37Rv) or from the attenuated H37Ra strain (20 µg/ml) was added to 
AM or IM for 2 h. Data show means ± SEM of four experiments with cells derived from two different donors. * 
P < 0.05. 
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Next, we examined cell reaction upon treatment with DNA from virulent (H37Rv) or 
attenuated (H37Ra) mycobacteria. Both AM and IM treated with DNA from virulent 
bacteria (H37Rv) showed a minimal induction of TNF- compared to cells treated with 
DNA from non-virulent Mycobacteria (H37Ra, figure 19 B; BCG, figure 18 A). The lack of 
IL10 and IL6 induction by H37Rv DNA in both AM and IM confirmed its low activatory 
potential (figure 18 D, 18 F).  
Observations for H37Ra DNA complied with the findings for BCG-DNA for both AM and 
IM, i.e. high TNF- induction and absence of IL10 induction in AM contrasting a distinct 
IL10 response in IM. 
Taken together, these data obtained on mRNA level suggested that the activation profiles 
of AM and IM upon TLR4 and TLR9 stimulation are markedly different, indicating that both 
cell types differ in their functional properties. We therefore extended cytokine mRNA 
profiling to protein quantification using a fluorescent bead-based immunoassay and 
additionally determined the cytokine levels of IL1 receptor antagonist (IL1ra), granulocyte-
colony stimulating factor (G-CSF), interferon-inducible protein 10 (IP10), IL1, IL12p40, 
IL12p70, and IFN at baseline and after LPS activation in AM and IM (figure 19). These 
data revealed that AM and IM constitutively produced IL10, IL6, and IL1ra. Most 
remarkably, the baseline production of these anti-inflammatory and regulatory cytokines 
was markedly higher in IM than in AM. In detail, IL10 production was 1.9-fold ( 0.2), IL6 
secretion 3.3-fold (0.4), and IL1ra secretion 2.5-fold (0.4) higher in IM compared to AM 
(figure 19 A-C). Moreover, granulocyte-colony stimulating factor (G-CSF) was only 
detectable in IM at baseline (figure 19 D). Upon LPS treatment, IM still produced 
significantly more IL10 as well as IL1ra than AM. In contrast, production of the 
proinflammatory cytokines IL1 and IL12p40 following LPS activation was significantly 
higher in AM compared to IM. IFN and IL12p70 were actually only secreted by AM, but 
not by IM, upon LPS challenge (figure 19 E). The concentrations of IP10 and TNF- were 
both above detection limit in LPS-treated cells. 
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Figure 19: LPS-induced cytokine secretion – AM or IM were left untreated (Co) or treated with LPS (100 
ng/ml) for 6 h. Supernatants were removed and used for measurement of cytokine protein production. Data 
are normalized to total cellular protein values. Data show means ± SEM of 2-4 independent experiments 
performed in triplicate with cells derived from different donors. * P < 0.05. nd: not detectable. IP10 and TNF-
 were above detection limit. The multiplex cytokine assay was performed by Dominik Monz (Department of 
Neonatology, Saarland University Hospital). 
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3.2.6 Response to MyD88-dependent and -independent TLR activation 
As the differential activatory potential of LPS in AM and IM might be related do a distinct 
utilization of MyD88-dependent and -independent pathways (Andreakos et al., 2004), we 
also examined cytokine levels in response to Pam3CSK4 (TLR1/2 agonist) and Poly(I:C) 
(TLR3 agonist).  
Induction patterns of IL1ra, IL10, IL12p40, IL1 and IFN upon Pam3CSK4 treatment were 
found to be quite similar to those observed in response to LPS (figure 20). In contrast to 
the data obtained for TLR4 activation, however, the Pam3CSK4-induced secretion of IL6 as 
well as G-CSF was markedly stronger in AM than in IM (figure 20 B and C). In addition, 
AM produced significantly more TNF- in response to Pam3CSK4 than IM, which also 
resembled the findings for TLR3 activation (figure 20 E). Remarkably, IP10 was not 
inducible by Pam3CSK4 (figure 20 F), but solely by Poly(I:C) treatment (figure 20 F) in both 
cell types. Besides IP10, only TNF- was significantly upregulated by Poly(I:C) in both 
macrophage populations, suggesting that the induction of IL10 and IL12p40 is largely 
MyD88 dependent. The same might be true for IL1, although we only detected negligible 
amounts of this cytokine upon Pam3CSK4 treatment (Figure 20 I). Moreover, an increase in 
IL6, G-CSF and IFN secretion occurred in AM, but not in IM, upon Poly(I:C) treatment. 
Interestingly, both the MyD88-dependent as well as the -independent agonist induced 
IL1ra in IM to about the same extent (Figure 20 D). Similarly, IFN was equally inducible by 
both Poly(I:C) and Pam3CSK4 in AM (Figure 20 H). 
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Figure 20: Cytokine secretion upon TLR1/2 (MyD88 dependent) or TLR3 (MyD88 independent) 
activation – AM or IM were left untreated (Co) or treated with Pam3CSK4 (100 ng/ml) or Poly (I:C) (10 µg/ml) 
for 6 h. Supernatants were removed and used for measurement of cytokine protein production. Data are 
normalized to total cellular protein values. Data show means ± SEM of 2-4 independent experiments 
performed in triplicate with cells derived from different donors. * P < 0.05 compared to Co; # P < 0.05 
compared to similarly treated AM. The multiplex cytokine assay was carried out by Dominik Monz 
(Department of Neonatology, Saarland University Hospital). 
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3.3 Discussion 
 
3.3.1 Isolation procedure 
Human IM are less accessible than AM, which is why IM have in the past mostly been 
characterized using animal models (Lohmann-Matthes et al., 1994; Laskin et al., 2001). 
Our approach for macrophage isolation from human lung interstitial was based on a 
previously described method for isolation of epithelial cells (Elbert et al., 1999) and allows 
parallel isolation of AM, IM and epithelial cells. The digestion procedure we used slightly 
differed from those previously described for isolation of human IM (Fathi et al., 2001; 
Ferrari-Lacraz et al., 2001). 
We are aware that donor specifics, such as medication or smoking behaviour might alter 
macrophage functions. In fact, smoking has been shown previously to increase basal 
levels of TNF-, IL1 or IL8 in human AM (Ito et al., 2001) and to cause changes in 
morphology and surface molecule expression in rat AM (Lohmann-Matthes et al., 1994). 
Nevertheless, our results reveal many similarities of AM from lung tissue compared to AM 
from bronchoalveolar lavage described in the literature, as detailed below. 
 
3.3.2 Morphology  
Human as well as rat AM were previously described as large, mature cells, which closely 
resemble other tissue macrophages (Fathi et al., 2001; Laskin et al., 2001). In contrast, IM 
of human, rat or hamster origin were shown to be smaller than AM, more uniform in size 
and to generally resemble more closely peripheral blood monocytes (Bedoret et al., 2009; 
Laskin et al., 2001; Lavnikova et al., 1993; Kobzik et al., 1988). Our findings were similar 
to those described in the literature, which indicates that we were able to successfully 
separate macrophage populations. 
 
3.3.3 CD14 and HLA-DR expression 
Studies using primary rat AM and IM suggest that AM and IM do not differ in CD14 
expression (Lohmann-Matthes et al., 1994). We were able to show that CD14 is marginally 
expressed in human AM as well as IM. Low CD14 expression was reported previously for 
human AM obtained from bronchoalveolar lavage (Lensmar et al., 1999; Haugen et al., 
1998). CD14 expression by human IM is not described in the literature, but our results 
resemble findings reported for other tissue macrophage populations (Lensmar et al., 
1999).  
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Several studies using rat, mouse as well as human macrophages reported a higher MHC-
II expression in IM compared to AM (Bedoret et al., 2009; Ferrari-Lacraz et al., 2001; 
Lohmann-Matthes et al., 1994; Zetterberg et al., 1998). Our own results resemble those 
findings, indicating that IM are more involved in acquired immune responses than AM. 
 
3.3.4 Comparison to dendritic cells 
Lung DC are a small subset of pulmonary mononuclear cells, which exhibit low 
autofluorescence and are known to be loosely adherent (Cochand et al., 1999; Demedts et 
al., 2005; Van Haarst et al., 1994; Havenith et al., 1993). Moreover, this cell type 
possesses an immature phenotype along with a rather weak CD83 expression (Cochand 
et al., 1999). Subsets of lung DC are known to express CD1a (Demedts et al., 2005). Our 
macrophage preparations displayed high autofluorescence, were highly adherent and 
shared no phenotypic characteristics with DC regarding CD83 or CD1a expression. 
Therefore, the presence of DC in our cell preparations can be excluded for the most part. 
 
3.3.5 Phagocytic Activity 
Both macrophage types displayed phagocytic activity, which underlines the macrophage 
phenotype of IM. Phagocytic activity was comparable in AM and IM. This finding 
resembles observations for Fc-dependent phagocytosis in the animal model (Lohmann-
Matthes et al., 1994). Differences in phagocytic activity have been shown previously for 
human AM and IM phagocytosing Saccharomyces cerevisiae (Fathi et al., 2001). As this 
process is Fc-independent, these findings can not be compared to our results. 
 
3.3.6 TLR expression 
In the present study, expression of TLR1-10 mRNA levels were examined in both AM and 
IM for the first time. TLR1-10 mRNA expression by AM obtained from bronchoalveolar 
lavage was previously described by Maris et al. (2006). According to this study, TLR1, 
TLR4, TLR7, TLR8 are strongly and TLR2, TLR6 weakly expressed, whereas TLR3, 
TLR5, TLR9 and TLR10 were not detectable. Our results for TLR1, TLR4, TLR6, TLR8 
and TLR10 expression by AM resemble those observations. In contrast to Maris et al., we 
observed a strong expression of TLR2 mRNA, which is in line with results by Suzuki et al. 
(2005) as well as ourselves (Kiemer et al., 2009). Contrary to Maris et al., we were able to 
detect TLR3, TLR5 and TLR9 mRNA, suggesting a higher sensitivity of our assay. In fact, 
Chapter II 
 
 
 63
our real time PCR analysis is linear over 8 orders of magnitude, down to a concentration of 
10-6 attomole / µl. 
No significant differences between AM and IM concerning the TLR mRNA expression 
profile were found. Still, we can not exclude that TLR protein expression or localization 
differs in the different macrophage populations, which might both cause a differential cell 
reaction upon ligand binding. 
 
3.3.7 Baseline cytokine expression and response to LPS 
 
TNF- 
Previous studies using rat macrophages revealed that AM express higher amounts of the 
proinflammatory cytokine TNF- compared to IM in response to LPS (Lohmann-Matthes et 
al., 1994; Franke-Ullmann et al., 1996). Our data suggest that this is also true for human 
AM and IM. Moreover, the effect was not restricted to TLR4 activation, as TLR1/2 and 
TLR3 activation gave equivalent results. 
  
IL10, IL6 and G-CSF 
Although IL10 is one of the most important anti-inflammatory mediators in human immune 
response (Opal and DePalo, 2000; Moore et al., 2001), its expression by human AM and 
IM has not been investigated before. AM display low basal IL10 levels, which might allow 
efficient defence against inhaled particles and pathogens, whereas the fast induction of 
IL10 upon LPS treatment suggests an autoregulatory mechanism. As for IM, basal IL10 
mRNA and protein levels were found to be significantly higher than in AM and to increase 
after LPS treatment. A recently published study comparing murine AM and IM showed that 
IL10 levels were markedly higher in IM (Bedoret et al., 2009). Our data demonstrate that 
this is also true for human IM. In the animal model, IM were shown to inhibit lung DC 
maturation and migration in an IL10-dependent manner, thereby preventing Th2 
sensitization to harmless inhaled antigens (Bedoret et al., 2009). Our findings suggest that 
this regulatory function might also be exhibited by human IM, indicating that IM play a 
crucial role in immune homeostasis. 
IL6 has proinflammatory as well as anti-inflammatory properties. Studies using knockout 
mice demonstrated that in innate immunity IL6 acts predominantly as an antiinflammatory 
cytokine by attenuating the synthesis of proinflammatory cytokines (Libert et al., 1994; 
Xing et al., 1998). Exogenous IL6 was also shown to reduce the extent of pulmonary 
inflammation caused by hemorrhagic shock in rats, possibly by attenuating NF-B activity 
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(Meng et al., 2000). Futhermore, IL6 is involved in the specific immune response by 
upregulating B-cell differentiation, T-cell proliferation, and antibody secretion (Xing et al., 
1998). The high constitutive expression of IL6 we found in IM both on mRNA and protein 
level indicates that IM display a pronounced immunoregulatory capacity and suggests that 
they are more involved in specific immune responses than AM. 
Additional to its ability to promote increased release of granulocytes from the bone 
marrow, G-CSF prolongs the life-span of neutrophils in the air spaces by delaing their 
apoptosis (Matute-Bello et al., 2000). Accordingly, G-CSF is associated with severity of 
pulmonary neutrophilia in acute respiratory distress syndrome and hemorrhagic shock 
(Aggarwal et al., 2000; Meng et al., 2000). Both AM and IM secreted G-CSF in response to 
LPS. Baseline expression of G-CSF, however, was only detected in IM. Interestingly, a 
recently published study revealed that MyD88-dependent IL10, IL6 and G-CSF induction is 
involved in the up-regulation of arginase 1 during mycobacterial infection in murine 
macrophages (Qualls et al., 2010). Macrophage arginase 1 exerts its anti-inflammatory 
action by competing with NO synthases for arginine, a substrate common to both types of 
enzymes, to inhibit NO production and prevent tissue damage (Munder et al., 1998). 
Qualls et al. demonstrated that arginase 1 expression was controlled by IL6, IL10 and G-
CSF in a STAT3 dependent manner, and only the combined blockade of all three 
cytokines was sufficient to completely inhibit the induction of arginase 1 upon 
mycobycterial infection, suggesting that IL6, IL10 and G-CSF share some of their 
autocrine-paracrine functions. Thus, one could assume that IM express higher levels of 
arginase 1 than AM, which may explain the impaired NO production upon TLR4 activation 
previously described for rat IM (Franke-Ullmann et al., 1996). Interestingly, arginase 1 is 
also considered to be a marker for the anti-inflammatory M2 macrophage phenotype in the 
mouse model, although the relevance of this association for human macrophages remains 
controversial (Stempin et al., 2010).  
 
IL1ra, IL12, IL1 and IFN 
IL1ra is a major antiinflammatory cytokine that functions as a specific inhibitor of the two 
other functional members of the IL-1 family, IL-1α and IL-1β (Opal and DePalo, 2000; 
Arend et al., 2008). Our data demonstrate that IM secrete higher amounts of IL1ra when 
compared to AM, both at baseline and upon TLR4 activation. In contrast, LPS induced 
secretion of proinflammatory cytokines was low in IM when compared to AM (IL1, 
IL12p40) or even completely absent (IL12p70 and IFN). These findings clearly underline 
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the anti-inflammatory phenotype of IM previously described in the literature based on data 
obtained from murine or rat macrophages (Lohmann-Matthes et al., 1994; Franke-Ullmann 
et al., 1996; Laskin et al., 2001; Bedoret et al., 2009). 
 
3.3.8 Differential response to TLR1/2, TLR3 and TLR4 activation 
Upregulation of cytokine levels by TLR4 activation was markedly stronger than observed 
after treatment with the TLR3 ligand Poly(I:C), which correlates with the observation that 
TLR3 mRNA expression was low in both cell types. Moreover, we also found that cells 
were more responsive towards LPS than Pam3CSK4. As TLR4 mRNA levels did not largely 
differ from TLR1 and TLR2 mRNA levels, a higher expression of TLR4 on protein level, 
distinct trafficking mechanisms and/or suboptimal ligand concentrations are suggested to 
cause the differences observed in the activatory potential of LPS vs. Pam3CSK4. 
Additionally, LPS might amplify cytokine induction due to synergistic effects of MyD88-
dependent and –independent pathways (Kawai and Akira, 2006). Of all mediators 
examined, however, IL1ra and IFN were the only cytokines, which were inducible via both 
the MyD88- and the TRIF-related pathway. 
IP10 was the only cytokine exclusively induced by TRIF signalling. A cell-type specific 
restriction of IP10 upregulation to the TRIF-dependent pathway was reported before for 
the myeloid lineage (Lundberg et al., 2007). Accordingly, both AM and IM secreted IP10 in 
response to TLR3 activation to about the same extent, indicating the presence of 
functional TLR3. Apart from IP10, cytokine induction upon Poly(I:C) treatment was low 
when compared to LPS and Pam3CSK4 or even absent. As the activation of intracellular 
TLR3 might follow kinetics different from those of extracellular TLR1/2 and TLR4 and we 
did not perform studies on time- and dose-dependency, the relevance of this finding 
presently remains elusive.  
We observed marked differences between AM and IM concerning both TLR1/2 as well as 
TLR3 activation. In detail, we observed a higher induction of IL6 and G-CSF in AM than in 
IM after Pam3CSK4 treatment, which contrasts our findings of a similar expression of 
these two cytokines in both cell populations upon LPS challenge. The upregulation of IL6 
and G-CSF occurred in a largely MyD88 dependent manner, as previously described in 
the literature for murine macrophages (Qualls et al., 2010). However, IL6 and G-CSF were 
also induced by Poly(I:C) to a moderate extent, although the induction was restricted to 
AM. This suggests that TLR1/2 and TLR3 protein expression / localization and/or 
downstream signalling differ largely between AM and IM. As for TLR3, differential 
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downstream effects seem more likely, as the IP10 response was comparable in both cell 
types. 
 
3.3.9 Cell reaction upon TLR9 activation 
Despite the weak expression of TLR9 in AM and IM, cells reacted strongly upon 
stimulation with mycobacterial DNA. Methylation or digestion of mycobacterial DNA as well 
as chloroquine pretreatment lead to an abrogation of the macrophage response (Chapter 
I), which indicates that gene expression upon treatment with isolated DNA is not due to 
contaminants in DNA preparations, but due to TLR9 activation. It has been shown 
previously for human monocyte-derived macrophages as well as a mouse macrophage 
cell line that TLR9 activation is higher upon treatment with bacterial DNA than after 
oligonucleotide treatment, which might be due to oligonucleotide structure (Kiemer et al., 
2009; Kerkmann et al., 2005; Roberts et al., 2005a). Moreover, it has been reported for 
human in vitro differentiated macrophages as well as for AM from BAL that DNA from 
virulent strains has a lower potential to activate macrophage TLR9 than DNA from 
attenuated strains (Kiemer et al., 2009). Several studies indicate that the virulent H37Rv 
strain is able to methylate cytosines, whereas the H37Ra strain is not (Hemavathy et al., 
1995; Srivastava et al., 1981), which might explain why H37Rv DNA fails to activate TLR9.  
We were able to show that IM are less responsive to bacterial DNA than AM concerning 
TNF- induction, which resembles our findings for TLR4 activation. Similar to the results of 
the TLR4 activation experiments, IL6 as well as IL10 expression were much higher in IM 
compared to AM, which once again emphasizes the immunoregulatory function of IM.  
Moreover, IL10 was only induced in IM, but not in AM, upon mycobacterial DNA treatment. 
Absence of IL10 induction after TLR9 activation by mycobacterial DNA has been reported 
before (Juarez et al., 2010) and might be part of a mechanism of AM to overcome the 
immunosuppressive environment of the alveoli. Lung epithelial cells have been shown to 
constitutively express IL10, which is accompanied by an impaired responsiveness of AM 
towards IL10 (Fernandez et al., 2004). In the same study, it was also observed that 
activation of human AM through TLR2, TLR4 or TLR9 leads to inhibition of IL10 receptor 
function associated with a reduced ability to activate STAT3. IL10 is known to induce its 
own transcription via several positive feedback loops involving STAT3 (Staples et al., 
2007; Lang et al., 2002). A low capacity of AM to activate STAT3, as previously reported 
for murine AM (Jose et al., 2009), might explain the lack of IL10 induction in AM upon 
TLR9 activation as well as to the low basal levels of IL10 in comparison to IM. In this 
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manner, the higher baseline production of the STAT3 activating cytokines IL6 and G-CSF 
in IM compared to AM possibly also contributes to the higher expression of IL10 in 
unstimulated IM. 
 
Taken together, the present results confirm and extend limited data obtained with murine 
and human AM and IM characterizing phenotypic differences. We were able to 
demonstrate functional and morphological differences as well as similarities between AM 
and IM from human lung tissue, leading to the conclusion that the heterogenity of lung 
macrophages should be taken into consideration in future studies on their role in TLR-
mediated inflammatory response. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parts of the results presented in this chapter have been published in:  
 
Differential cell reaction upon Toll-like receptor 4 and 9 activation in human alveolar and 
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Hoppstädter J, Diesel B, Zarbock R, Breinig T, Monz D, Koch M, Meyerhans A, Gortner L, 
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4.1 Introduction 
 
Glucocorticoid-induced leucine zipper (GILZ) was originally identified as a 
dexamethasone-responsive gene by comparing mRNA species expressed in 
dexamethasone-treated and untreated murine thymocytes (D'Adamio et al., 1997). 
Glucocorticoids influence the regulation of various physiological processes, including 
inflammation, immune response, metabolism, cell growth and development. 
Glucocorticoids exert their immunosuppressive and anti-inflammatory effects via their 
action on innate and adaptive immunity. They are of extraordinary value for the therapy of 
inflammatory and autoimmune diseases.  
Similar to dexamethasone treatment, GILZ overexpression in macrophages was reported 
to inhibit the production of inflammatory mediators as well as TLR2 expression (Berrebi et 
al., 2003). Many of these functions are under control of the transcription factor NF-B, 
whose nuclear translocation is inhibited by GILZ. Accordingly, overexpression of GILZ in 
epithelial cells was shown to impair NF-B activation in response to IL1 receptor and TLR 
activation, whereas knockdown of GILZ inhibits the ability of dexamethasone to suppress 
IL1-induced chemokine expression (Eddleston et al., 2007). The induction of GILZ has 
also been proven crucial for the mediation of anti-inflammatory actions of glucocorticoids in 
other cell types, such as T cells, mast cells and dendritic cells (Ayroldi et al., 2001; Berrebi 
et al., 2003; Godot et al., 2006; Hamdi et al., 2007; Mittelstadt and Ashwell, 2001).  
Despite the well-studied role of GILZ upon glucocorticoid treatment, hardly anything is 
known about the regulation of GILZ during the immune response in the absence of 
pharmacological intervention. Recently, however, Eddleston et al. reported that cytokines 
involved in airway inflammation, namely TNF-, IL1 and IFN, can reduce GILZ mRNA 
levels in epithelial cells (Eddleston et al., 2007). In line with those findings, GILZ was found 
to be downregulated in granulomas of tuberculosis patients and nasal explant cultures 
from patients suffering from chronic rhinosinusitis (Berrebi et al., 2003; Zhang et al., 2009). 
Interestingly, knockdown of GILZ in airway epithelial cells resulted in elevated baseline 
levels of the chemokine IL8 (Eddleston et al., 2007), suggesting that the mere absence of 
GILZ provokes an inflammatory response. 
The lung is the organ with the highest GILZ expression, and macrophages have been 
reported to be the major source of human GILZ (Berrebi et al., 2003; Cannarile et al., 
2001). This indicates that GILZ plays a pivotal role in respiratory immune homeostasis. 
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Therefore, the aim of this chapter was to investigate mechanisms regulating GILZ 
expression in human alveolar macrophages under inflammatory conditions. 
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4.2 Results 
 
4.2.1 Constitutive and dexamethasone-induced GILZ expression in AM 
As limited data is available in the literature on expression levels and regulatory actions of 
GILZ in AM, we determined constitutive expression of GILZ in this cell type. We assessed 
GILZ mRNA expression by using quantitative real-time RT-PCR with human in vitro 
differentiated macrophages as well as THP-1 monocytic cells as positive controls. 
Additionally, we examined GILZ expression in IM, which represent another pivotal lung 
macrophage cell population (Bedoret et al., 2009; Chapter II). GILZ mRNA levels were 3-
fold higher in both AM and IM compared to blood monocyte-derived macrophages as well 
as differentiated and non-differentiated THP-1 cells (figure 21 A). As reported for other cell 
types (Eddleston et al., 2007; D’Adamio et al., 1997), GILZ mRNA and protein amounts 
were increased in AM by dexamethasone treatment in a time- and dose-dependent 
manner (figures 21 B – D). 
 
 
 
Figure 21: Constitutive expression and induction of GILZ by dexamethasone – A: RNA was isolated 
from AM, IM, in vitro differentiated macrophages (M), THP-1 cells and PMA-differentiated THP-1 
macrophage like cells (THP-1 M) and real-time RT PCR analysis for GILZ was performed. Data were 
normalized to -Actin. Data show means ± SEM of at least 5 independent experiments. Primary cells were 
from at least 5 different donors. *P < 0.05. B, C: AM were left untreated (Co) or treated with dexamethasone 
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(Dex) for 4 h at the indicated concentrations (B) or with 100 nM Dex for the indicated time points (C) followed 
by real-time RT-PCR analysis for GILZ. Data are normalized to -actin and represent means ± SEM of two 
independent experiments performed in triplicate with cells derived from two different donors. * P < 0.05 
compared to Co. D: Western Blot analysis of AM treated with Dex (1 µM) for the indicated time points. 
Tubulin protein expression served as a loading control. One representative out of three independent 
experiments with cells originating from different donors is shown. 
 
 
 
4.2.2 TLR9 activation attenuates GILZ expression 
Within the project investigating the reaction of human AM upon treatment with 
mycobacterial DNA as a TLR9 ligand (see also Chapter II), the effects on the expression 
of pro- and anti-inflammatory mediators was investigated. In this context, we aimed to 
determine whether TLR9 ligands affect GILZ expression. When we treated AM with DNA 
from M. bovis BCG as natural TLR9 ligand, we found a rapid and dose-dependent 
decrease of GILZ mRNA and protein (figure 22 A and B). Determination of TNF- mRNA 
levels demonstrated a strong activation of the cells. Also the synthetic oligonucleotide 
ODN2006 as TLR9 ligand activating AM (as assessed by TNF- mRNA induction) 
attenuated GILZ mRNA levels already 2 h after treatment (figure 22 C and D). As 
observed previously, however, the synthetic oligonucleotide showed weaker effects on 
macrophages than genomic bacterial DNA. 
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Figure 22: Downregulation of GILZ upon TLR9 activation – A, B: AM were treated with BCG DNA for 2 h 
at the indicated concentrations (A) or with 20 µg/ml BCG DNA for the indicated time points (B) followed by 
real-time RT-PCR analysis for GILZ and TNF-. Data are normalized to -actin and represent means ± SEM 
of 3-4 independent experiments with cells from different donors. * P < 0.05 compared to GILZ in untreated 
controls, # P < 0.05 compared to TNF- in untreated controls. C: AM were treated with BCG DNA (20 µg/ml) 
for the indicated time points. Western blot analysis was performed using tubulin as a loading control. Data 
show one representative out of two independent experiments performed in triplicate with cells from different 
donors. D, E: AM were treated with ODN2006 oligonucleotides (40 µg/ml) for 2 h followed by real-time RT-
PCR for GILZ and TNF-. Data are normalized to -actin and represent means ± SEM of 3 independent 
experiments with cells from different donors. * P < 0.05 compared to Co. 
 
 
 
4.2.3 GILZ downregulation in response to TLR4 activation  
In order to determine whether downregulation of GILZ was an effect specific for TLR9 
activation, we used LPS as a ligand for TLR4. GILZ was quickly downregulated after LPS 
addition. This was accompanied by activation of AM, as indicated by a significant induction 
of TNF- mRNA upon LPS challenge (figures 23 A and B). GILZ mRNA levels were 
already downregulated to 20% of untreated controls at a LPS concentration of 10 ng/ml 
and were not further decreased by increasing LPS concentrations (figure 23 A). Maximal 
LPS-mediated reduction of GILZ mRNA occurred at 2 h (figure 23 B). Similar results were 
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obtained with in vitro differentiated macrophages (figure 23 C) as well as the THP-1 cell 
line (data not shown). 
Next, we tested whether the transient decrease of GILZ mRNA levels attenuates GILZ 
protein in AM. In fact, LPS reduced GILZ protein very quickly (figure 23 D). Interestingly, 
GILZ protein levels were decreased for up to 24 h, even though GILZ mRNA showed to 
rise again after reaching a minimum after 2 h of treatment. These results suggested that 
GILZ downregulation might not solely be mediated by alteration of mRNA levels, but might 
involve attenuated translation or protein stability. 
 
 
 
 
Figure 23: Downregulation of GILZ by LPS – A-C: AM (A, B) or in vitro differentiated macrophages (C) 
were treated with LPS for 2 h at the indicated concentrations (A) or with 100 ng/ml LPS for the indicated time 
points (B, C) followed by real-time RT-PCR analysis for GILZ and TNF-. Data are normalized to -actin and 
represent means ± SEM of 4 independent experiments with cells from different donors. * P < 0.05 compared 
to GILZ in untreated controls, # P < 0.05 compared to TNF- in untreated controls. D: AM were treated with 
LPS (100 ng/ml) for the indicated time points. Western blot analysis was performed using tubulin as a 
loading control. Data show one representative out of three independent experiments with cells from different 
donors. 
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We then sought to check for an in vivo relevance for these findings. GILZ protein as well 
as mRNA levels were significantly decreased in lungs of LPS-treated mice compared to 
control animals (figure 24), which corroborated our in vitro findings. 
 
 
 
 
Figure 24: In vivo downregulation of GILZ under inflammatory conditions - C57BL/6 mice were injected 
intraperitoneally with 50 µg LPS diluted in physiological salt solution (n = 5) or the equal amount of salt 
solution only (Co, n = 4). 4 h after injection, mice were sacrificed and the lungs were removed to determine 
GILZ levels. A: Lung tissue was lysed, and equal protein amounts were assessed by Western Blot analysis 
using tubulin as a loading control. B: Relative GILZ protein signal intensities were quantified and normalized 
to tubulin values. Data are expressed as percentage of Co values. * P < 0.05 compared to Co. C: RNA was 
isolated from lung tissue and real-time RT-PCR analysis for GILZ was performed. Data are normalized to -
actin and show means ± SEM. * P < 0.05 compared to Co. 
 
 
 
4.2.4 Enhanced expression of proinflammatory cytokines due to reduced GILZ 
levels 
To determine the functional implications of GILZ downregulation, GILZ knockdown using 
siRNA was performed. As shown in figure 25 A, transfection of THP-1 cells with siGILZ 
resulted in reduced GILZ protein expression compared to both control siRNA transfected 
and untransfected cells. We then treated siGILZ cells or the respective control transfected 
cells with LPS and measured IL8 as well as TNF- mRNA levels (figure 25 B and C). As 
expected, LPS treatment for 0.5 and 1 h induced IL8 as well as TNF- mRNA in 
untransfected THP-1 cells. Transfection with control siRNA did not alter IL8 or TNF- 
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expression compared to untransfected cells, both at baseline and upon LPS stimulation. In 
contrast, knockdown of GILZ resulted in a small but significant increase in basal IL8 mRNA 
levels (figure 25 B). Moreover, LPS-induced IL8 as well as TNF- mRNA expression was 
significantly enhanced in GILZ knockdown cells. 
 
 
 
Figure 25: Knockdown of GILZ drives proinflammatory responses – THP-1 cells were transfected with 
either control siRNA (siCo) or GILZ siRNA (siGILZ) or left untreated (Co) for 24 hours. A: Western Blot 
analysis for GILZ using tubulin as a loading control. Data show one representative out of four independent 
experiments. B, C: siGILZ, siCo or Co cells were treated with LPS for the indicated time points, and IL-8 (B) 
and TNF- (C) expression was measured by real-time RT PCR. Data are normalized to β-actin and 
represent means of four independent experiments performed in triplicate ± SEM. * P < 0.05  
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4.2.5 GILZ downregulation upon MyD88-dependent and –independent TLR activation 
Reduced GILZ expression following TLR4 and TLR9 activation suggested that cell 
activation via TLRs generally decreased GILZ levels. In order to test this assumption, we 
employed other TLR ligands and determined GILZ mRNA levels. TLR ligands mimicking 
bacterial or viral molecular patterns, i.e. Pam3CSK4 (TLR1/2 ligand), flagellin (TLR5 
ligand), FLS-1 (TLR2/6 ligand), imiquimod (TLR7 ligand), ssRNA40 (TLR8 ligand), and 
bacterial DNA (TLR9 ligand, see 4.2.2), reduced GILZ mRNA levels after 2 h in AM (figure 
26 A). GILZ downregulation was paralleled by a marked activation of cells, as assessed by 
TNF- induction (figure 26 B). We also determined the influence of TLR1/2 activation on 
GILZ protein expression. In fact, GILZ protein amounts were reduced after Pam3CSK4 
addition (figure 26 C), which resembled our observations for LPS.  
 
 
 
 
Figure 26: GILZ downregulation upon MyD88-dependent TLR activation – A, B: AM were left untreated 
(Co) or treated with either Pam3CSK4 (250 ng/ml), flagellin (250 ng/ml), FSL-1 (250 ng/ml), imiquimod (7.5 
µg/ml), ssRNA40 (7.5 µg/ml) or bacterial DNA (20 µg/ml), followed by real-time RT-PCR analysis for GILZ 
(A) or TNF- (B). Data are normalized to -actin and represent means ± SEM of four independent 
experiments performed with cells derived from four different donors. * P < 0.05 compared to Co. C: AM were 
treated with Pam3CSK4 (100 ng/ml) for the indicated time points. Western blot analysis was performed using 
tubulin as a loading control. Data show one representative out of two independent experiments with cells 
from different donors  
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Treatment of AM with the synthetic analogue of double-stranded RNA and TLR3 ligand 
Poly(I:C) also increased TNF- mRNA levels after 2 h (figure 27 A). TNF- induction was 
not due to activation of cytosolic Poly(I:C) responsive elements (Barral et al., 2009), as 
inhibition of TLR3-dependent signalling by chloroquine completely abrogated cell 
activation (figure 27 A). Interestingly, TLR3 activation was not paralleled by GILZ mRNA 
downregulation (figure 27 B), and Poly(I:C) did not alter GILZ mRNA expression at 2 h at 
any of the concentrations tested (figure 27 C). As the lack of effect of Poly(I:C) on GILZ 
mRNA might be due to a different time course transmitted via the MyD88-independent 
TLR3 pathway compared to the other TLR ligands utilizing MyD88 as an adapter molecule, 
we performed time-course studies with the TLR3 ligand for up to 8 h. Although TNF- 
mRNA levels were markedly increased one to eight hours after treatment, no decrease in 
GILZ mRNA could be observed at any time point (figure 27 D). Similar to AM, Poly(I:C) did 
not decrease GILZ mRNA in THP-1 cells (data not shown). This observation suggests that 
GILZ mRNA downregulation is mediated (I) independent of MyD88 and (II) independent of 
TNF-. Most interestingly, however, Western blot analysis showed that GILZ protein levels 
are in fact reduced after treatment with Poly(I:C) despite a lack of effect on GILZ mRNA 
(figure 27 E). GILZ protein downregulation was mediated via TLR3 activation, as it was 
inhibited by chloroquine pretreatment. These findings let us hypothesize that GILZ is 
regulated on two levels, i.e. on mRNA and protein level. 
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Figure 27: TLR3 activation reduces GILZ protein, but not mRNA levels – A, B: AM were either left 
untreated (Co), or treated with chloroquine (CQ, 10 µM), Poly(I:C) (10 µg/ml, 2 h) or a combination of both 
whereby CQ was added to the cells 1 h before Poly(I:C). Real-time RT-PCR analysis for TNF- (A) or GILZ 
(B) was performed. Data are normalized to -actin and represent means ± SEM of three independent 
experiments performed with cells derived from different donors. * P < 0.05 compared to Co. C, D: AM were 
left untreated (Co) or treated with Poly(I:C) for 2 h at the indicated concentrations (C) or with 10 µg/ml 
Poly(I:C) for the indicated time points (D) followed by real-time RT-PCR analysis for GILZ and TNF-. Data 
are normalized to -actin and represent means ± SEM of six independent experiments with cells obtained 
from six different donors. * P < 0.05 compared to Co values. n.s: not significant. E: AM were treated with 
Poly(I:C) (10 µg/ml) for the indicated time points, followed by immunoblotting for GILZ using tubulin as a 
loading control. Data show one representative out of three independent experiments with cells form different 
donors. F: AM were either left untreated (Co) or treated with CQ (10 µM) and/or Poly(I:C) (10 µg/ml, 8 h). CQ 
was added to cells 1 h prior to Poly(I:C) challenge, and Western blot analysis for GILZ was performed. 
Tubulin served as a loading control. One representative out of three independent experiments with cells from 
different donors is shown. 
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4.2.6 MyD88-dependent GILZ mRNA downregulation 
Our findings indicated that downregulation of GILZ mRNA requires the adapter molecule 
MyD88. To specify the role of MyD88, we performed an siRNA-mediated MyD88 
knockdown and checked the ability of LPS and Pam3CSK4 to decrease GILZ mRNA levels. 
MyD88 protein levels were effectively knocked down in PMA-differentiated THP-1 cells by 
MyD88 siRNA 72 h post transfection when compared with levels seen in cells transfected 
with control siRNA (figure 28 A). Treatment of control siRNA cells with LPS or Pam3CSK4 
reduced GILZ mRNA levels. Effects were comparable to those detected in untransfected 
control cells: GILZ mRNA decreased by 70 % at 2 h after treatment. This effect was 
significantly abrogated in MyD88 siRNA cells. Under these conditions LPS and Pam3CSK4 
only reduced GILZ mRNA levels by 30 % (figure 28 B). Employment of a MyD88 inhibitory 
peptide resulted in similar effects, although inhibition of MyD88 was not as efficient as the 
knockdown procedure (figure 28 C). Taken together, these data demonstrate that GILZ 
mRNA downregulation upon TLR activation requires the adapter molecule MyD88. 
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Figure 28: GILZ mRNA downregulation requires MyD88 – A: Differentiated THP-1 cells were transfected 
with either control siRNA (siCo) or MyD88 siRNA (siMyD88) or left untreated (Co) for up to 96 h, followed by 
immunoblotting for MyD88 using tubulin as a loading control. Data show one representative out of 4 
independent experiments. B: siMyD88, siCo or Co cells were treated with LPS (100 ng/ml) or Pam3CSK4 
(100 ng/ml) 70 h after transfection for 2 h, and GILZ mRNA was assessed by real-time RT-PCR. Data are 
normalized to β-actin and represent means of three independent experiments performed in triplicate ± SEM. 
* P < 0.05. C: Differentiated THP-1 cells were treated with either MyD88 inhibotory peptide (MyD88 IP, 10 
µg/ml) or control peptide (Co IP, 10µg/ml) or left untreated for 24 h, followed by addition of LPS (100 ng/ml) 
or Pam3CSK4 (100 ng/ml) for 2 h. GILZ mRNA was quantified by real-time RT-PCR. Values are normalized 
to Actin and represent means of two independent experiments performed in triplicate. * P < 0.05.  
 
 
 
4.2.7 Decrease of GILZ mRNA half life in response to LPS 
GILZ mRNA downregulation might either occur on the level of transcription or on the level 
of mRNA stability. Since effects on GILZ mRNA were very rapid, we hypothesized a 
destabilization of GILZ mRNA upon TLR activation. In order to determine potential 
changes in GILZ mRNA half-life, we incubated AM with the transcription inhibitor 
actinomycin D in the presence or absence of LPS and determined changes in GILZ mRNA 
levels. Control cells displayed a t1/2 of GILZ mRNA of 2.3 h, whereas GILZ mRNA half-life 
was only 1.3 h in LPS-treated cells (figure 29 A), confirming the hypothesis of a reduced 
mRNA stability in TLR-activated AM. Similar results were obtained when repeating the 
actinomycin D experiments with in vitro differentiated macrophages (figure 29 B), 
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indicating that the shortening of GILZ mRNA half life after LPS treatment is not restricted 
to a single macrophage type. 
 
 
 
Figure 29: GILZ mRNA destabilization upon TLR activation – AM (A) or in vitro differentiated 
macrophages (B) were either left untreated or treated with actinomycin D (10 µg/ml) in the absence or 
presence of LPS (100 ng/ml). RNA was isolated at the indicated time points, and real-time PCR analysis for 
GILZ was performed. Data are normalized to -Actin and represent means ± SEM of five (A) or three (B) 
independent experiments with cells obtained from different donors. Curve fitting was done using Origin 
software. 
 
 
 
4.2.8 Involvement of TTP in GILZ mRNA destabilization 
A prime mechanism of 3’UTR dependent mRNA destabilization is mediated via RNA 
binding proteins (Eberhardt et al., 2007). Tristetraprolin (TTP) is an RNA binding protein 
critically involved in the regulation of many inflammation-associated mediators. Our data 
indicate that TTP is induced in AM in a MyD88-dependent fashion, since its upregulation 
was only seen after LPS or Pam3CSK4, but not after Poly(I:C) treatment (figure 30 A).  
To evaluate whether TTP plays a role in regulating GILZ expression, we transiently 
overexpressed TTP mRNA in THP-1 cells. As shown in figure 30 C, Western blot analysis 
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revealed enhanced TTP protein expression in TTP vector transfected cells, whereas no 
change of TTP protein expression was seen in control vector (CoV) transfected cells as 
compared to untransfected controls.  
We then determined expression of TNF- mRNA, whose regulation by TTP is well 
described (Carballo et al., 1998), similar to the recently identified TTP target IL10 mRNA 
(Stoecklin et al., 2008; Tudor et al., 2009). Overexpression of TTP significantly decreased 
TNF- and IL10 mRNA, thus confirming TTP functionality (figure 30 B). Interestingly, these 
findings were accompanied by decreased GILZ expression both at mRNA and protein 
level, indicating a TTP-mediated GILZ downregulation (figure 30 B and C). 
 
 
 
 
Figure 30: MyD88 dependent TTP induction and influence of TTP overexpression on GILZ expression 
– A: AM were either left untreated or treated with LPS (100 ng/ml), Pam3CSK4 (100 ng/ml) or Poly(I:C) (10 
µg/ml) for 8 h. Western blot analysis for TTP was performed using tubulin as a loading control. One 
representative out of two independent experiments performed in triplicate with cells obtained from different 
donors is shown. B: THP-1 cells were transfected with either control (CoV) or TTP expression (TTP) vector 
and harvested after 24 h, followed by real-time RT-PCR analysis for TNF-, IL10 and GILZ. Data are 
normalized to -actin and represent means ± SEM of four independent experiments performed in triplicate. * 
P < 0.05 compared to CoV. C: Total protein was isolated from CoV or TTP transfected and untransfected 
(Co) THP-1 cells and assessed by Western blot analysis for GILZ and TTP. Tubulin served as a loading 
control. One representative out of four independent experiments is shown. 
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To support these results and assess the influence of TTP on TLR-mediated GILZ 
regulation, we knocked down TTP expression using shRNA. We transfected THP-1 cells 
with two different shRNA constructs directed against the human TTP mRNA (shTTP1 and 
shTTP2). As a control, cells were transfected with a construct expressing an shRNA, 
which targets the luciferase gene (shLuc). Subsequently, cells were treated with 
Pam3CSK4 in order to induce MyD88-dependent GILZ downregulation.  
TTP was efficiently knocked down by both shRNAs 24 h post transfection (figure 31 A). As 
previously seen in AM, LPS and Pam3CSK4 treatment induced TTP in control transfected 
shLuc THP-1 cells, whereas TTP induction upon TLR activation was undetectable in either 
shTTP1 or shTTP2 cells (figure 31 E). As expected, Pam3CSK4 upregulated TNF- as well 
as IL10 mRNA, which was significantly enhanced by the knockdown of TTP when 
compared to mRNA induction in shLuc cells (figure 31 B and C).  
shRNA-mediated downregulation of TTP also abrogated GILZ downregulation upon 
activation with Pam3CSK4 both at mRNA and protein level (figures 31 D and E). We also 
detected similar effects for GILZ protein when challenging cells with LPS (figure 31 E), 
further supporting the role of TTP in GILZ downregulation. 
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Figure 31: Impact of TTP knockdown on TLR-mediated decrease in GILZ expression – THP-1 cells 
were transfected with a control shRNA construct (shLuc) or one of two shRNA vectors targeting TTP 
(shTTP1, shTTP2). A: Cells were lysed 24 h after transfection, and TTP was assessed by Western blot 
analysis using tubulin as a loading control. One representative out of four independent experiments is 
shown. B, C, D: 22 h after transfection, shLuc, shTTP1 or shTTP2 cells were either treated with Pam3CSK4 
(100 ng/ml) or left untreated for 2 h and real-time RT-PCR for TNF- (B), IL10 (C) or GILZ (D) mRNA was 
performed. Values are normalized to β-actin and represent means of four independent experiments 
performed in triplicate ± SEM. Data are expressed as x-fold (B, C) or percentage (D) of values for untreated 
shLuc cells. * P < 0.05. E: 20 h after transfection, shLuc, shTTP1 or shTTP2 cells were treated with 
Pam3CSK4 (100 ng/ml) for 4 h or left untreated. Western blot analysis for GILZ and TTP was performed 
using tubulin as a loading control. One representative out of four independent experiments is shown. 
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4.2.9 Proteasome-dependent GILZ downregulation 
As the MyD88-independently acting Poly(I:C) is capable of reducing GILZ mRNA, but not 
protein levels, we hypothized that GILZ protein might be downregulated in a proteasome-
dependent fashion in response to TLR3 activation. Thus, we employed the proteasome 
inhibitor MG-132 prior to Poly(I:C) addition. As shown in figure 32 A, MG-132 pretreatment 
completely abrogated GILZ downregulation upon stimulation with Poly(I:C) in AM. DMSO, 
the solvent for MG-132, did not influence GILZ protein expression (data not shown). 
Interestingly, MG-132 treatment also inhibited MyD88-facilitated, i.e Pam3CSK4- and LPS-
mediated downregulation of GILZ protein (figure 32 B and C).  
 
 
 
Figure 32: Abrogation of GILZ protein downregulation by MG-132 – AM were treated with MG-132 (10 
µM) 1 h prior to addition of either (A) Poly(I:C) (10 µg/ml), (B) Pam3CSK4 (100 ng/ml) or (C) LPS (100 ng/ml) 
for 4 h. Western blot analysis for GILZ was performed using tubulin as a loading control. One representative 
out of 2-4 independent experiments with cells from different donors is shown. 
 
 
Since Myd88-dependent GILZ downregulation was shown to be regulated on mRNA level, 
we wondered whether MG-132 also affected GILZ mRNA levels upon LPS treatment.  
In fact, LPS treatment failed to decrease GILZ mRNA amounts when AM or in vitro 
differentiated macrophages were pretreated with MG-132 (figure 33 A and C). This was 
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paralleled by an inhibition of TNF- induction, most likely via inhibition NF-B activation. 
DMSO did neither influence GILZ nor TNF- mRNA expression (figure 33 B and D). 
 
 
 
 
Figure 33: Inhibition of GILZ mRNA downregulation by MG-132 – AM (A, B) or in vitro differentiated 
macrophages (C, D) were either left untreated (-) or pretreated with MG-132 (10 µM, 1h) or an equal volume 
of DMSO as a solvent control. Cells were incubated for an additional 2 h in absence (Co) or presence of LPS 
(100 ng/ml), followed by real-time RT-PCR analysis for GILZ (A, C) and TNF- (B, D). Data are normalized to 
-actin and represent means ± SEM of two (A, B) or three (C, D) independent experiments with cells from 
different donors. * P < 0.05. 
 
 
 
4.2.10 TNF--mediated GILZ downregulation 
As TNF- has previously been reported to reduce GILZ levels in epithelial and endothelial 
cells (Eddleston et al., 2007; Hirschfelder et al., 2010), we speculated that TNF- induction 
might conbtribute to the effects observed after TLR activation. Thus, we incubated AM with 
TNF- (10 ng/ml) and determined GILZ mRNA and protein expression. TNF- treatment 
decreased GILZ mRNA as well as protein levels (figure 34). 
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Figure 34: TNF- decreases GILZ expression – A: AM were either left untreated or treated with TNF- (10 
ng/ml) for 2 h, followed by real-time RT-PCR for GILZ. Values are normalized to -actin and represent means 
of two independent experiments performed in triplicate with cells from different donors. * P < 0.05. B: AM 
were left untreated (Co) or treated with TNF- (10 ng/ml) for the indicated time points. Western blot analysis 
for GILZ was performed using tubulin as a loading control. One representative out of three independent 
experiments is shown.  
 
 
 
4.2.11 GILZ mRNA expression in endotoxin tolerance 
Macrophages exposed to LPS show reduced responses to a second stimulation with LPS, 
which is termed endotoxin or LPS tolerance. We wondered whether GILZ downregulation 
might be affected in LPS tolerant cells. When AM were stimulated with 1 µg/ml LPS for 2 
h, these cells displayed a significant increase in production of TNF-mRNA. However, 
when the cells were preincubated with 100 ng/ml LPS for 24 h, TNF- mRNA induction 
was dramatically reduced. In fact, TNF- mRNA levels did not exceed those observed in 
cells that were only pretreated, indicating that the cells were LPS tolerant (Figure 35 A). 
Remarkably, desensitized cells lost their ability to reduce GILZ mRNA levels in response 
to LPS, suggesting that GILZ might play a role in macrophage desensitization. We also 
observed that GILZ mRNA amounts were slightly increased by the initial LPS treatment, 
although data did not reach statistical significance (figure 35 B). 
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Figure 35: LPS tolerant AM fail to decrease GILZ levels – AM were left untreated (-) or pretreated with 
100 ng/ml LPS for 24 h. Cells were washed and then incubated in the absence or presence of 1 µg/ml LPS 
for an additional 2 h. Real-time RT-PCR was performed for TNF- (A) and GILZ (B). Data are normalized to 
-actin and represent means of three independent experiments performed in triplicate with cells obtained 
from different donors. * P < 0.05 compared to untreated cells. 
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4.3 Discussion 
 
Lung macrophages represent key players in pulmonary inflammation as associated with 
asthma, chronic obstructive pulmonary disease (COPD) or allergic diseases (Sabroe et al., 
2007; O’Donnell et al., 2006). Whereas the scientific interest in reducing macrophage 
activation mostly focuses on the reduction of inflammatory mediators (Gordon, 2007), few 
is known about the regulation of anti-inflammatory regulators, such as GILZ. 
Glucocorticoids are currently the most widely used class of anti-inflammatory drugs in the 
treatment of inflammatory lung diseases, and they are considered to exert their actions to 
a significant extent via induction of GILZ (Eddleston et al., 2007; Ayroldi and Riccardi, 
2009). GILZ mediates its anti-inflammatory properties mainly via inhibition of the NF-B 
pathway (Ayroldi et al., 2001; Eddleston et al., 2007). Moreover, GILZ was reported to 
inhibit AP-1 activation and to interfere with Raf / Ras signalling (Ayroldi et al., 2002; 
Mittelstadt and Ashwell, 2001; Ayroldi et al., 2007; Ayroldi and Riccardi, 2009). Thus, GILZ 
expression affects signalling pathways, which are pivotal to inflammatory processes. 
 
4.3.1 Constitutive and dexamethasone-induced GILZ expression in pulmonary 
macrophages 
Here we present the first report of constitutive GILZ expression in primary human lung 
macrophages, both in AM and in IM. Interestingly, although IM express higher levels of 
IL10 than AM (Bedoret et al., 2009; Chapter II), and IL10 is able to induce GILZ expression 
(Berrebi et al., 2003), expression levels do not differ between AM and IM. As expected, we 
found that GILZ is upregulated by the glucocorticoid dexamethasone in AM on mRNA as 
well as protein level. GILZ upregulation by glucocorticoids was originally reported for 
murine lymphocytes and thymocytes (D'Adamio et al., 1997) and is mediated via activation 
of the glucocorticoid receptor, which subsequently interacts with the three glucocorticoid 
response element sites found in the promoter region of the GILZ gene (Ayroldi and 
Riccardi, 2009). Glucocorticoid-induced GILZ upregulation was also observed in human 
cells, such as epithelial cells (Eddleston et al., 2007), monocytes (Berrebi et al., 2003), 
mast cells (Godot et al., 2006), and dendritic cells (Cohen et al., 2006). Our findings 
demonstrate that a rapid and persistent glucocorticoid-mediated GILZ induction also 
occurs in AM, suggesting that the induction of GILZ is crucial for the mediation of anti-
inflammatory actions of glucocorticoids in this cell type. 
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4.3.2 TLR-mediated GILZ downregulation  
The regulation of GILZ in inflammatory conditions is poorly understood. TLRs play a key 
role in both infectious and noninfectious inflammatory lung diseases, as they are capable 
of sensing different microbial as well as endogenous molecules whereby the latter are 
released after cell damage (Opitz et al., 2010). We assessed the effect of TLR activation 
on the level of GILZ expression in AM. When we treated AM with the TLR4 agonist LPS or 
mycobacterial DNA as a ligand of TLR9, both GILZ mRNA and protein levels were quickly 
decreased. Most interestingly, we also detected severely decreased GILZ mRNA and 
protein levels in lungs of LPS-exposed mice. Along with reports of decreased GILZ levels 
in inflammatory bowel disease, tuberculosis and chronic rhinosinusitis (Berrebi et al., 2003, 
Zhang et al., 2009), these observations demonstrate the in vivo relevance of our findings. 
To assess the functional implications of GILZ downregulation, we used siRNA to knock 
down GILZ in THP-1 monocytic cells and then examined TNF- and IL8 levels in the 
presence or absence of LPS. Although GILZ knockdown cells displayed significantly 
enhanced levels of TNF- as well as IL8 upon TLR4 activation, the effects we observed 
were quite small. This might be due to the fact that the effects of GILZ knockdown merely 
add to TLR-mediated GILZ downregulation. Thus, the knockdown procedure might only be 
able to affect inflammatory processes to a limited extent. Interestingly, we also detected 
slightly increased IL8 expression levels in GILZ siRNA cells in the absence of any other 
stimulation, which is in accordance with findings previously described for airway epithelial 
cells (Eddleston et al., 2007) and might be caused by an increased nuclear translocation of 
NF-B (Hirschfelder et al., 2010). In contrast, lung epithelial cells with a stable GILZ 
knockdown did not display increased cytokine levels compared to GILZ expressing cells 
(Gomez et al., 2010). It has to be noted, however, that the early cellular response upon 
decreased GILZ expression can not be detected in stably transfected cells. Since 
activation of NF-B results in a functional feedback loop, e.g. via diminished degradation 
of of IB (Medvedev et al., 2000), an activation induced by GILZ knockdown is considered 
to be only transient. 
When we explored the effects of other TLR ligands, we found that activation of all TLRs 
with the exception of TLR3 leads to diminished GILZ mRNA amounts in AM. Our data 
show that GILZ protein levels are reduced after treatment with Poly(I:C) despite a lack of 
effect on GILZ mRNA. These findings let us hypothesize that GILZ is regulated via distinct 
pathways affecting either mRNA or protein levels. 
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4.3.3 MyD88- and TTP-dependent GILZ mRNA downregulation 
As TLR3 represents the only TLR that does not utilize the adaptor molecule MyD88 for 
signal transduction (Kawai and Akira, 2006), we examined the role of MyD88 in GILZ 
mRNA regulation by MyD88 knockdown. GILZ mRNA downregulation upon TLR activation 
was markedly abrogated in MyD88 knockdown cells, indicating that the effect does in fact 
require functional MyD88.  
MyD88 was reported to be critically involved in the recognition of bacterial as well as viral 
infections in the respiratory tract, mainly via the TLR pathway (Opitz et al., 2010). MyD88 
knockout mice show an impaired expression of proinflammatory mediators and a reduced 
pathogen clearance after infection with Klebsiella pneumoniae (Cai et al., 2009). Mice 
lacking MyD88 are also highly susceptible towards Legionella pneumophila, Streptococcus 
pneumoniae as well as Haemophilus influenzae infections (Hawn et al., 2006; Wieland et 
al., 2005; Albiger et al., 2005). The potential inability to downregulate the expression of the 
anti-inflammatory factor GILZ might contribute to an insufficient host response in those 
mice. Interestingly, a MyD88-independent upregulation of the anti-inflammatory S100A8 
protein has been reported in macrophages (Endoh et al., 2009) supporting the notion of 
MyD88 as a critical determinant for a differential activation profile.  
Gene expression can be regulated by both transcriptional and post-transcriptional 
mechanisms. Post-transcriptional modulation of gene expression is commonly procured by 
changes in mRNA stability, which can be modulated by various extracellular stimuli. 
Regulation of mRNA stability permits cells to rapidly decrease or increase mRNA levels, 
and therefore provides a mechanism for fast and tight regulation of protein production. In 
this manner, cells are enabled to dynamically change gene expression profiles depending 
on environmental challenges (Wilusz et al., 2001; Wilusz and Wilusz, 2004). Thus, we 
wondered whether mRNA destabilization might account for TLR-mediated GILZ mRNA 
downregulation and found that GILZ mRNA half life was indeed significantly shortened 
after LPS treatment.  
The rate of mRNA decay is often determined by cis-regulatory elements containing AU-
rich elements (ARE) found in the 3’UTR. These AREs mostly induce a destabilization of 
the respective mRNA and were found in mRNAs coding for numerous cellular regulators, 
such as COX-2, IL10, and a number of cytokines involved in the inflammatory response 
(Lasa et al., 2001; Bakheet et al., 2001; Stoecklin et al., 2008). Since GILZ mRNA is 
regulated via mRNA stability, we analyzed its 3'UTR sequence. This approach revealed 
one copy of the AUUUA pentamer and a U-rich region, which both represent potential 
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binding sites for destabilizing RNA binding proteins (Chen and Shyu, 1995). Therefore, we 
assessed the effect of this region on GILZ mRNA stability by transfecting THP-1 cells with 
a luciferase construct containing the GILZ 3'UTR and observed that GILZ 3'UTR-luciferase 
mRNA was in fact significantly destabilized upon TLR activation (Hoppstädter et al., 
2010b).  
Several proteins are known to bind to AREs (Hollams et al., 2002), and many of them have 
been shown to regulate mRNA stability. These include the tristetraprolin (TTP) family of 
Zinc-finger RNA binding proteins (Lai et al., 1999). LPS has been shown previously to 
increase TTP mRNA and protein levels, e.g. in THP-1 cells (Baseggio et al., 2002; 
Fairhurst et al., 2003, Brooks et al., 2004) or human primary monocytes (Carrick and 
Blackshear, 2007). Our data show for the first time that this is also true for AM. Moreover, 
our observations reveal that TTP induction upon TLR activation occurs in a MyD88-
dependent manner, which gave us a first hint of a possible involvement of TTP in GILZ 
mRNA decay. Both TTP overexpression and knockdown experiments in THP-1 cells 
confirmed this assumption.  
IL10 mRNA has only recently been shown to be regulated by TTP in murine macrophages 
(Stoecklin et al., 2008; Tudor et al., 2009), although these observations have not been 
described for human cells yet. TNF- mRNA represents the best characterized TTP target 
(Taylor et al., 1996; Carballo et al., 1998; Lai et al., 1999). IL10 and TNF- were both 
downregulated when overexpressing TTP. Vice versa, knockdown of TTP and subsequent 
treatment with Pam3CSK4 led to higher induction of TNF- as well as IL10 in shTTP cells 
compared to control cells. Most importantly, TTP overexpression also resulted in 
decreased GILZ amounts, both on mRNA and protein level. In addition, our results 
demonstrate that attenuation of TTP expression by the use of RNAi abrogates TLR1/2- as 
well as TLR4-mediated GILZ downregulation. These observations document an 
involvement of TTP in the regulation of GILZ expression, suggesting that GILZ mRNA 
might be degraded due to direct interaction with TTP. However, it is also possible that 
GILZ mRNA interacts with additional RNA-binding proteins that are antagonistic to the 
destabilizing function of TTP, such as Human Antigen R (HuR) (Anant and Houchen, 
2009). Our observation that overexpression of TTP enhances the degradation of GILZ 
mRNA in the absence of any other stimulus supports the notion that GILZ mRNA is 
sensitive to the balance of different ARE-binding proteins. Thus, the composition of the 
entire RNA-protein complex rather than the binding of an individual protein might 
determine the fate of GILZ mRNA in accordance with the concept of post-transcriptional 
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operon networks in eukaryotic systems. These networks are considered to be regulated by 
groups of RNA-binding proteins, whose binding in addition may be modulated by miRNAs 
(Keene and Tenenbaum, 2002; George and Tenenbaum, 2006). Interestingly, analysis of 
GILZ 3’-UTR by www.mircorna.org revealed 40 potential miRNA binding sites. The 
presence of the binding site for miR-16 might be of special importance, since it has been 
shown to be involved in TTP-mediated mRNA turnover (Jing et al., 2005). 
 
4.3.4 Proteasome-dependent GILZ downregulation 
The 26S proteasome plays a central role in the maintenance of cellular homeostasis, as it 
represents the major extralysosomal degradative machinary in eukaryotic cells. Generally, 
the proteasome degrades proteins tagged by ubiquitin for destruction. Many substrates are 
regulatory proteins that must be tightly regulated, such as transcription factors and   
proteins involved in the cell cycle (Hochstrasser, 2009). A recently published study by 
Delfino et al. (2010) delivered evidence for polyubiquitination and proteosomal degradation 
of GILZ in thymocytes. Interestingly, GILZ was found to be protected from degradation by 
inhibition of ubiquitination in glucocorticoid treated cells, suggesting that a prolonged GILZ 
protein half-life contributes to the increase of GILZ expression upon glucocorticoid 
treatment. 
Our results employing the proteasome inhibitor MG-132 also suggest that GILZ protein 
might be regulated by proteasome degradation upon TLR activation: Poly(I:C)-induced 
downregulation of GILZ protein was abrogated by treatment with the proteasome inhibitor. 
It is also possible, however, that an NF-B dependent reduction of GILZ was abrogated by 
the proteasome inhibitor, since MG-132 treatment also prevents IB from degradation. 
Potential NF-B dependent mechanisms of GILZ downregulation might include the 
induction of miRNAs, resulting in decreased mRNA stability and/or translational 
repression. As Poly(I:C)-mediated decrease of GILZ protein levels was not paralleled by a 
reduction of GILZ mRNA amounts and Poly(I:C) is known to activate NF-B (Blasius and 
Beutler, 2010), a repression of GILZ translation seems most likely. 
Most interestingly, LPS- and Pam3CSK4 mediated GILZ mRNA and protein reduction was 
completely inhibited by MG-132 pretreatment, indicating that the proteasome is not only 
involved in TRIF-dependent GILZ protein downregulation, but also in MyD88-dependent 
downregulation of GILZ mRNA and protein. In accordance with our findings, Deleault et al. 
(2008) reported that MG-132 stabilizes TTP target mRNAs in monocytes and 
macrophages, since TTP function requires the proteasome. The mechanisms underlying 
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TTP/proteasome interactions in mRNA decay are as yet unknown. It seems likely that the 
proteasomal degradation of TTP represents one step in a process involving several 
cellular components, such as the exosome or P-Body (Lykke-Andersen and Wagner, 
2005; Mukherjee et al., 2002; Kedersha et al., 2005; Stoecklin et al., 2004) and possibly 
the RNA induced silencing complex (RISC) (Jing et al., 2005). 
An overview of potential TLR activation-induced GILZ downregulation mechanisms as 
suggested by our data and the literature is given in figure 36. Further studies are needed 
to clarify the role of the proteasome and miRNA in this regulatory network. 
 
 
 
 
Figure 36: Potential mechanisms of GILZ downregulation. Ub: ubiquitin. See text for additional details. 
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4.3.5 TNF- mediated GILZ downregulation 
TNF- has previously been shown to reduce GILZ levels in epithelial cells (Eddleston et 
al., 2007), which is in accordance with our findings for TNF-treated AM. TNF- might act 
in several ways to decrease GILZ similar to those suggested for TLR activation, i.e. via 
TTP-induction, NF-B dependent miRNA induction and/or promotion of proteasomal GILZ 
degradation. TNF- was previously shown to increase TTP protein levels in primary 
mouse macrophages (Carballo et al., 1998), THP-1 cells (Fairhurst et al., 2003) and 
human glioma cell lines (Suswam et al., 2008), thereby inducing its own downregulation. In 
addition, NF-B activation by TNF- is well described for many cell types including or 
human AM (Li et al., 2006). Thus, NF-B- or TTP- dependent GILZ downregulation could 
be expected to not only occur after TLR activation, but also upon TNF-challenge. 
However, endogenous TNF- is unlikely to play a major role in GILZ downregulation in 
our in vitro system, as an increase in TNF- production did not induce GILZ mRNA 
destabilization upon Poly(I:C) treatment. This assumption was confirmed by our finding 
that GILZ downregulation was inhibited by TTP knockdown, although TNF- levels were 
increased. Nevertheless, we can not exclude a contribution of endogenous TNF- to GILZ 
downregulation upon TLR activation at the time being. 
 
4.3.6 GILZ in endotoxin tolerance 
Endotoxin tolerance describes the phenomenon that previous exposure to a low level of 
LPS induces a transient period of hyporesponsiveness after subsequent challenge with 
LPS (Biswas and Lopez-Collazo, 2009). Clinically, this state is associated with 
monocytes/macrophages in sepsis patients where it contributes to a high risk of secondary 
infections and increased mortality (Monneret et al., 2008). Numerous molecules have been 
identified to contribute to attenuated TLR signalling in tolerant cells, including IRAK-M, 
suppressor of cytokine-signaling-1 (SOCS-1), Src homology 2-containing inositol-5′-
phosphatase (SHIP), and IB isoforms. At the nuclear level, increase in the NF-B subunit 
p50 homodimer expression and increased activation of peroxisome-proliferator activated 
receptors- (PPAR) have been linked to the tolerance phenotype (Fan and Cook, 2004; 
Biswas and Lopez-Collazo, 2009). In addition, miRNAs like miR-155, miR-146, and miR-9 
induced by TLR4 signalling act in a negative feedback fashion, inhibiting various levels of 
the MyD88 or TRIF signaling pathway (Baltimore et al., 2008).  
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Thus, it seemed likely that GILZ regulation is altered in endotoxin tolerance. We found that 
GILZ mRNA downregulation was indeed completely abrogated in LPS-tolerant AM. In fact, 
GILZ expression was even slightly, but not significantly, enhanced. The inability to 
downregulate the expression of the anti-inflammatory factor GILZ might contribute to an 
insufficient immune response in tolerant cells, suggesting that increased GILZ expression 
may contribute to the tolerant phenotype. However, additional experiments are needed to 
elucidate the role of GILZ in endotoxin tolerance. 
 
In summary, we present the first observation of GILZ expression in primary human lung 
macrophages. We also show that the expression of GILZ in AM is actively regulated, being 
induced by glucocorticoids and downregulated by TLR activation in a MyD88-dependent 
fashion. The RNA binding protein TTP and the proteasome are critically involved in TLR-
mediated GILZ downregulation. Finally, we suggest that GILZ might play a role in 
endotoxin tolerance. GILZ has emerged as a potential target for treatment of inflammatory 
lung diseases, and an understanding of its regulation under inflammatory conditions might 
help to develop strategies to influence its expression. 
 
 
 
 
 
 
 
 
 
Parts of the results presented in this chapter have been submitted for publication as: 
 
Downregulation of Glucocorticoid-Induced Leucine Zipper in alveolar macrophages upon 
Toll-like receptor activation occurs MyD88-dependently. 
Hoppstädter J, Diesel B, Eifler LK, Schmid T, Brüne B, Kiemer AK.  
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5.1 Materials 
 
Cell media, fetal calf serum (FCS), penicillin, streptomycin and glutamine were from PAA 
(Pasching, Austria). TLR ligands (Pam3CSK4, Poly(I:C), LPS, flagellin, FLS-1, imiquimod, 
ssRNA40, ODN2006 and ODN2006 GC control) were obtained from Invivogen (San 
Diego, CA, USA) and diluted and stored according to the manufacturer's guidelines. 
Immunostimulatory sequences (ISS1018) were purchased from Dynavax (Berkeley, CA, 
USA). Chloroquine (CQ, diphosphate salt) was obtained from Sigma-Aldrich (St. Louis, 
MO, USA). CQ was dissolved in water at a stock concentration of 100 mM, syringe-filtered 
(0.2 µM), aliquoted, and stored at -20 °C until use. MG-132 (Calbiochem, Nottingham, UK) 
and cytochalasin D (Sigma-Aldrich, St. Louis, MO, USA) were diluted in DMSO (stock 
concentrations: 10 mM and 10 mg/ml, respectively) under sterile conditions, aliquoted and 
stored at -20°C. Real Time RT-PCR primers and dual-labelled probes were obtained from 
Eurofins MWG Operon (Ebersberg, Germany). Taq-Polymerase (5 U/µl), 10 x Taq buffer 
and the dNTP mix (containing dATP, dCTP, dGTP and dTTP at a concentration of 10 mM, 
each) were from Genscript (Piscataway, NJ, USA). SMART pool siRNA targeting GILZ or 
MyD88 mRNA as well as control siRNA were purchased from Dharmacon (Chicago, IL, 
USA) and diluted in DEPC-treated PBS as recommended by the supplier. Lipofectamine 
LTX reagent, Lipofectamine 2000 and Opti-MEM I reduced serum medium were obtained 
from Invitrogen (Carlsbad, CA, USA). The MyD88 inhibitor peptide and the respective 
control peptide were from Imgenex (San Diego, CA, USA). Goat anti-GILZ antibody (sc-
26518) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA), rabbit anti-
MyD88 (ab2064) and rabbit anti-TTP (ab36558) antibodies were purchased from Abcam 
(Cambridge, MA, USA). Mouse anti-tubulin (T9026) was from Sigma-Aldrich (St. Louis, 
MO, USA). IRDye© 800 conjugated anti-goat antibodies (605-7352-125) were obtained 
from Rockland (Gilbertsville, PA, USA). IRDye© 680 or 800 conjugated anti-mouse (926-
32220) and anti-rabbit (926-32221) antibodies were from LI-COR Biosciences (Lincoln, 
NE, USA). FITC-labelled anti-CD14 (11014973) and FITC-IgG1 (114714) were obtained 
from eBioscience (San Diego, CA, USA) , PE-labelled anti-HLA-DR (R7267), FITC-
labelled anti-CD68 (F7135), FITC-labelled anti-CD1a (F7141) as well as PE-IgG2a  (X 
0950), FITC-IgG2a (X933) and PE-IgG1 (X928) isotype controls were purchased from 
Dako (Carpinteria, CA, USA). PE-labelled anti-CD83 (556855), PE-labelled anti-CD90 
(555596), and PE-IgG1 (554680) were from BD Biosciences (San Jose, CA, USA). 
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Restriction enzymes were obtained from New England Biolabs (Ipswich, MA, USA). Other 
chemicals were purchased either from Sigma-Aldrich (St. Louis, MO, USA) or Roth 
(Karlsruhe, Germany) unless marked otherwise. 
 
 
5.2 Mice 
 
C57BL/6 mice were kept under controlled conditions in terms of temperature, humidity, day 
/night rhythm and food delivery. Animals were 5 weeks of age when experiments were 
done. All animal procedures were performed in accordance with the local animal welfare 
committee. 
Mice were injected intraperitoneally either with 50 µg LPS diluted in saline or the equal 
amount of salt solution only. 4 h after injection, mice were sacrificed and the lungs were 
removed to determine GILZ levels. Murine lung tissue was kindly provided by Sonja M. 
Keßler (Saarland University, Pharmaceutical Biology). 
 
 
5.3 Cell culture 
 
5.3.1 Alveolar macrophages (AM) 
Alveolar macrophages were isolated from human non-tumor lung tissue, which was 
obtained from patients undergoing lung resection. The use of human material for isolation 
of primary cells was reviewed and approved by the local Ethics Committees (State Medical 
Board of Registration, Saarland, Germany). Isolation was performed referring to a protocol 
for the recovery of type II pneumocytes previously described by Elbert et al. (1999). After 
visible bronchi were removed, the lung tissue was sliced into small pieces of about 1 cm3 
and washed at least three times with BSS (balanced salt solution; 137 mM NaCl, 5 mM 
KCl, 0.7 mM Na2HPO4, 10 mM HEPES, 5.5 mM glucose, pH 7.4). The washing buffer was 
collected and cells were obtained by centrifugation (15 min, 350 x g). Remaining 
erythrocytes were lysed by incubation with hypotonic buffer (155 mM NH4Cl, 10 mM 
KHCO3, 1 mM Na2EDTA) and the cell suspension was washed with PBS (137 mM NaCl, 
2.7 mM KCl, 10.1 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4) three times. Subsequently, cells 
were resuspended in AM/IM medium (RPMI 1640, 5 % [v/v] FCS, 100 U/ml penicillin G, 
Experimental procedures 
 
 
105 
100 µg/ml streptomycin, 2 mM glutamine), seeded at a density of 0.5-1 x 106 cells/well in a 
12- or 6-well plate and incubated at 37 °C for 2 h. Adherent cells were washed at least 5 
times with PBS and cultivated with medium for 3-4 days. Medium was changed every two 
days.  
 
5.3.2 Lung interstitial macrophages (IM) 
After recovering alveolar macrophages, lung tissue was chopped into pieces of 0.6 mm 
thickness using a McIlwain tissue chopper. To remove remaining alveolar macrophages 
and blood cells, the tissue was washed with BSS over a 100 µm cell strainer until the 
filtrate appeared to be clear. The tissue was then digested using a combination of 150 mg 
trypsin type I (T-8003, Sigma-Aldrich, St. Louis, MO, USA) and 0.641 mg elastase 
(LS022795, CellSystems, Remagen, Germany) in 30 ml BSSB for 40 min at 37°C in a 
shaking water bath. After partial digestion, the tissue was brought to DMEM/F12 medium 
containing 25 % FCS and 350 U/ml DNase I (D5025, Sigma-Aldrich, St. Louis, MO, USA). 
Remaining undigested lung tissue in the solution was disrupted by repeatedly pipetting the 
cell suspension slowly up and down. After filtration through gauze and a 40 µm cell 
strainer, cells were incubated in a 1:1 mixture of DMEM/F12 medium and SAGM 
(Cambrex, East Rutherford, NJ, USA), containing 5% [v/v] FCS and 350 U/ml DNase I in 
Petri dishes in an incubator at 37°C and 5% CO2 for 90 min in order to let macrophages 
attach to the plastic surface. Afterwards, non-adherent cells were removed by washing 
with PBS, remaining cells were detached from plates by treatment with trypsine/EDTA 
solution (PAA, Pasching, Austria) and seeded at a density of 0.5-1 x 106 cells/well in a 12- 
or 6-well plate. As surface receptor expression might be influenced by different isolation 
procedures, cells were cultured with AM/IM medium for 3-4 days to restore receptors as 
shown previously for tissue macrophages isolated by enzyme perfusion (Kiemer et al., 
2002b). Medium was changed every other day. 
 
5.3.3 Monocyte-derived macrophages 
Peripheral blood mononuclear cells (PBMC) were obtained from healthy adult blood 
donors (Blood Donation Center, Saarbrücken, Germany) using Percoll (GE Healthcare, 
Munich, Germany) as described previously (Kiemer et al., 2009). Briefly, the buffy coat 
was diluted with PBS at a ratio of 2:1. Subsequently, the Percoll solution (density 1.077 
g/ml; 55 % [v/v] Percoll in PBS) was overlayed with an equal amount of the buffy coat 
mixture, followed by centigugation (30 min, 500 x g, w/o break). The cell layer containing 
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mononuclear cells was removed and washed twice with PBS. Subsequently, erythrocytes 
were lysed by addition of sterile water, and lysis was instantly stopped by PBS addition. 
Cells were washed twice with PBS and resuspended in medium (RPMI1640 supplemented 
with 20 % [v/v] FCS, 100 U/ml penicillin G, 100 µg/ml streptomycin, 2 mM glutamine). 
Thereafter, cells were allowed to adhere to culture flasks for 2 h at 37°C. Non-adherent 
cells were removed by washing, and the adherent monocytes were harvested by 
trypsine/EDTA treatment. After 5 min, digestion was stopped with RPMI containing 20 % 
[v/v] FCS, penicillin (100 U/ml), and streptomycin (100 μg/ml). Monocytes were then 
seeded at a density of 0.5-1 x 106 cells/well in a 12- or 6-well plate and differentiated into 
macrophages in RPMI-1640 containing 20 % FCS [v/v] for 7 days. Medium was changed 
every other day. 
 
5.3.4 Monocyte-derived immature and mature dendritic cells (iDC, mDC) 
Monocytes were obtained as described by Schütz et al. (2006). In brief, PBMC were 
isolated from buffy coats using Ficoll-Paque (GE Healthcare, Munich, Germany). The 
mononuclear cell layer was removed and washed with PBS. Erythrocytes were lysed in 
hypotonic buffer (see 5.2.4) and washed twice with PBS. Subsequently, cells were allowed 
to adhere to culture flasks for 2 h at 37 °C. Non-adherent cells were removed by washing, 
and the adherent monocytes were harvested as described above. To generate immature 
DCs (iDC), monocytes were cultured for 5 d in RPMI 1640 containing 10 % [v/v] FCS, 
penicillin (100 U/ml), and streptomycin (100 μg/ml) in the presence of GM-CSF (800 U/ml, 
Berlex Bioscience Inc., Richmond, CA, USA) and IL4 (20 U/ml, Strathmann Biotec, 
Hamburg, Germany) with one-quarter of the medium being replaced by fresh cytokine-
containing medium on day 2 post-isolation. Mature dendritic cells (mDC) were generated 
by adding 100 ng/ml LPS (Sigma-Aldrich, St. Louis, MO, USA) to iDC cultures for an 
additional 48 h. iDC and mDC were kindly provided by Tanja Breinig (Saarland University, 
Department of Virology). 
 
5.3.5 Cell lines 
 
THP-1 cells 
THP-1 cells were cultivated in RPMI-1640 with 10 % [v/v] FCS and kept at a density of 2 x 
105 – 1 x 106 cells / ml. For differentiation, cells were treated with 100 nM PMA (Sigma-
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Aldrich, St. Louis, MO, USA), seeded at a density of 0.2-0.5 x 105 cells / well in a 12- or 6-
well plate and incubated for 48 h. 
 
MRC-5 and HSF-1 cells 
The fibroblast cell lines MRC-5 and HSF-1 were cultured in Dulbecco's modified Eagle's 
medium (DMEM) supplemented with 10 % [v/v] FCS, penicillin (100 U/ml), and 
streptomycin (100 μg/ml) at 37 °C and 5 % CO2. Upon reaching confluence, cells were 
washed with PBS and detatched from culture flasks by treatment with trypsine/EDTA 
solution (PAA, Pasching, Austria). After 10 min, digestion was stopped with DMEM 
containing 20 % FCS [v/v], penicillin (100 U/ml), and streptomycin (100 μg/ml). The 
suspension was centrifuged and resuspended in DMEM with 10 % [v/v] FCS, penicillin 
(100 U/ml), and streptomycin (100 μg/ml) and appropriate aliquots of the cell suspension 
were added to new culture vessels. 
 
Freezing and thawing of cells 
For freezing, cell suspensions were washed with PBS and cells were resuspended in ice 
cold freezing medium (70 % [v/v] RPMI 1640, 20 % [v/v] FCS, 10 % [v/v] DMSO). After 
cells were transferred into cryovials, they were stored at -80 °C for 2 d and afterwards in 
liquid nitrogen at -196 °C.  
To minimize the cytotoxic effects of DMSO, cells were rapidly thawed for 2 or 3 min and 
instantly transferred into the respective pre-warmed cell growth medium. After 
centrifugation, cells were resuspended in growth medium and cultured as described 
above. 
 
5.3.6 Determination of cell viability 
Viable cell counts were assessed using a hemocytometer and trypan blue (0.5 % [v/v] in 
PBS) exclusion.  
Additionally, MTT assays were performed in order to determine potential cytotoxic effects 
of cell treatment. Cells were seeded at a density of 2 x 104 cells per well in a 96-well plate 
and treated as indicated. Afterwards, cells were washed and 200 µl medium containing 
MTT (0.5 µg/ml, Sigma-Aldrich, St. Louis, MO, USA) were added for 2 h. After medium 
was removed, cells were lysed and the water-insoluble purple formazan was solubilized by 
the addition of 80 µl DMSO. Absorbance was detected at a wavelength of 550 nm using a 
Sunrise absorbance reader (Tecan, Grödig, Austria).  
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5.4 Bacterial culture 
 
5.4.1 Escherichia coli (E.coli) strains 
 
Culture 
The following strains were used as host organisms for plasmid amplification:  
 
 XL1 Blue (Stratagene, Santa Clara, CA, USA), genotype endA1 gyrA96(nalR) thi-1 
recA1 relA1 lac glnV44 F'[::Tn10 proAB+ lacIq Δ(lacZ)M15] hsdR17(rK- mK+)  
 
 TOP10 (Invitrogen, Carlsbad, CA, USA), genotype F- mcrA Δ(mrr-hsdRMS-mcrBC) 
φ80lacZΔM15 ΔlacX74 nupG recA1 araD139 Δ(ara-leu)7697 galE15 galK16 
rpsL(StrR) endA1 λ- 
 
 GT116 (Invivogen, San Diego, CA, USA), genotype F¯ mcrA Δ(mrr-hsdRMS-
mcrBC) Φ80lacZΔM15 ΔlacX74 recA1 endA1 Δdcm ΔsbcC-sbcD. 
 
E.coli GT116 were employed to amplify shRNA encoding plasmids, as this strain is more 
compatible with hairpin structures. For all other vectors, the XL1 Blue or TOP10 strains 
were used. 
Bacteria were either grown in Luria-Bertani (LB; 10% tryptone [w/v], 5% yeast extract [w/v],  
5% [w/v] NaCl, diluted in H2O, pH 7.5) medium supplemented with ampicillin (100 µg/ml) 
or Low Salt LB (10 % tryptone [w/v], 5 % yeast extract [w/v], 2.5 % [w/v] NaCl, pH 7.5) 
containing zeocin (25 µg/ml, Invivogen) at 37°C and 5% CO2. For selection of single 
clones, LBamp or Low salt LBzeo agar (30 % [w/v] agar in LB containing the respective 
antibiotic) plates were used. 
 
Generation of competent E.coli 
Competent E.coli were generated using the CaCl2 method. Briefly, 100 ml of an overnight 
culture (OD650 = 0.4) were incubated on ice for 30 min, centrifuged (2,000 x g, 5 min, 4°C)  
and resuspended in 2.5 ml ice cold CaCl2 solution containing 75 mM CaCl2 and 15% 
glycerol. Another 20 ml ice cold CaCl2 were added, and the mixture was incubated on ice 
for 20 min. Cells were obtained by centrifugation (2,000 x g, 5 min, 4°C), resuspended in 
2.5 ml CaCl2, aliquoted and stored at -80 °C. 
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Transformation 
Transformation was carried out by adding 50-150 ng plasmid DNA to 100 µl competent 
bacteria. After incubation on ice for 20 min, bacteria were heat-shocked for 2 min at 42 °C 
and 900 µl prewarmed LB were added, followed by incubation at 37 °C for 1.5 h. 100 µl of 
the suspension were plated on LBamp or LBzeo plates and incubated at 37 °C and 5 % CO2 
over night. 
 
5.4.2 Culture of mycobacteria 
Mycobacteria (M. bovis BCG Pasteur ATCC 27289, wild-type M. bovis ATCC19210, 
H37Rv ATCC 27294, H37Ra ATCC 25177) were grown in Middlebrook 7H9 broth 
containing 10 % [v/v] ADC, 0.2 % [v/v] glycerol and 0.05 % [v/v] Tween 80 (7H9-ADCT) or 
on Middlebrook 7H10 agar containing OADC (Becton Dickinson, Franklin Lake, NJ, USA), 
0.5 % glycerol and antifungal cycloheximide (100 µg/ml). Medium was replaced once a 
week. Antibiotics included hygromycin (50 µg/ml) and kanamycin (25 µg/ml). Mycobacteria 
were grown by the group of Prof. Lee W. Riley (UC Berkeley). 
 
 
5.5 Plasmid generation 
 
5.5.1 Vectors for mammalian cell transfections 
 
shRNA vectors 
Two shRNA plasmids termed shTTP1 and shTTP2 encoding different siRNAs directed 
against the human TTP mRNA were created by cloning double-stranded oligonucleotides 
into the BbsI sites of psiRNA-h7SKGFPzeo (Invivogen, San Diego, CA, USA) according to 
the manufacturer's instructions. After cloning, insert sequences were checked using the 
Eurofins MWG sequencing service. 
 
Oligonucleotide sequences (5’  3’): 
 
shTTP1:  
ACCTCGGGATCCGACCCTGATGAATATCAAGAGTATTCATCAGGGTCGGATCCCTT 
 
shTTP2 as described by Fechir et al. (2005):  
ACCTCACAAGACTGAGCTATGTCGGATCAAGAGTCCGACATAGCTCAGTCTTGTTT 
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Sequence of the small interfering RNA (siRNA) repeats directed against the human 
tristetraprolin mRNA are underlined. 
 
TTP expression vector 
The plasmids pZeo-hTTP-sense and -antisense (CoV) were derived from the pZeoSV2(-) 
expression plasmid (Invitrogen, Carlsbad, CA, USA) and were a kind gift of Hartmut 
Kleinert (Department of Pharmacology, Johannes Gutenberg University, Mainz, Germany). 
 
5.5.2 Real-Time RT-PCR standard plasmids 
Standards of the PCR product of the gene of interest were cloned into the pGEM-T Easy 
vector (Promega, Madison, WI, USA) according to the manufacturer's guidelines. Standard 
plasmids were provided by Prof. Dr. Alexandra K. Kiemer (Saarland University, 
Pharmaceutical Biology). See 5.9.2 for primer sequences. 
 
 
5.6 Isolation of bacterial DNA 
 
5.6.1 Plasmid purification 
Plasmid DNA was isolated from overnight cultures by using the Mini or Midi plasmid 
isolation kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. 
Plasmids for transfections were purified using the EndoFree Maxi Plasmid isolation kit 
(Qiagen, Hilden, Germany) in order to avoid endotoxin contaminations of the plasmid 
preparations.  
 
5.6.2 Isolation, digestion and methylation of mycobacterial DNA 
Before DNA isolation, mycobacteria were centrifuged and boiled for 10 min. DNA was 
isolated according to a previously published method (Santos et al., 1992). Briefly, bacteria 
from cultures at OD600 = 1 were pelleted and resuspended in TE (10 mM Tris, 1 mM EDTA, 
pH 8). TE-saturated phenol pH 8 and glass beads were added and the suspension was 
vortexed for 3 min. The phenol phase was re-extracted with TE, followed by the addition of 
0.2 vol 5 % [w/v] sodium deoxycholate and incubation at 56 °C for 90 min. Protein was 
removed by at least three cycles of extraction with phenol:chloroform:isoamyl. DNA was 
precipitated by the addition of sodium acetate/ethanol, washed in 70% ethanol, and 
resuspended in Tris buffer. Any residual RNA was digested with RNase (Qiagen, Hilden, 
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Germany) and residual protein was removed by chloroform:isoamyl extraction. DNA was 
again precipitated, washed, and resuspended in Tris buffer. The isolation was performed 
under sterile conditions in order to avoid bacterial contamination from the surrounding 
area. DNA was kindly provided by Prof. Dr. Alexandra K. Kiemer (Saarland University, 
Pharmaceutical Biology). Additional precipitation and washing steps including purification 
with Triton X-114 were included to assure purity of the DNA (Cotten et al., 1994). We 
checked all DNA preparations with a commercially available LAL assay (Cambrex, East 
Rutherford, USA) in order to exclude LPS contaminations.  
For further control experiments, DNA was either digested with DNase or cytosine residues 
(C5) were methylated by the SssI methyltransferase (Buryanovet al., 2005).  
DNA was digested with DNase (500 µg/ml, D-4513, Sigma-Aldrich, St. Louis, MO, USA) 
for 2 h at 37 °C under sterile conditions. After digestion, DNase was heat-inactivated and 
the required volume of the reaction correlative with the amount of DNA digested was 
added to a culture of monocyte-derived macrophages. In addition, appropriate volumes of 
a mock reaction (w/o DNA) as well as mock-treated H37Ra-DNA, which was 
homologously treated in the absence of DNase, were added to cells.  
Cytosine residues of BCG DNA were methylated by SssI methyltransferase under sterile 
conditions according to the manufacturer’s instructions. In order to determine whether 
methylation in fact occurred, digestion was performed with HpaII as a restriction enzyme 
sensitive to CG methylation. After methylation, SssI was heat-inactivated and the required 
volume of the reaction correlative with the amount of DNA methylated as well as a suitable 
volume of a mock reaction (w/o DNA) was added to a culture of monocyte-derived 
macrophages. In addition, BCG DNA, which was homologously treated in the absence of 
SssI, was added to cells.  
 
5.6.3 Determination of DNA concentrations 
DNA concentrations were determined by measuring the extinction of the DNA solutions at 
260 nm, whereas an extinction of 1 equates a concentration of 50 µg/ml. The purity of the 
DNA preparations was checked by absorption measurement at 280 nm, the characteristic 
absorption maximum of aromatic amino acids. Measurements were done with a BioMate 
UV-Vis spectrophotometer (ThermoElectron, Oberhausen, Germany). 
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5.7 Agarose gel electrophoresis 
 
5.7.1 Detection of DNA 
Depending on the DNA size, 0.5 – 2 % [w/v] agarose gels containing 0.04 % [v/v] ethidium 
bromide were used for DNA detection. Upon addition of a suitable volume of 6 x loading 
buffer (18 % Ficoll, 0.5 M EDTA, 60 ml 10 x TBE, 0.04 % bromphenol blue, 0.04 % 
xylencyanol, H2O ad 100 ml), DNA was loaded onto a gel and seperated in TBE (89.1 mM 
Tris, 89.1 mM boric acid, 2.21 mM EDTA in H2O) at 100 V. To determine the size of the 
DNA, a 50 bp ladder (Fermentas, St. Leon-Rot, Germany) or a 1 kb ladder (Invitrogen, 
Carlsbad, CA, USA) were used. Detection of the DNA bands was carried out using a UV 
transilluminator and the software ArgusX1 (Biostep, Stollberg, Germany). 
 
5.7.2 Detection of RNA 
In contrast to DNA gels, RNA gels contained 1 % fomaldehyde to ensure denaturation of 
the samples and were prepared with MOPS buffer (0.02 M MOPS, 5 mM sodium acetate, 
0.5 mM EDTA in DEPC-treated H2O, pH 7) instead of TBE with 1% [w/v] agarose. Prior to 
loading onto the gels, RNA was boiled at 65 °C for 5 min in an appropriate volume of 
loading buffer (10 ml formamide, 3.5 ml formaldehyde, 1.5 ml 10 x MOPS). Samples were 
separated in MOPS buffer at 100 V and detected as described in 4.7.1. 
 
 
5.8 RNA isolation and reverse transcription 
 
5.8.1 RNA isolation 
Total RNA was extracted using either RNeasy mini or micro kit columns (Qiagen, Hilden, 
Germany) according to the manufacturer's instructions. DNA was digested during the RNA 
isolation procedure using the RNase-Free DNase1 kit (Qiagen, Hilden, Germany). RNA 
integrity was checked using agarose gel electrophoresis. 
 
5.8.2 Measurement of RNA concentrations 
Photometric determination of RNA concentrations at 260 nm was carried out using a 
BioMate UV-Vis spectrophotometer (ThermoElectron, Oberhausen, Germany). An 
extinction of 1 equates a concentration of 40 µg/ml. 
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5.8.3 Alu PCR 
To confirm the absence of DNA in our RNA preparations, a PCR for Alu elements, which 
occur in large numbers throughout the human genome, was performed using the following 
primer:  5’-TCATGTCGACGCGAGACTCCATCTCAA A-3’. 
 
One reaction consisted of: 
 
Taq-Polymerase 2.5 U 
dNTPs 800 µM 
10 x Taq-buffer 2.5 µl 
MgCl2 (50 mM) 5 mM 
primer (50 µM) 100 nM 
template 100 ng RNA 
H2O ad 25 µl 
 
5 ng THP-1 DNA (provided by Christoph Meyer, formerly Saarland University, 
Pharmaceutical Biology) served as a positive control.  
The PCR was carried out in a Thermocycler PX2 (ThermoElectron, Oberhausen, 
Germany) using the following conditions: 
 
denaturation 5 min 94 °C   
denaturation 1 min 94 °C  
annealing 1 min 56 °C 30 cycles 
elongation 1 min 72 °C }  
final elongation 10 min 72 °C  
 
Products were detected by agarose gel electrophoresis. RNA was considered to be DNA -
free when no product was visible.  
 
5.8.4 Reverse transcription 
250 - 500 ng of RNA were denatured at 65 °C for 5 min, placed on ice, and then reverse 
transcribed in a total volume of 20 µl using oligo-dT primers (5'-TTT TTT TTT TTT TTT 
TTT-3') and the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 
Foster City, CA, USA) according to the manufacturer’s instructions. The resulting cDNA 
was diluted by addition of 80 µl TE buffer (AppliChem, Darmstadt, Germany) and used for 
real-time RT-PCR. 
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5.9 Real-time RT-PCR 
 
5.9.1 Primer and probe sequences 
 
Table1: Primer sequences as used for real-time RT PCR. 
 
mRNA primer sense, 5' 3' primer antisense, 5' 3' 
huGILZ TCCTGTCTGAGCCCTGAAGAG AGCCACTTACACCGCAGAAC 
huIL6 AATAATAATGGAAAGTGGCTATGC AATGCCATTTATTGGTATAAAAAC 
huIL8 TGCCAGTGAAACTTCAAGCA ATTGCATCTGGCAACCCTAC 
huIL10 CAACAGAAGCTTCCATTCCA AGCAGTTAGGAAGCCCCAAG 
huTNF- CTCCACCCATGTGCTCCTCA CTCTGGCAGGGGCTCTTGAT 
huIP10 GAGCCTACAGCAGAGGAACC AAGGCAGCAAATCAGAATCG 
hu -actin TGCGTGACATTAAGGAGA AG GTCAGGCAGCTCGTAGCTCT 
muGILZ GGGATGTGGTTTCCGTTAAA ATGGCCTGCTCAATCTTGTT 
mu18S GCGCTTCTCTTTCCGCCA AGCTCTCCGACACCTCTT 
huTLR1 AGCAAAGAAATAGATTACACATCA TTACCTACATCATACACTCACAAT 
huTLR2 GCAAGCTGCGGAAGATAATG CGCAGCTCTCAGATTTACCC 
huTLR3 GAATGTTTAAATCTCACTGC AAGTGCTACTTGCAATTTAT 
huTLR4 ATGAAATGAGTTGCAGCAGA AGCCATCGTTGTCTCCCTAA 
huTLR5 GTACAGAAACAGCAGTATTTGAG TCTGTTGAGAGAGTTTATGAAGAA 
huTLR6 TTTACTTGGATGATGATGAATAGT AGTTCCCCAGATGAAACATT 
huTLR7 CCATACTTCTGGCAGTGTCT ACTAGGCAGTTGTGTTTTGC 
huTLR8 AAGAGCTCCATCCTCCAGTG CCGTGAATCATTTTCAGTCAA 
huTLR9 GGGACAACCACCACTTCTAT TGAGGTGAGTGTGGAGGT 
huTLR10 CAACGATAGGCGTAAATGTG GAACCTCGAGACTCTTCATTT 
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Table 2: Probe sequences as used for real-time RT-PCR. 
 
mRNA probe, 5' FAM  3' BHQ1
huGILZ CCCGAATCCCCACAAGTGCCCGA 
huIL6 TCCTTTGTTTCAGAGCCAGATCATTTCT 
huIL8 CAGACCCACACAATACATGAAGTGTTGA 
huIL10 AGCCTGACCACGCTTTCTAGCTGTTGAG 
huTNF- CACCATCAGCCGCATCGCCGTCTC 
huIP10 TCCAGTCTCAGCACCATGAATCAAA 
hu -actin CACGGCTGCTTCCAGCTCCTC 
huTLR1 ATTCCTCCTGTTGATATTGCTGCTTTTG 
huTLR2 ATGGACGAGGCTCAGCGGGAAG 
huTLR3 TTCAGAAAGAACGGATAGGTGCCTT 
huTLR4 AAGTGATGTTTGATGGACCTCTGAATCT 
huTLR5 AGGATCTCCAGGATGTTGGCTG 
huTLR6 GTCGTAAGTAACTGTCZGGAGGTGC 
huTLR7 ATAGTCAGGTGTTCAAGGAAACGGTCTA 
huTLR8 TGACAACCCGAAGGCAGAAGGCT 
huTLR9 ACTTCTGCCAGGGACCCACGG 
huTLR10 ATTAGCCACCAGAGAAATGTATGAACTG 
 
 
5.9.2 Standard dilution series 
To confirm real-time RT-PCR effiency and to quantify target mRNAs in a cDNA sample, 
standards from 10 to 0.0001 attomoles of the PCR product cloned into pGEM-T Easy 
(Promega, Madison, WI, USA), were run alongside the samples to generate a standard 
curve. Plasmids were isolated as described in 5.6.1 and diluted in TE-buffer (AppliChem, 
Darmstadt, Germany). The required amount of plasmid DNA was calculated as follows: 
 
c (target-DNA) [µmol/ml] = c (plasmid) [µg/ml] / MW * L 
 
with MW = molecular weight of the DNA (approx. 660 g/mol) and L = length of plasmid and 
insert in bp. 
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5.9.3 Experimental procedure 
 
Real-time RT-PCR using dual-labelled probes 
Reaction mixtures were assembled on ice and 20 µl of the mixture were added to 5 µl 
template cDNA or standard plasmid solutions in a 96 well plate. dNTP-, probe- and MgCl2-
concentrations for each target gene are listed in table 3. 
The iCycler iQ5 (Bio-Rad, Richmond, CA, USA) was used for real-time RT-PCR. Primer 
and probe sequences are given in table 1 and 2. All samples and standards were analyzed 
in triplicate. The starting amount of cDNA in each sample was calculated using the iCycler 
iQ5 software package (Bio-Rad, Richmond, CA, USA). Absolute mRNA amounts were 
normalized to -actin mRNA levels. 
 
A reaction mixture for one sample consisted of: 
 
Taq-Polymerase 2.5 U 
10 x Taq-buffer 2.5 µl 
Primer sense 500 nM 
Primer antisense  500 nM 
dNTPs 200 or 800 µM 
dual-labelled probe 60 or 100 nM 
MgCl2  3-9 mM 
Template 5 µl 
H2O ad 25 µl 
 
The reaction conditions were as follows: 
 
denaturation 8 min 95 °C   
denaturation 15 s 95 °C  
annealing 15 s 57-60 °C 40 cycles 
elongation 15 s 72 °C } 
final elongation 25 s 25 °C  
 
Target gene specific annealing tempertaures are given in table 3. 
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Table 3: dNTP-, dual-labelled probe-, MgCl2- and anneling temperatures as used for real-time RT-PCR. 
 
mRNA dNTPs probe MgCl2 annealing
huTLR1 800 µM 60 nM 9 mM 57 °C
huTLR2 800 µM 100 nM 6 mM 60 °C 
huTLR3 800 µM 60 nM 7 mM 59 °C 
huTLR4 800 µM 100 nM 5 mM 58 °C 
huTLR5 800 µM 60 nM 7 mM 59 °C 
huTLR6 800 µM 100 nM 8 mM 57 °C 
huTLR7 800 µM 60 nM 5 mM 58 °C 
huTLR8 800 µM 60 nM 5 mM 58 °C 
huTLR9 800 µM 60 nM 7 mM 58 °C 
huTLR10 800 µM 60 nM 9 mM 59 °C 
huGILZ 200 µM 100 nM 4 mM 60 °C 
huIL6 200 µM 100 nM 4 mM 57 °C 
huIL8 200 µM 100 nM 4 mM 59 °C 
huIL10 200 µM 100 nM 4 mM 60 °C 
huTNF- 200 µM 100 nM 3 mM 60 °C 
huIP10 200 µM 60 nM 4 mM 60 °C 
hu -actin 200 µM 60 nM 4 mM 60 °C 
 
 
Real-time RT-PCR using SYBR Green 
For murine GILZ and 18S PCR, the Dynamo Flash SYBR Green qPCR kit (Finnzymes) 
was used according to the manufacturer’s guidelines. The reaction conditions resembled 
those described above. An annealing temperature of 60 °C was used for both muGILZ and 
18S. The starting cDNA quantity was calculated using the iCycler iQ5 software (Bio-Rad 
Richmond, CA, USA). Absolute muGILZ mRNA amounts were normalized to 18S mRNA 
levels. 
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5.10 Western Blot analysis 
 
5.10.1 Preparation of protein samples 
Cells were lysed in SB lysis buffer (50 mM Tris-HCl, 1 % [m/v] SDS, 10 % [v/v[ glycerol, 5 
% [v/v] -mercaptoethanol, 0.004 % [m/v] bromphenol blue) supplemented with a protease 
inhibitor mixture (Complete®, Roche Diagnostics, Basel, Switzerland) according to the 
manufacturer's instructions. Murine lung tissue was disrupted using a Kontes tissue 
grinder and lysed accordingly. In general, 100 µl lysis buffer were employed for lysis of 2 x 
105 cells or 1 mg of tissue. Subsequently, samples were sonicated for 5 s and centrifuged 
(10 min, 20,000 x g, 4 °C). Supernatants were removed and stored at -80 °C. 
 
5.10.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Composition of 15 % gels: 
resolving gel   stacking gel   
H20 4.6 ml H20 6.8 ml 
30 % acrylamide / 
0.8 % bisacrylamide 
solution  
10 ml 30 % acrylamide / 
0.8 % bisacrylamide 
solution  
1.7 ml 
Tris (1.5 M, pH 8.0) 5 ml Tris (1 M, pH 6.8) 1.25 ml 
SDS (10 % [w/v]) 200 µl SDS (10 % [w/v]) 100 µl 
APS (10 % [w/v]) 200 µl APS (10 % [w/v]) 100 µl 
TEMED 20 µl  TEMED 10 µl  
 
Procedure 
Samples were thawed on ice and denatured for 5 min at 95 °C. A prestained protein 
marker (Fermentas, St. Leon-Rot, Germany) was used to estimate the molecular masses. 
Equal sample amounts and a suitable marker volume were loaded onto the gel and 
separated in electrophoresis buffer (24.8 mM Tris, 1.92 mM glycine, 0.1 % [w/v] SDS) for 
130 min at 80 V, followed by 2 h at 120 V. Gel preparation and electrophoresis were 
carried out using the Mini PROTEAN system (Bio-Rad, Richmond, CA, USA). 
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5.10.3 Blotting 
The Mini-Transblot cell (Bio-Rad, Richmond, CA, USA) system was emplyed to transfer 
separated protein samples onto a polyvinylidene fluoride (PVDF) membrane (Immobilon-
FL, Millipore, Billerica, MA, USA). Prior to blotting, the membrane was incubated for 30 s in 
methanol. Sponges, blotting papers, the gel and the membrane were equilibrated in 
transfer buffer, followed by gel sandwich preparation. Blotting was carried out at 80 mA 
over night. Afterwards, the membrane was incubated in Rockland Blocking Buffer for near-
infrared Western Blotting (RBB, obtained from Rockland, Gilbertsville, PA, USA) for 1 h for 
30 min in order to block unspecific binding sites. 
 
5.10.4 Immunodetection 
 
Antibodies were either diluted in PBST (0.1 % [v/v] tween 20 in PBS) containing  5 % [m/v] 
dried milk, gelatine buffer (0.75 % [w/v] gelatine A , 0.1 % [v/v] tween 20, 20 mM Tris, 137 
mM NaCl, ph 7.5) or RBB according to table 4. 
 
Table 4: Antibody dilutions used for immunodetection. 
Antibody dilution 
anti-human/mouse GILZ, goat IgG 1:200 in gelatine buffer 
anti-human MyD88, rabbit IgG 1:500 in PBST + 5 % [m/v] dried milk  
anti-human TTP, rabbit IgG 1:2,000 in PBST + 5 % [m/v] dried milk
anti-human tubulin, mouse IgG 1:1,000 in PBST + 5 % [m/v] dried milk
IRDye© 800CW conjugated goat anti-mouse IgG  1:10,000 in RBB 
IRDye© 680 conjugated mouse anti-rabbit IgG  1:5,000 in RBB 
IRDye© 800 conjugated donkey anti-goat IgG  1:10,000 in RBB 
 
Membranes were incubated with primary antibodies for 3 h at room temperature (MyD88, 
tubulin) or 37 °C (GILZ) or overnight at 4 °C (TTP). Subsequently, they were washed  
either in PBST + 5 % [m/v] dried milk or gelatine buffer for GILZ blots (2 x 5 min), followed 
by additional washing steps in PBST (2 x 5 min). Afterwards, membranes were incubated 
with the secondary antibody for 1.5 h at room temperature. After washing twice in PBST 
and PBS for 5 min, blots were scanned with an Odyssey Infrared Imaging System (LI-COR 
Biosciences, Lincoln, NE, USA) and relative signal intensities were determined using the 
Odyssey software.  
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5.11 Transfection of THP-1 cells 
 
5.11.1 Plasmid transfection 
Plasmids were introduced into THP-1 cells using Lipofectamine LTX transfection reagent 
according to the manufacturer’s guidelines for transfection of THP-1 cells. Briefly, 2 x 105 
cells were plated in 1 ml growth medium per well in 12 well plates. For each well, 1 µg 
plasmid DNA was diluted in a total volume of 200 µl Opti-MEM, mixed with 1 µl of PLUS 
reagent and incubated for 15 min at room temperature. Subsequently, 6.25 µl 
Lipofectamine LTX were added and the transfection mix was incubated for another 25 min 
at room temperature prior to its addition to THP-1 cells. For TTP overexpression assays, 
cells were harvested 24 h after they were transfected with pZeo-hTTP-sense or the 
antisense control construct. Knockdown of TTP was performed by transfecting THP-1 cells 
with shTTP1 or shTTP2 plasmids. The psiRNA-LucGL3 plasmid (Invivogen) was 
transfected as control vector. 
 
5.11.2 siRNA transfection 
For knockdown of GILZ or MyD88 by siRNA, cells were transfected with siGILZ or 
siMyD88 and respective control siRNA using Lipofectamine 2000 transfection reagent as 
recommended by the supplier. In short, THP-1 cells were seeded in 12 well plates at a 
density of 2 x 105 cell per well. For each well, 2 µl of Lipofectamine 2000 were mixed with 
100 µl of Opti-MEM and incubated at room temperature for 5 min. 40 pmol siRNA were 
diluted in 100 µl Opti-MEM and added to the Lipofectamine 2000 solution. After incubation 
at room temperature for an additional 20 min, the Lipofectamine 2000 / siRNA / Opti-MEM 
mixture was added to the cells. Experiments were performed either 24 h (siGILZ) or 72 h 
(siMyD88) after transfection. 
 
 
5.12 Determination of mRNA stability 
 
To analyze the effects of LPS treatment on GILZ mRNA stability, the transcription inhibitor 
actinomycin D (10 µg/ml, Sigma-Aldrich, St. Louis, MO, USA), either alone or in 
combination with LPS (100 ng/ml), was added to AM. 0.5 to 4 h thereafter, cells were 
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harvested and RNA was isolated. The relative amount of GILZ mRNA was determined by 
real-time RT-PCR.  
 
 
5.13 Flow cytometry 
 
5.13.1 Antibodies 
Antibodies and respective isotype controls (table 5) were used in an antibody / cell number 
ratio as recommended by the supplier. 
 
Table 5: Antibodies used for flow cytometry. 
Antibody Isotype control 
FITC-labelled mouse anti-human CD14, clone 61/D3 FITC-IgG1, mouse 
FITC-labelled mouse anti-human CD1a, clone NA1/34 FITC-IgG2a , mouse 
FITC-labelled mouse anti-human CD68, clone KP1 FITC-IgG1, mouse 
PE-labelled mouse anti-human HLA-DR, clone AB3 PE-IgG2a  ,mouse 
PE-labelled mouse anti-human CD83, clone HB15e PE-IgG1 , mouse 
PE-labelled mouse anti-human CD90, clone 5E10 PE-IgG1 , mouse 
 
 
5.13.2 Cell staining and analysis 
Adherent cellswere detached from the plates in TEN buffer (40 mM Tris, 1 mM EDTA, 150 
mM NaCl) before staining. For extracellular staining of CD83, CD90 and CD1a, cells were 
washed with PBS, resuspended in FACS buffer I and then divided into aliquots, each 
containing up to 1x106 cells. Each aliquot was incubated with a specific or isotype control 
antibody for 30 min on ice. The cells were washed in FACSwash and resuspended in 1% 
(w/v) cold paraformaldehyde in PBS, pH 7.6. HLA-DR and CD14 staining were performed 
similarly, except that FACS buffer II (PBS containing 0.05% (w/v) NaN3 and 0.5% (w/v) 
BSA for HLA-DR) or III (PBS with 1% (w/v) NaN3 and 0.5% (w/v) BSA for CD14) were 
used instead of FACS buffer I. Intracellular staining of CD68 was done using the IntraStain 
Reagents (Dako, Carpinteria, CA, USA) according to the manufacturer's instructions.  
The stained cells were examined on a FACSCalibur, and results were analysed using the 
CellQuest software (BD Biosciences, San Jose, CA, USA). Results are reported as relative 
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mean fluorescence intensity (MFI; mean fluorescence intensity of specifically stained cells 
related to mean fluorescence intensity of isotype control).  
 
 
5.14 Phagocytosis Assay 
 
5.14.1 Sample preparation 
To visualize the uptake of microspheres by macrophages, cells were incubated with 1.75 
µm latex beads (Fluoresbrite Carboxylated YG microspheres; Polysciences, Warrington, 
PA, USA) at a 100:1 bead / cell ratio for 4 h in medium containing 5 % [v/v] FCS. To block 
fluoresphere uptake, cytochalasin D (10 µg/ml) was added 1 h prior to addition of latex 
beads. Alternatively, macrophages were pretreated by incubation for 1 h at 4 °C and 
further incubated with fluorespheres at the same temperature as the pretreatment. After 
the incubation with latex beads, cells were washed 4-5 times with ice cold PBS to remove 
remaining fluorospheres, and detatched from plates using trypsin/EDTA buffer (PAA, 
Pasching, Austria). Afterwards, cells were assessed for fluorosphere uptake by flow 
cytometry or confocal laser scanning microscopy. 
 
5.14.2 Flow cytometry assessment of fluorosphere uptake  
After washing, cells were resuspended in ice-cold PBS, examined on a FACSCalibur and 
results were analysed using the CellQuest software (BD Biosciences, San Jose, CA, 
USA).  
 
5.14.3 Confocal laser scanning microscopy   
Staining was performed in a wet chamber. AM and IM were washed with PBS and fixed on 
coverslips for 10 min in PBS supplemented with paraformaldehyde 3.7 % [w/v]. Cells were 
washed three times with PBS before permeabilization with 0.25 % [v/v] Triton X-100 for 10 
min. After washing with PBS, blocking was performed for 30 minutes with BSA 1% [w/v] in 
PBS. F-actin was stained for 30 min with rhodamin-phalloidine (3.8 µM, Sigma-Aldrich, St. 
Louis, MO, USA), and the coverslips were washed twice with PBST and once with PBS. 
Nuclei were stained for 5 min with TOTO-3 iodide (1:500, Invitrogen, Carlsbad, CA, USA) 
followed by three washing steps with PBS. A glass slide was covered with 3 µl Fluorsave 
(Calbiochem, Nottingham, UK) and put upside down onto the coverslips. Preparations 
were dried for 24 h at 4 °C. Images were captured using a LSM 510 Meta run by LSM 510 
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software (Carl Zeiss, Oberkochen, Germany). Confocal laser scanning microscopy was 
done by Robert Zarbock (Saarland University, Pharmaceutical Biology). 
 
 
5.15 Pappenheim staining 
 
Air-dried macrophage preparations were stained using May-Grünwald solution (Roth, 
Karlsruhe, Germany) for 5 min, followed by addition of the same volume of distilled water 
and incubation for another 5 min, after which the staining solution was removed. 
Subsequently, preparations were incubated with Giemsa solution (1:20; Roth, Karlsruhe, 
Germany) for 15 min, washed with distilled water and visualized using light microscopy. 
 
 
5.16 Cytokine measurement 
 
AM and IM were seeded at a density of 1 x 105 cells per well in 96 well plates. On day 4 
post seeding, cells were incubated in a total volume of 100 µl medium in the presence or 
absence of LPS (100 ng/ ml), Pam3SCK4 (100 ng/ml) or Poly(I:C) (10 µg/ml) for 6 h. The 
supernatants were collected and stored at -80 °C until use in the multiplex cytokine assay. 
For cytokine measurement, a Milliplex MAP Human Cytokine Kit (Millipore, Billerica, MA, 
USA) was used, containing the following cytokines: IL1, IL1ra, IL6, IL10, IL12p40, IL-
12p70, G-CSF, TNF-, IP10, and IFN. The immunoassay procedure was performed using 
a serial dilution of the 10,000 pg/ml human cytokine standard according to the 
manufacturer’s instructions. The plate was read on the Luminex 200 System (Luminex, 
Austin, TX, USA). Total cellular protein concentrations were determined by Pierce BCA 
protein assay (Fisher Scientific, Nidderau, Germany) using a Sunrise absorbance reader 
(Tecan, Grödig, Austria) according to the manufacturer’s instructions. Cytokine 
measurement was supported by Dominik Monz (Department of Neonatology, Saarland 
University Hospital). 
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5.17 Atomic Force microscopy 
 
ISS1018 or BCG DNA (6 mg/ml) diluted in PBS without Ca2+ and Mg2+ (Applichem, 
Darmstadt, Germany) were deposited on pretreated mica (25 mm MgCl2 spin coating for 1 
min), incubated for 5 min, washed with purified water, and dried under vacuum as 
described earlier (Kerkmann et al., 2005). All images were performed using a Dimension 
3100 Scanning Probe Microscope (Veeco, Melville, NY, USA) operating in dynamic mode 
at ambient conditions using etched silicon cantilevers (Ultrasharp NSC/11, MikroMasch, 
Portland, Oregon, USA) with a spring constant 3 N/m and a resonance frequency of  45 
kHz. The nominal tip radius was < 10.0 nm. Atomic force microscopy was performed by 
Ralf Jungmann (Saarland University, Department of Physics). 
 
 
5.18 Statistics 
 
Data analysis and statistics were performed using Origin software (OriginPro 7.5G; 
OriginLabs, Northampton, MA, USA). All data are displayed as mean values  SEM. 
Statistical differences were estimated by independent two-sample t-test. Differences were 
considered statistically significant when P values were less than 0.05. 
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6. Summary 
 
Pulmonary macrophages play a key role in host defence against inhaled particles and 
pathogens. In this work pulmonary macrophage action upon TLR activation was examined. 
  
The role of TLR activation by mycobacterial DNA during tuberculosis infection has only 
recently been a matter of interest, and non-methylated CpG-rich bacterial DNA is now 
recognized as the natural ligand for TLR9. Since TLR9 expression and responsiveness in 
macrophages is controversially discussed, we aimed to investigate TLR9 activation in 
human macrophages. We demonstrated that macrophages are markedly activated by 
DNA isolated from attenuated mycobacterial strains, whereas synthetic CpG 
oligonucleotides have a much lower stimulatory potency. AM activation upon treatment 
with DNA isolated from virulent bacteria was lower compared to attenuated mycobacteria. 
These differences between the stimulatory activities of DNA from virulent versus 
attenuated mycobacteria might indicate a mechanism how virulent strains evade the host 
immune response.  
 
Interestingly, we found that the response to TLR9 activation largely differs in AM and IM, 
which represent the two major macrophage populations in human lungs. Investigations on 
pulmonary macrophages mostly focus on AM as a well-defined cell population, whereas 
characteristics of IM are rather ill-defined. We therefore extended our investigations on the 
phenotypic differences in AM and IM. We showed that IM are smaller and morphologically 
more heterogeneous than AM, whereas phagocytic activity was similar in both cell types. 
HLA-DR expression was markedly higher in IM compared to AM. Although analysis of TLR 
expression profiles revealed no differences between the two cell populations, AM and IM 
clearly varied in cell reaction upon activation. Both macrophage populations were 
responsive towards MyD88-dependent and -independent TLR activation. Whereas AM 
expressed higher amounts of inflammatory cytokines upon activation, IM were more 
efficient in producing immunoregulatory cytokines, such as IL10, IL1ra, and IL6. Thus, AM 
appear to be more effective as a first line of defence against inhaled pathogens, whereas 
IM show a more pronounced regulatory function. 
 
Induction of glucocorticoid-induced leucine zipper (GILZ) by glucocorticoids is critical for 
their anti-inflammatory action, whereas GILZ expression is reduced under inflammatory 
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conditions. The mechanisms regulating GILZ expression during inflammation, however, 
have as yet been unknown. Within the project investigating the reaction of AM upon 
treatment with mycobacterial DNA as a TLR9 ligand, we aimed to determine whether 
TLR9 ligands affect GILZ expression. We herein show that GILZ mRNA and protein 
amounts were significantly diminished upon TLR9 activation. Moreover, lungs of LPS-
exposed mice as well as LPS-treated human AM and THP-1 cells displayed decreased 
GILZ expression. We also demonstrated that LPS treatment reduces GILZ mRNA stability. 
This effect was strictly dependent on the adapter molecule MyD88, as shown by using 
specific ligands or a knockdown strategy. Overexpression and knockdown of the mRNA 
binding protein TTP modulated GILZ mRNA expression, suggesting an involvement of 
TTP in GILZ mRNA destabilization. Remarkably, activation of TLR3, i.e. signalling via the 
TRIF-dependent pathway, resulted in diminished GILZ protein-, but not mRNA-levels. This 
finding indicates that GILZ downregulation utilizes distinct pathways. Moreover, we show 
that the proteasome is critically involved in TLR-mediated GILZ downregulation on mRNA 
and protein level. Suppression of GILZ results in inflammatory cell activation, which might 
represent a regulatory mechanism in TLR activation. Interestingly, this mechanism seems 
to be absent in endotoxin tolerance. 
 
Taken together, this work provides insight into the differential expression of pro- and anti-
inflammatory mediators upon TLR activation in pulmonary macrophages and may 
contribute to a better understanding of processes involved in pulmonary immune 
homeostasis. 
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